|  |  |
| --- | --- |
| **Date Prepared:** | **6/262020** |
| **Name:** | **Joseph Vincent Bonventre** |
| **Office Address:** | Harvard Institutes of Medicine  4 Blackfan Circle, Room 576  Boston, MA 02115 |
| **Home Address:** | 101 Boston Post Road, Wayland, MA 01778 |
| **Work Phone:** | **617 525-5960** |
| **Work Email:** | [**Joseph\_bonventre@hms.harvard.edu**](mailto:Joseph_bonventre@hms.harvard.edu) |
| **Work FAX:** | **617 525-5965** |
| **Place of Birth:** | Brooklyn, NY |

[Education](http://cv.hms.harvard.edu/index.php?page=education)

|  |  |  |  |
| --- | --- | --- | --- |
| Year | Degree  (Honors) | Fields of Study  (Thesis advisor for doctoral research degrees) | Institution |

|  |  |  |  |
| --- | --- | --- | --- |
| June 1970 | BS  With distinction | Engineering Physics | Cornell University  Ithaca, NY |
| June 1976 | MD | Medicine | Harvard Medical School Harvard-MIT Division of Health Sciences and Technology, Boston and Cambridge, MA |
| June 1979 | PhD | Biophysics | Harvard University  Cambridge, MA |

[Postdoctoral Training](http://cv.hms.harvard.edu/index.php?page=postdoc)

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Title | Specialty/Discipline  (Lab PI for postdoctoral research) | Institution |

|  |  |  |  |
| --- | --- | --- | --- |
| July 1976-June 1977 | Intern | Medicine | Massachusetts General Hospital, Boston, MA |
| July 1977-June 1978 | Assistant Resident | Medicine | Massachusetts General Hospital |
| July 1978-June1980 | Clinical and Research Fellow | Medicine | Massachusetts General Hospital |
| July 1978-June 1979 | Fellow | Renal Medicine | Massachusetts General Hospital |
| July 1978-June 1980 | Research Fellow | Medicine | Harvard University |

[Faculty Academic Appointments](http://cv.hms.harvard.edu/index.php?page=academic_appt)

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Academic Title | Department | Academic Institution |

|  |  |  |  |
| --- | --- | --- | --- |
| July 1980-June 1981 | Instructor | Medicine | Harvard Medical School |
| July 1981-June 1988 | Assistant Professor | Medicine | Harvard Medical School |
| July 1986-June 1988 | Assistant Professor | Health Sciences and Technology | Massachusetts Institute of Technology, Cambridge, MA |
| July 1988-June 1998 | Associate Professor | Medicine | Harvard Medical School |
| July 1988-June 1998 | Associate Professor | Health Sciences and Technology | Massachusetts Institute of Technology |
| July 1998-June 2007 | Master | Health Sciences and Technology | Harvard-MIT Division of Health Sciences and Technology Society, Harvard Medical School |
| July 1998-June 2010 | Robert H. Ebert Professor | Molecular Medicine | Harvard Medical School |
| June 2010-  June 2019 | Samuel A. Levine Professor | Medicine | Harvard Medical School |
| June 2019- | Constantine L. Hampers, MD Distinguished Chair | Renal Medicine | Harvard Medical School |

[Appointments at Hospitals/Affiliated Institutions](http://cv.hms.harvard.edu/index.php?page=hospital_appt)

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Position Title | Department (Division, if applicable) | Institution |

|  |  |  |  |
| --- | --- | --- | --- |
| July 1980-June1981 | Clinical Assistant | Medicine | Massachusetts General Hospital |
| July 1981-June 1985 | Assistant | Medicine | Massachusetts General Hospital |
| July 1985-June 1989 | Assistant Physician | Medicine | Massachusetts General Hospital |
| July 1990-June 1996 | Associate Physician | Medicine | Massachusetts General Hospital |
| July 1997-June 2009 | Physician | Medicine | Massachusetts General Hospital |
| July 2002- | Physician | Medicine | Brigham and Women’s Hospital |
| July 2009- | Consultant | Medicine | Massachusetts General Hospital |

Other Professional Positions

|  |  |  |
| --- | --- | --- |
| Year(s) | Position Title | Institution |

|  |  |  |
| --- | --- | --- |
| 1986-1987 | National Advisor | Artificial Heart Program of the Humana Heart Institute |
| 1987-1989 | Panel of Advisors | Merck Sharp and Dohme Research Laboratories |
| 1988-1989 | Consultant-Member | National Kidney and Urologic Diseases Advisory Board, National Institutes of Health |
| 1988-1989 | Advisor | Division of Kidney, Urological and Hematological Diseases, NIDDK, NIH, regarding Manpower and Training |
| 1992-2001 | Scientific Advisory Board | Geltex Pharmaceuticals Corp. (Charter member) |
| 1992 | Chairman of session: Membrane Activating and Transduction Mechanisms in Renal Vascular Cells | FASEB Conference |
| 1993 | Program Chairman | International Society for Renal Biochemistry |
| 1993- | Medical Advisory Board | MA, RI, NH and Vermont Chapter of the National Kidney Foundation |
| 1994 | Urodilatin Project Advisory Group | Boehringer Mannheim Corp. |
| 1994 | Co-Chair, Symposium on “Gene expression in ischemia: Role in cell death and cell protection” | 19th Princeton Stroke Conference, Boston MA |
| 1994-2002 | Consultant | Biogen Corp. |
| 1995-1998 | Consultant | Creative Biomolecules Inc. |
| 1995- | External Advisory Committee | Vanderbilt U. Cytochrome P450 Program Project Grant |
| 1996 | Consultant | Pfizer Pharmaceuticals |
| 1996 | Advisor to Director | Cornell University Bioengineering Program |
| 1996-2002 | Scientific Advisory Board | Theravance (Charter member) |
| 1996-1998 | Scientific Advisory Board | SAMTex Corp. (Charter member) |
| 1997-2004 | Co-Founder, Chairman of Medical Advisory Board, and member of Board of Directors | PatientKeeper, Inc (formerly VirtMed Corp.) |
| 1997-2000 | President | National Kidney Foundation of MA, NH and RI |
| 1997-2000 | Chairman, Medical Advisory Board | National Kidney Foundation of MA, NH and RI |
| 1997- | Board of Directors | National Kidney Foundation of Massachusetts, Rhode Island, New Hampshire and Vermont |
| 1997 | Organizing Chair | NIH Conference on Acute Renal Failure, Washington DC |
| 1998 | Co-Chair | NIH-ASN Acute Renal Failure Review Group |
| 1998-2017 | National Medical and Scientific Advisory Board | National Kidney Foundation |
| 1998-2001 | Advisor | Partners-Genzyme Consortium |
| 1998-2010 | RenaGel Physician Advisory Board | Genzyme Corp. |
| 1998-2010 | Consultant | Genzyme |
| 1999 | Physician Advisory Board | Hoechst Marion Roussel, Inc |
| 1999-2000 | Board of Directors | National Space Biology Research Institute, Nominating Committee member |
| 2000 | Organizing Committee | NIH Conference on a Clinical Trial Network for Acute Renal Failure |
| 2000 | Co-PI | NSF funded consortium on Bioengineering Education. Consortium includes HST, U of Texas at Austen, Vanderbilt U, and Northwestern |
| 2000-2001 | Consultant | Millennium Pharmaceuticals |
| 2001-2008 | Scientific Advisory Board | Actuality Systems, Inc (Charter member) |
| 2001-2004 | Scientific Advisory Board | SurfaceLogix, Inc (Charter member) |
| 2002 | Leader of focus group on Animal Models of ARF | Acute Dialysis Quality Initiative, Vicenza, Italy |
| 2002-2007 | Scientific Advisory Committee | MIT Laser Biomedical Research Center |
| 2002-2009 | Scientific Advisory Committee | National Resource for Imaging Mass Spectrometry |
| 2002 | Chair | ASN-NKF Task Force on Collaborative Research Initiatives |
| 2003-2011 | Co-founder and Member of Scientific Advisory Board | Pacific Biosciences |
| 2004- | Board of Advisors | Cornell University School of Engineering |
| 2005 | Consultant | Fibrogen |
| 2005-2006 | Consultant | RenaMed Biologics |
| 2006 | Consultant | Astrazeneca |
| 2006 | Consultant | Isis Pharmaceuticals |
| 2006 | Consultant | Merck & Co., Inc. |
| 2006 | Organizing Chair, Session on Prevention of Acute Renal Failure | Nephroprevention Conference, Toronto, Canada |
| 2006-2007 | Consultant | Roche Palo Alto LLC |
| 2007 | Consultant | PTC Therapeutics |
| 2007-2012 | Consultant | Sanofi Aventis |
| 2007 | Consultant | Gene Logic |
| 2007 | Consultant | Kai Pharmaceuticals |
| 2007-2017 | Consultant | Eli Lilly and Company |
| 2007-2010 | Scientific Advisory Board | CorMedix |
| 2008-2010 | Consultant | Dutch Kidney Foundation on Future of Biomedical Scientific Research |
| 2008-2011 | Consultant | Johnson & Johnson Research and Development |
| 2008-2013 | Board of Directors | AMAG, Inc. |
| 2009 | Consultant | Akesis Pharmaceuticals |
| 2009 | Renal Safety Biomarkers Project Team | The Biomarkers Consortium, NIH |
| 2010 | Research Advisory Committee | Brigham and Women’s Hospital |
| 2011 | Scientific Advisory Board | Dicerna |
| 2011 | Scientific Advisory Board | Celgene |
| 2011-2012 | Consultant | Millennium Pharmaceuticals |
| 2012 | BioRepository Expert Panel | NIH |
| 2012 | Consultant | Dicerna |
| 2012-2014 | Consultant | Sanofi |
| 2013-2014 | Consultant | Adventrx |
| 2013-2016 | Consultant | Astellas |
| 2013-2017 | Consultant | UCB Celltech |
| 2013-2017 | Consultant | Keryx |
| 2013-2018 | Consultant | Abbvie |
| 2013-2020 | Consultant | DXNow |
| 2013- | Consultant | Pharmaco-Kinesis |
| 2014 | Consultant | Thrasos |
| 2014 | Consultant | Concert Pharma |
| 2014-2015 | Consultant | Medivation |
| 2014-2019 | Consultant | PTC Therapeutics |
| 2015 | Consultant | Astrazeneca |
| 2015 | Consultant | Amgen |
| 2015 | Consultant | CamCo |
| 2015 | Consultant | Mast Therapeutics |
| 2015 | Consultant | Relypsa |
| 2015-2016 | Consultant | Pfizer |
| 2015-2017 | Consultant | Takeda |
| 2015-2017 | Consultant | Celgene |
| 2015-2017 | Consultant | Portola |
| 2015-2017 | Consultant | Cerespir |
| 2016-2018 | Advisory Council Member | National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health |
| 2017 | Consultant | Akashi |
| 2017 | Consultant | Merck and Co |
| 2017 | Consultant | Amicus |
| 2017 | Consultant | Catabasis |
| 2017 | Consultant | Eloxx |
| 2017 | Consultant | Mitobridge |
| 2017 | Consultant | Renalco |
| 2017- | Consultant | Biomarin Pharma |
| 2017- | Founder, Consultant | Goldfinch Bio |
| 2018 | Consultant | ECB Celltech |
| 2018 | Consultant | Eleven Biosciences |
| 2018- | Board of Advisors | Medssenger |
| 2018- | Consultant | Rubius Therapeutics |
| 2019- | Consultant | Goldilocks Therapeutics |
| 2019- | Consultant | Aldeyra Therapeutics |
| 2019- | Scientific Advisory Board | Angion Bio |
| 2019- | Steering Committee | ASN/FDA Kidney Health Initiative |
| 2019- | Consultant | Medibeacon |
| 2019- | Consultant | Pacific Biosciences |
| 2019- | Scientific Advisory Board | Sentien |
| 2019- | Consultant | Southern Medical University, Guangzhou |
| 2020- | Consultant | Cadent |
| 2020- | Consultant | Praxis |
| 2020- | Founder, Owner | Verinano |

Major Administrative Leadership Positions

Local

|  |  |  |
| --- | --- | --- |
| Year(s) | Position Title | Institution (note if specific department) |

|  |  |  |
| --- | --- | --- |
| 1979-1986 | Organize Renal Grand Rounds and Journal Club | Massachusetts General Hospital |
| 1980-1986 | Conference leader and lecturer in Renal Pathophysiology | Harvard Medical School |
| 1981 | Co-Director, lecturer (6-7 lectures) and section leader, Renal preparation Pathophysiology Course | Harvard-MIT Program in Health Sciences and Technology (HST) |
| 1992-1997 | Harvard-MIT Health Sciences and Technology Society | Harvard Medical School |
| 1992-1997 | Director of Student Affairs | Harvard-MIT Division of Health Sciences |
| 1992-1997 | Associate Director | Harvard-MIT Division of Health Sciences and Technology |
| 1997-2007 | Co-Director | Harvard-MIT Division of Health Sciences and Technology |
| 1998-2007 | Director | Harvard-MIT Division of Health Sciences and Technology |
| 1998-2007 | Master, Health Sciences and Technology Society | Harvard Medical School |
| 2007-2009 | Co-Director, BWH-BRI Technology in Medicine Initiative | Brigham and Women’s Hospital |
| 2007-2009 | BWH Co-Director, Center for Integration of Medicine and Innovative Technology (CIMIT) | Brigham and Women’s Hospital |
| 2002- | Chief, Renal Division | Brigham and Women’s Hospital |
| 2002- | Chief, Biomedical Division of Engineering in Medicine | Brigham and Women’s Hospital |

Committee Service

Local

|  |  |  |
| --- | --- | --- |
| Year(s) of  Membership | Name of Committee | Institution/Organization |
| Dates of Role(s) | Title of Role(s) |

|  |  |  |
| --- | --- | --- |
| 1986-1994 | Board of Advisors Standing Committee | Harvard Medical School |
| 1992-1998 | Council for Student Affairs, member | Harvard Medical School |
| 1992-1996 | Co-Chairman, HST MD Curriculum Committee | Harvard Medical School |
| 1992-2007 | Thesis Honors Selection Committee, member | Harvard-MIT Division of Health Sciences and Technology |
| 1993-1996 | Chairman, Committee to Design and Implement New PhD Program in Biological Engineering and Biological Physics | Harvard and MIT |
| 1994 | Selection Advisory Committee, Associate Dean for Information | Harvard Medical School |
| 1994-1996 | Steering Committee, Integrated Student Information System | Harvard Medical School |
| 1994-1995 | Curriculum Review Committee | Harvard-MIT Division of Health Sciences and Technology |
| 1994-1995 | Self Study Committee | Harvard Medical School |
| 1994-1995 | Self-Study Subcommittee on Medical Students in preparation for Liaison Committee on Medical Education | Harvard Medical School |
| 1995-2006 | Medical Engineering and Medical Physics Admission Committee | Harvard-MIT Division of Health Sciences and Technology |
| 1995-1997 | Faculty Advisory Board | Harvard Medical School Business Association |
| 1995 | PhD Thesis Review Committee member for H. McNamee, Cell and Developmental Biology Program, Division of Medical Sciences | Harvard Medical School |
| 1995 | Committee on Years 3 and 4 | Harvard Medical School |
| 1995-2007 | HMS Academic Societies Promotion and Review Board | Harvard Medical School |
| 1995-2007 | Faculty Standing Committee, Harvard MD-PhD Program | Harvard University |
| 1995-1996 | Ad hoc reviewer, Clinical Nutrition Research Center at Harvard Pilot Feasibility studies | Harvard University |
| 1996-2007 | Chairman, HST MD Curriculum Committee | Harvard-MIT Division of Health Sciences |
| 1997-2007 | Co-Chair, Harvard-MIT HST Joint Faculty Committee | Harvard-MIT Division of Health Sciences |
| 1997-2007 | Personnel Committee | Harvard-MIT Division of Health Sciences |
| 1998- | Co-Chair, Joint Faculty Committee | Harvard-MIT Division of Health Sciences |
| 1997-1998 | Search Committee to select Dean of Admissions | Harvard Medical School |
| 1998-2007 | Committee of Masters | Harvard Medical School |
| 1998- | Committee of Professors | Harvard Medical School |
| 1998-2000 | MD/PhD Review Committee | Harvard Medical School |
| 1998-2001 | Lemelson Award Committee | MIT |
| 1998-2002 | Council of Administrative Deans | Harvard Medical School |
| 1998 | Chair, Ad Hoc Promotion Committee | Harvard Medical School |
| 1998-2001 | Committee on Medicine Clerkships | Harvard Medical School |
| 1999 | Edgerly Grant Review Committee | MIT |
| 1999 | Committee to Revise Pre-Medical Advising | MIT |
| 1999 | Committee to Review MD-PhD Program | Harvard Medical School |
| 1999 | Search Committee, Director MD-PhD Program | Harvard Medical School |
| 1999 | Committee to select the 2000 Lemelson-MIT Invention Apprenticeship winner | MIT |
| 1999 | Committee on Professionalism | Harvard Medical School |
| 2000 | Chair, Search Committee for Martinos Chair and Director of the Martinos Imaging Center | MIT, MGH and Harvard |
| 2000-2003 | Council for Health Sciences | MIT |
| 2000-2003 | Steering Committee, Harvard-MIT MD PhD Program | Harvard and MIT |
| 2001-2002 | Future Research Directions Planning Task Force | MGH |
| 2002 | Search Committee for Chief of Pediatric Nephrology | MGH |
| 2002 | Liaison Committee on Medical Education | Harvard Medical School |
| 2002- | Member, The Academy of Harvard Medical School | Harvard Medical School |
| 2002-2007 | Steering Committee, The Academy of Harvard Medical School | Harvard Medical School |
| 2002-2003 | Chair, Harvard Medical School Strategic Planning Committee on Biomedical Informatics and Computational Biology | Harvard Medical School |
| 2002-2005 | Council for Educational Policy | Harvard Medical School |
| 2002-2007 | Program in Medical Education Executive Committee | Harvard Medical School |
| 2002- | Steering Committee, Biomedical Enterprise Program | HST/MIT |
| 2003-2004 | Search Committee, Faculty Dean for Admissions | Harvard Medical School |
| 2003-2004 | Steering Committee, Committee for Educational Reform | Harvard Medical School |
| 2005 | Academy at Harvard Medical School Faculty Awards Selection Committee for the AY05 HMS Excellence in Teaching Awards | Harvard Medical School |
| 2005 | Ad Hoc Committee, Promotion Review Committee | Harvard Medical School |
| 2005-2006 | Executive Committee, Center for Biomedical Innovation | MIT |
| 2006 | Ad Hoc Search Committee, Professor of Medicine | HST/MIT |
| 2005-2007 | Curriculum Committee | Harvard Medical School |
| 2006 | Ad Hoc Search Committee, Professor of Medicine, Genetics Division | Brigham and Women’s Hospital |
| 2006 | In-Depth Concentrations Design Group | Harvard Medical School |
| 2006-2010 | Leader, Kidney Disease Program | Harvard Stem Cell Institute |
| 2007- | Milton Fund Committee | Harvard Medical School |
| 2009 | Ad Hoc Search Committee, Professor of Pathology | Harvard Medical School |
| 2009-2012 | Nephrology Chief Search Committee | Children’s Hospital Boston |
| 2016- | Executive Committee, Harvard Stem Cell Institute | Harvard University |
|  |  |  |

Professional Societies

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1980- | | | American Society of Nephrology | | |
| 1986, 1987 | | Chairman of workshops on the “Measurement of Intracellular Free Calcium Concentration” at the Annual Meetings of the American Society of Nephrology (ASN), Washington, DC | | |
| 1988 | | Chairman of Symposium: “Regulation of Intracellular Ca2+”. 21st Meeting of the American Society of Nephrology, San Antonio, Texas | | |
| 1990 | | Course Organizer: Receptors, Post-Receptor Events and Signalling. Am. Soc. Nephrology Workshop, Washington, D.C. | | |
| 1996-1998 | | American Society of Nephrology Young Investigator Award Committee | | |
| 1997 | | Co-Chair, American Society of Nephrology Basic Science Meeting on Mechanisms of Injury and Repair | | |
| 1998 | | Co-Chair, NIH-ASN Acute Renal Failure Review Group | | |
| 1998-2006 | | ASN representative to Program Committee of Annual Meeting of Continuous Renal Replacement Therapies | | |
| 2000 | | Program Committee, American Society of Nephrology | | |
| 2001-2005 | | Clinical Science Committee, American Society of Nephrology | | |
| 2001 | | Council Nominating Committee, American Society of Nephrology | | |
| 2002-2003 | | Chair, ASN-NKF Task Force on collaborative research initiatives | | |
| 2005 | | Acute Kidney Injury Clinical Initiative of the American Society of Nephrology | | |
| 2006-2012 | | Member, Council of the American Society of Nephrology | | |
| 2009-2012 | | Finance Committee, American Society of Nephrology | | |
| 2010-2011 | | President, President Elect, Past President, American Society of Nephrology | | |
| Year(s) of  Membership | | Society Name | |  |
| Dates of Role(s) | Title of Role(s) | |

|  |  |  |
| --- | --- | --- |
| 1980- | | International Society of Nephrology |
| 1994-2006 | Member, International Commission on Acute Renal Failure of the International Society of Nephrology |
| 1995-1997 | North American and European Representative to Program Committee for Acute Renal Failure theme, Meeting of the International Society of Nephrology, Sydney, Australia, 1997 |
| 1995 | Co-Chair, Satellite Symposium of International Society of Nephrology on Acute Renal Failure, Cairns, Australia |
| 1998-1999 | Program Committee for Acute Renal Failure theme, International Society of Nephrology, Buenos Aires, Argentina |
| 1998-1999 | Organizing Committee, Satellite Meeting on Acute Renal Failure Santiago, Chile |
| 1995 | Chairman of Symposium on Growth Factors and Recovery from Acute Renal Failure, Int. Congress of Nephrology, Madrid, Spain |
| 1997 | Organizer, Acute Renal Failure theme, International Congress of Nephrology, Sydney, Australia: *“Acute Renal Failure, integrins and adhesion molecules”* |
| 1999 | Co-Chair, Acute Renal Failure theme, International Congress of Nephrology, Buenos Aires, Argentina |
| 1999 | Organizing Committee, Acute Renal Failure satellite symposium, Santiago, Chile |
| 2002 | Organizer, ISN Forefronts in Nephrology, Post Graduate Course, Antwerp, Belgium: *Genomics of Acute Renal Failure* |
| 2005 | Organizing Committee, 18th Congress of the International Society of Nephrology, Singapore |
| 2005 | Organizing Committee, Satellite Symposium on Acute Renal Failure, Penang, Malaysia |
| 2005 | Chairman of Symposium, “Issues in Clinical Nephrology: Acute Renal Failure”. 18th Congress of the International Society of Nephrology, Singapore |
| 2005 | Co-chair of the Symposium “Early Diagnostic Modalities in ARF”, Satellite Symposium on Acute Renal Failure, Penang, Malaysia |
| 2007 | Co-chair, Satellite Meeting on Acute Kidney Injury, International Society of Nephrology, Bahia, Brazil |
| 1982- | | American Federation for Clinical Research |
|  |  |
| 1982- | | New York Academy of Sciences |
|  |  |
| 1982- | | Salt and Water Club |

|  |  |  |  |
| --- | --- | --- | --- |
| 1983- | | American Physiological Society | |
|  | |  | |
| 1985- | | American Heart Association, Kidney Council | |
|  | |  | |
| 1987-1997 | | American Society of Renal Biochemistry and Metabolism | |
| 1993 | | Program Chair, Am. Soc. Of Renal Biochemistry and Metabolism | |
|  | |  | |
| 1987- | | American Society for Clinical Investigation | |
|  | |  | |
| 1980- | | American Association for the Advancement of Science | |
|  | |  | |
| 1991-1995 | | American Society for Biochemistry and Molecular Biology | |
|  | |  | |
| 1993- | | Association of American Physicians | |
|  | |  | |
| 1998- | | American Institute for Medical and Biological Engineering | |
| 1998 | | Education Subcommittee of the American Institute for Medical and Biological Engineering Fellows Selection Committee | |
| 2007- | | Association of Specialty Professors | |
| 2012- | | American Clinical and Climatological Association | |
|  | | Council Member | |

Grant Review Activities

|  |  |  |
| --- | --- | --- |
| Year(s) of  Membership | Name of Committee | Institution/Organization |
| Dates of Role(s) | Title of Role(s) |

|  |  |  |
| --- | --- | --- |
| 1984-1989 | Special Study Sections | NIH |
|  | Reviewer |  |
| 1986-1987 | New England Regional Research Review Board | AHA |
| 1987 | Young Investigator Award Review Committee | NKF |
| 1988-1991 | National Renal Research Review Board | AHA |
| 1991 | National Renal Research Review Board | AHA |
|  | Co-Chairman |  |
| 1992 | Pathology A Study Section, | NIH |
|  |  | Ad Hoc Member |
| 1992 | National Research Review Board, American Heart Association | AHA |
| 1993 | Research and Fellowship Grant Committee, | NKF of Michigan |
| 1993 | Review Board, Clinician Scientist Award | NKF |
| 1993 | NIH Study Section, Barnes Hospital Clinical Research Center Application | NIH |
| 1993-1994 | Study Section, Case Western Reserve Program Project Application | NIH |
| 1993-2000 | Research Board | Veterans Administration |
|  |  | External Reviewer |
| 1991-1998 | Review Board | Kidney Foundation of Canada |
|  |  | External Reviewer |
| 1993-1994 | Reviewer | Human Frontier Science Program |
| 1992- | D Study Section | NIDDK |
| 1992-1995 | Research Review Board | Massachusetts Chapter of AHA |
| 1993-1996 | Shankman, Murray and Volunteer/Donor Grant Review Committee, | Massachusetts Chapter of the NKF |
|  | Chairman |  |
| 1995 | Review Board | Israel Science Foundation |
|  |  | External Reviewer |
| 1995-1996 | Site Visit Review Committee for Program Project application: Molecular Therapy for Renal Disease | Mt. Sinai School of Medicine |
|  | Chairman |  |
| 1996 | Review Board | Belgian National Fund for Scientific Research |
|  |  | External Reviewer |
| 1996 | Teleconference review | NIDDK |
|  |  | Ad Hoc Reviewer |
| 1997 | D Study Section, Ad Hoc teleconference review | NIDDK |
|  | Chair |  |
|  | PhD Examiner | University of Antwerp, Belgium |
| 1997-2001 | General Medicine B Study Section | NIH |
|  |  | Charter Member |
| 2001 | Review Board | Council for Medical and Health Research, The Netherlands |
|  |  | Ad Hoc reviewer |
| 2001 | O’Brien Center Study Section Review | NIH |
| 2001 | Research Grant Review | Netherlands Organization for Health |
| 2001 | Special Emphasis Study Section | NIH |
| 2002 | Renal and Urological Sciences Study Section | NIH |
|  | Boundary Team |  |
| 2004 | GRIP Grant Review Committee | Genzyme Corporation |
| 2005 | Ad Hoc Special Emphasis Panel P30 PKD Core Centers Review | NIH |
|  | Chairman |  |
| 2006 | NIH National Institute of Dental and Craniofacial Research Special Emphasis Panel | NIH |
|  | Chairman |  |
| 2006 | Ad Hoc PBKD Grant Review | NIH |
| 2007 | Special Emphasis Panel Teleconference Review | NIDDK |
| 2009 | Special Emphasis Panel | NIDDK |
|  | Chair |  |
| 2009  2009 | Ad Hoc Challenge Grant Review  ASN Council Leadership Representative  to ASN Grants Review Committee | NIH  ASN |
| 2009 | Harvard Catalyst Grant Review Board | Harvard University |
| 2010 | Director’s Grant Review Board | NIH |
| 2012 | BioRepository Expert Panel | NIH |
| 2012 | Review Committee, BRI Translatable Technologies & Care Innovation RFA | Biomedical Research Institute  Brigham and Women’s Hospital |
| 2013 | Transformative Grants Study Section | NIH |
| 2014 | External Panel Review, ASSESS-AKI | NIH |
| 2015 | Peer Reviewer | Kidney Research UK |
| 2015 | Consortium Grant review | Dutch Kidney Foundation |
| 2016 | Department of Defense DOD CDMRP Panel | US Department of Defense |
| 2016 | External Panel Review for ASSESS-AKI | NIDDK |
| 2017 | External Panel Review for ASSESS-AKI | NIDDK |
| 2018 | Consortium Grant review | Dutch Kidney Foundation |
| 2018 | Peer Review Panel | Wellcome Trust |
| 2018 | Peer Review Panel | Academy of Medical Sciences |
| 2018 | Esternal Reviewer | Israel Science Foundation |
| 2019 | Queen's Pilot Research Seed Grant Review Panel | Queen’s Medical Hospital, Hawaii |
| 2019 | Department of Defense DOD CDMRP Panel | US Department of Defense |
| 2020 | Grant Review Panel | The Netherlands Organisation for Health Research and Development |

Editorial Activities

|  |
| --- |
| Journals for which you serve as a reviewer |

|  |
| --- |
| American Journal of Physiology: Regulatory, Integrative and Comparative Physiology |
| American Journal of Physiology: Renal Physiology |
| Clinical Journal of American Society of Nephrology |
| Clinical Pharmacology and Therapeutics |
| Critical Care Medicine |
| Journal of American Society of Nephrology |
| Journal of Clinical Investigation |
| Kidney International |
| Laboratory Investigation |
| Nephrology Dialysis Transplantation |
| New England Journal of Medicine |

Other Editorial Roles

|  |  |  |
| --- | --- | --- |
| Year(s) | Role | Journal Name |

|  |  |  |
| --- | --- | --- |
| 1987-1989 | Editorial Board | American Journal of Physiology: Renal Fluid and Electrolyte |
| 1989-1995 | Associate Editor | American Journal of Physiology: Renal Fluid and Electrolyte) |
| 1998- | Board of Consulting Editors | Journal of Clinical Investigation |
| 1998- | Editorial Review Board, | American Journal of Physiology: Renal |
| 2000-2015 | Associate Editor | Cell and Tissue Research |
| 2002- | Editorial Board | The Netherlands Journal of Medicine |
| 2002- | Editorial Board | American Journal of Physiology-Renal |
| 2003- | Editorial Board | Kidney International |
| 2005- | Editorial Board | Journal of the American Society of Nephrology |
| 2006- | Editor | Seminars in Nephrology |
| 2006- | Editorial Board | Clinical Translational Science |
| 2007- | Editorial Advisory Board | American Journal of Kidney Diseases |
| 2012 | Co-Guest Editor | Seminars in Nephrology: Progressive Nephropathy in Type 1 Diabetes – Detection and Therapeutic Targets |
| 2019- | Editorial Board | Journal of Renal Nutrition |

Honors and Prizes

|  |  |  |  |
| --- | --- | --- | --- |
| Year | Name of Honor/Prize | Awarding Organization | Achievement for which awarded  (if unclear from award title) |

|  |  |  |  |
| --- | --- | --- | --- |
| 1966-1970 | Chubb and Son Scholarship |  |  |
| 1966-1970 | New York State Regents Scholarship |  |  |
| 1966-1970 | Cornell Engineering Scholarship |  |  |
| 1969 | Phi Kappa Phi |  |  |
| 1969 | Tau Beta Pi (National Engineering Honor Society), Elected Junior of College |  |  |
| 1973 | Golden Eagle Award | Council of International Nontheatrical Events | Beeuwkes R, **Bonventre JV**, Miller ED and Barger AC. The Vascular and tubular organization of the kidney |
| 1973 | Silver Badge of the Italian Association of Scientific Cinematography | 7th International Exhibition of Scientific and Educational Films, Padua | Beeuwkes R, **Bonventre JV**, Miller ED and Barger AC. The Vascular and tubular organization of the kidney |
| 1975 | Presidents Award of the Microbeam Society |  |  |
| 1976 | Alpha Omega Alpha |  |  |
| 1978-1979 | National Kidney Foundation Fellowship |  |  |
| 1980-1983 | New Investigator Research Award | National Institutes of Health |  |
| 1987 | Member | American Society for Clinical Investigation |  |
| 1987-1992 | Established Investigator | American Heart Association |  |
| 1993 | Member | Associate of American Physicians |  |
| 1993-2001 | MERIT Award | NIDDK-NIH |  |
| 1994 | Eckel Visiting Professorship | Case Western Reserve University |  |
| 1997 | Fellow | American Institute for Medical and Biological Engineering |  |
| 1999 | Honorary Doctor of Humane Letters | Mt. Saint Mary College, Newburgh NY |  |
| 2000 | Keynote speaker | Second Latin American Conference on Acute Renal Failure |  |
| 2001 | Outstanding Physician Award | National Kidney Foundation of MA, RI, NH and Vermont |  |
| 2001 | Honorary Doctor of Humane Letters | Norwegian Technical and Natural Sciences University, Trondheim, Norway |  |
| 2001 | Edward Everett Anderson Visiting Professorship/  Whitney Lecture | University of Arkansas for Medical Sciences |  |
| 2001 | Keynote Speaker | 12th Congress of the International Pediatric Nephrology Association |  |
| 2001 | Honorary Doctorate | Norwegian University of Science and Technology |  |
| 2002 | Osler Award and Oration | Royal Society of Physicians, London |  |
|  |  |  |  |
| 2003 | Public Policy Award | National Kidney Foundation |  |
| 2003 | Kline Memorial Lecture | Northwestern University School of Medicine |  |
| 2007 | Bywaters Award | International Society of Nephrology |  |
| 2007 | Rapoport Visiting Professorship | University of Toronto |  |
| 2008 | Keynote Presenter | Korean Society of Nephrology Annual Meeting |  |
| 2008 | Plenary Lecture | Latin American Congress on Acute Renal Failure |  |
| 2009 | Rogosin Institute Annual Professorship | Weill Cornell Medical College |  |
| 2010 | Keynote Address | World Pharmaceutical Congress |  |
| 2010 | Plenary Lecture | XXV Meeting of the Brazilian Society of Nephrology |  |
| 2010 | Keynote Lecture | 3rd International Symposium on Molecular Targets in Renal Disease |  |
| 2010 | Distinguished Lecture | 31st Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics |  |
| 2011 - | MERIT Award | NIH/NIDDK |  |
| 2011 | Roscoe Robinson Visiting Professorship | Duke University |  |
| 2011 | Kleeman Visiting Professorship | Harbor/UCLA Medical Center |  |
| 2012 | Phillip C. Liverman Visiting Professorship | University of Virginia |  |
| 2012 | Opening Plenary Lecture | Brazilian Congress of Nephrology |  |
| 2013 | Plenary Lecture | Jahrestagung der Deutschen Gesellschaft für Nephrologie |  |
| 2013 | Magisterial Lecture | Annual Meeting of the Puerto Rican Society of Nephrology |  |
| 2013 | Keynote speaker | Annual Acute Kidney Injury Symposium, University of Pittsburgh |  |
| 2014 | Charles D. Swartz, M.D. Memorial Lecturer | Drexel University College of Medicine |  |
| 2015 | Vanderbilt Harrison Society Lecturer | Vanderbilt University |  |
| 2015 | Keynote Lecture | 45th Eastern Regional Meeting of the Japanese Society of Nephrology |  |
| 2016 | Keynote Speaker | MUC1 Kidney Team Annual Retreat, Broad Institute |  |
| 2016 | Chan Woo Cheung Visiting Professorship | Hong Kong Society of Nephrology Annual Scientific Meeting |  |
| 2016 | Cade Visiting Professor | University of Florida |  |
| 2017 | Cuneo Richardson Lecture | University of Miami |  |
| 2017 | Keynote Speaker | Takeda Safety Biomarker Symposium |  |
| 2018 | Keynote Speaker | Graduate School of Biomedical Science and Engineering Annual Meeting  Univeristy of Maine |  |
| 2018 | Plenary Lecture | 16th Asian Pacific Congress of Nephrology and 2018 Annual Congress of the Chinese Society of Nephrology |  |
| 2018 | Keynote Presentation | Third Annual iPS Cells for Disease Modeling and Drug DiscoveryWorld Preclinical Congress  Boston, MA |  |
| 2018 | Sullivan Lecture | University of Kansas |  |
| 2019 | Plenary Lecture | XLVII IMIN Update in Nephrology Course, Mexico City |  |
| 2019 | 32nd Annual  Conrad L. Pirani Lectureship | Columbia University College of Physicians and Surgeons, NY, NY |  |
| 2019 | Keynote Speaker | FASEB Acute Kidney Injury Science Research Conference, Pacific Grove, CA |  |
| 2019 | Keynote Speaker | APS 9th Annual International Conference of Aldosterone and ENaC in Health and Disease: The Kidney and Beyond, Estes Park, Colorado |  |
| 2019 | William E. Mitch Lecture in Nephrology | Emory University School of Medicine |  |

**Report of Funded and Unfunded Projects**

Funding Information

Past

|  |  |
| --- | --- |
| Grant title | Grant title |
| Grant type and number |
| Role on Project (if PI or site PI, total indirect costs) |
| Description of the major goals |

|  |  |
| --- | --- |
| 1980-1981 | Microprobe Study of Renal Concentration |
|  | NIH Individual National Research Service Award |
|  | PI |
| 1981-1983 | Microprobe Study of Renal Tissue and Isolated Cells |
|  | NIH New Investigator Award |
|  | PI |
| 1981-1983 | Project 2: Electron Microprobe Study of Renal Concentration |
|  | NIH Program Project Grant – Cardio-renal Function and Ischemic Injury |
|  | PI |
| 1981-1983 | Project 1: Protection of Kidney and Heart from Anoxic and Toxic Injury |
|  | NIH Program Project Grant – Cardio-renal Function and Ischemic Injury |
|  | Co-PI |
| 1981-2001 | Training in Cell Structure and Function in Nephrology |
|  | NIH |
|  | PI |
| 1984-1987 | Nucleotides in Anoxic and Ischemic Cell Injury |
|  | NIH |
|  | PI |
| 1986-1987 | Prevention and Treatment of Glomerular Disease with n-3 Fatty Acids |
|  | USA Corp. |
|  | PI |
| 1986-1989 | Electron Probe Analysis of Renal Concentration Mechanism |
|  | NIH |
|  | Co-PI |
| 1987-1992 | Pathophysiology of Acute Renal Failure |
|  | AHA Established Investigator Award |
|  | PI |
| 1987-1992 | O’Brien Kidney Center |
|  | Harvard University |
|  | PI |
| 1989-1990 | Mechanism of Disease Prevention of n-3 Fatty Acids |
|  | NIH |
|  | Co-PI |
|  | Berthold Linear Radioactivity Analyzer |
|  | MGH BRSG |
|  | PI |
| 1989-2004 | Interdepartmental Stroke Program |
|  | MGH |
|  | Co-PI |
| 1991-1993 | Arachidonic Acid Metabolites as Intracellular Mediators of Mesangial Cell Signal Transduction |
|  | Saerle |
|  | PI |
| 1993-2003 | Molecular Mediators of Diabetic Renal Hypertrophy |
|  | NIH |
|  | Co-PI |
| 1995-1999 | Osteogenic Protein-1 in Recovery from Acute Renal Failure |
|  | Creative Biomolecules |
|  | PI |
| 1995-1999 | Identification of Molecules Which Potentiate the Recovery of Kidney From Acute Renal Failure and Regeneration of Functional Nephrons |
|  | Biogen |
|  | PI |
| 1996 | Conference – ARF in the 21st Century |
|  | NIH |
|  | PI |
| 1997-1999 | Study of the possible role of an LTB4 antagonist to protect the mouse kidney against ischemic acute renal failure |
|  | Pfizer |
|  | PI |
| 1993-2003 | Molecular Mediators of Diabetic Renal Hypertrophy |
|  | NIH |
|  | Co-PI |
| 2000-2004 | Biochemical Toxicology and Molecular Stress Response |
|  | NIH |
|  | Co-PI |
| 2001 | ACE2 Antagonist Study |
|  | Millennium Pharmaceuticals |
|  | PI |
| 1987-2007 | Cellular Biology of Renal Function |
|  | NIH Program Project Grant |
|  | PI |
| 2004-2005 | KIM-1 as a Urine Marker for Nephrotoxicity |
|  | Schering-Plough |
|  | PI |
| 1987-2007 | Phospholipase A2 and Signal Transduction |
|  | NIH 5 PO1 DK38452- NIH/NIDDK |
|  | Project PI |
|  | Specific Aim 1: To determine the roles of PLIP-1 and PLIP-2 in the regulation and nuclear translocation of cPLA2. Specific Aim 2: To determine the role of cPLA2 interacting proteins in signal transduction effector pathways of growth factors and TNFβ |
| 1997-2007 | Engineering Research Center in Bioengineering Education |
|  | NSF |
|  | Co-PI |
| 09/30/05-08/31/07 | Harvard Center of Polycystic Kidney Disease Research |
|  | 1 P50 DK74030-01 NIH/NIDDK |
|  | Pilot and Feasibility Project PI |
|  | Specific Aims: To determine the role of Kim-1 in polycystin interactions with the E-cadherin/β-catenin system. To evaluate whether Kim-1 alters the expression of the cilia-associated proteins, athoph and cystin. To determine whether targeted overexpression of Kim-1 in the tubules of mice that are heterozygous for polycystin 1 (Pkd1+/-) undergo accelerated cyst formation and interstitial fibrosis compared to Pkd+/- mice that do not overexpress Kim-1 |
| 2005-2011 | Biomarkers in Acute Kidney Injury |
|  | 1R21/R33DK074099 NIH/NIDDK |
|  | PI ($354,884 R33 phase) |
|  | Specific Aims: For the R21 portion of this grant the specific aims are: 1) to establish the analytical capability to quantitatively analyze urine and serum for a number of biomarkers and identify the optimal methods for collecting, handling, and storing urine and serum samples; 2) using a cross sectional design, we will identify the one or more biomarkers that have the best test characteristics for differentiating between those individuals who do and do not have AKI. We will then identify sensitive and specific biomarkers for early stage of AKI; and construct disease state predictive models. In the R33 phase of this application, the Specific Aims are to determine whether 1) AKI is a common complication in patients undergoing coronary artery bypass grafting (CABG) and is an independent risk factor for mortality in CABG patients. 2) AKI is a common occurrence in critically ill patients admitted to the medical intensive care unit (MICU) and whether AKI is a powerful predictor of mortality in these patients. |
| 2005-2009 | Function of Omi/HtrA2 in Renal Tubular Cell Death |
|  | 2 R01 DK055734 NIH/NIDDK |
|  | Subcontract Co-PI ($24,714) |
| 2006-2009 | Harvard Stem Cell Institute Kidney Group |
|  | Harvard Stem Cell Institute |
|  | PI/PD ($78,750 Bonventre project) |
|  | Specific Aims: To define a stem cell population in the developing kidney. To focus on the use of animal models appropriate to understand the role of the stem cell in normal and abnormal repair of the kidney after injury. |
| 2009-2009 | Biomarkers of Acute Kidney Injury |
|  | Johnson and Johnson |
|  | PI ($379,275) |
|  | Specific Aim: To evaluate urinary biomarkers in patient undergoing CABG and patients in the MICU |
| 2011-2012 | Direct Reprogramming of Fibroblasts into Kidney Proximal Tubular Cells |
|  | Harvard Stem Cell Institute |
|  | PI/PD |
|  | Specific Aims: To reprogram fibroblasts into proximal tubule epithelial cells for patient-specific disease modeling, drug screening, tissue engineering. |
| 2009-2012 | Inducible Pluripotent Stem Cells and Kidney Regeneration |
|  | 1RC1 DK0864406-01 |
|  | PI ($313,966) |
|  | Specific Aims: The ultimate goal of the work is to develop a stepwise protocol for the differentiation of human iPS into renal progenitor cells. |
| 1999-2013 | Two novel cPLA2 binding proteins and cell death |
|  | 5RO1 DK054741-07 NIH/NIDDK |
|  | PI ($193,123) |
|  | Specific Aims: 1) To elucidate the mechanisms underlying the localization of Tip60, PLIP and SIRT2 and their interaction to cPLA2; 2) To determine the effects of these proteins on cell cycle regulation and whether these effects are functionally related to their interaction with cPLA2 and on cPLA2-dependent arachidonic acid release and PGE2 generation; and 3) To determine and elucidate the role of Tip60, PLIP, SIRT2 and cPLA2 in regulation of apoptosis following DNA damage. |
| 2007-2013 | SYSCODE Interdisciplinary Postdoctoral Training Grant |
|  | 1U54RR024358-01-NIH |
|  | Program Director ($494,643) |
|  | Specific Aims: To provide training at the intersection of multiple disciplines to better approach organ regeneration. Training is carried out in more than one laboratory. There are 4 positions the first year and 8 thereafter. |
| 2009-2013 | National Resource for Imaging Mass Spectrometry  (Claude Lechene, PI) |
|  | NIH/NIBIBP41 EB001974-09 |
|  | Co-PI |
|  | The major goal of this grant is to develop and use Multi-Isotope Imaging Mass Spectrometry (MIMS) to simultaneously image the distribution and measure the accumulation, at the intracellular level, of molecules labeled with stable isotopes. |
| 2013-2016 | Development of Antibody-based Therapeutics against Kidney Injury Molecule-1 (KIM-1) |
|  | NovoNordisk |
|  | PI ($643,454.00) |
|  | Specific Aim 1) To develop antibodies against KIM-1 to block KIM-1 mediated uptake of oxidized-low density lipoprotein (ox-LDL), advanced glycation end products (AGE’s) and other agents involved in the pathophysiology of diabetic nephropathy.  Specific Aim 2) To evaluate the reno-protective efficacy of the proposed therapeutic in rodent Type 1 and Type 2 diabetic nephropathy animal models |
| 2015-2018 | Predictors of progressive renal decline in Type 1 diabetes |
|  | 3-SRA-2015-106-Q-R Joslin Diabetes Center |
|  | Sub PI |
|  | Specific Aims: To perform measurements of concentration of candidate markers in baseline urines obtained in patients included in Joslin cohorts.  To analyze the results to develop a score of tubular damage that will be complementary/provide additional information to urinary albumin excretion rate in predicting risk of progressive renal decline and progression to ESRD. |
| 2016-2019 | Development of Antibody-based Therapeutics against Kidney Injury Molecule-1 (KIM-1) |
|  | PI ($572,652.00) |
|  | Boehringer-Ingelheim |
|  | Aims: To develop small molecule inhibitors against KIM-1 to block KIM-1 mediated uptake of oxidized-low density lipoprotein (ox-LDL), free fatty acids, advanced glycation end products (AGE’s) and other agents involved in the pathophysiology of chronic kidney disease. To evaluate the reno-protective efficacy of the proposed therapeutic in rodent models of chronic kidney disease.  Role: PI/PD |
| 2009-2020 | Urinary Biomarkers of Chronic Kidney Disease Pathology and Progression |
|  | 1U01 DK085660 |
|  | Co-PI ($1,419,885.00) |
|  | Specific Aims: To establish a validation site for urinary biomarkers of CKD draws from our experience with discovery and validation or tubular injury biomarkers in preclinical and clinical settings as well as interactions with the regulatory agencies. |

Current

|  |  |
| --- | --- |
| Grant title | Grant title |
| Grant type and number |
| Role on Project (if PI or site PI, total indirect costs) |
| Description of the major goals |
| 1984-2022 | Mechanisms of Ischemic Injury and Repair |
|  | R37 (DK39773)-NIH |
|  | PI ($1,601,138.00) |
|  | Specific Aim 1 (Repair). To define the roles of ATM and ATR in abnormal repair with cell cycle arrest, persistence of dedifferentiation and potentiation of inflammation and fibrosis after acute tubular injury. Specific Aim 2 (Injury). To define the role of sirtuin T2 (SIRT2) in the response to injury and to relate SIRT2 expression and activity to G2/M transition control and the profibrotic secretory phenotype. |
| 1985-2022 | Training Program in Academic Nephrology |
|  | 2 T32 DK007527 NIH/NIDDK |
|  | PI ($2,694,844.00) |
|  | Specific Aims: Brigham and Women’s Hospital academic training program in nephrology. Provides support for 8 postdoctoral fellows/yr. |
| 2005-2021 | Kidney Injury Molecule-1 in Epithelial Repair |
|  | 1RO1 DK072381 |
|  | PI ($1,028,180.00) |
|  | Specific Aim 1) To characterize how the phagocytic function of Kim-1 mediates an adaptive response that is protective of the kidney exposed to an acute injury to the proximal epithelium.  Specific Aim 2) To determine the role of KIM-1 interactions with apoptotic and necrotic cell surface calreticulin in modulation of the immunogenicity of cell death associated with acute kidney injury. |
| 2014-2024 | Harvard Summer Research Program in Kidney Medicine |
|  | 5R25DK101398-02 |
|  | PI ($470,701.00) |
|  | The Harvard Summer Research Program in Kidney Medicine (HSRPKM) will offer a robust and varied introduction to the world of nephrology for the undergraduate college student who is considering a career in science or medicine. The Program will span the nephrology divisions of four Harvard-affiliated hospitals – Brigham and Women’s Hospital (BWH), Beth Israel Deaconess Medical Center (BIDMC), Boston’s Children’s Hospital (BCH) andMassachusetts General Hospital (MGH). The Program runs for 8 weeks each summer and enrolls 14 students per session. |
| 2014-2024 | Organ Design and Engineering Training Program (ODET Program) |
|  | T32EB016652-NIH |
|  | PD ($1,408,380.00) |
|  | Specific Aims: To provide training at the intersection of engineering and developmental biology to better approach organ regeneration. Training is carried out in more than one laboratory. There are 6 positions/yr |
| 2017-2022 | Kidney microphysiological analysis platforms (MAP) to optimize function and model Disease |
|  | 1UG3TR002155 NCATS |
|  | Co-PI ($681,868.00) |
|  | 1)Optimize use of kidney organoids and develop efficient processes to direct differentiation of hiPSCs into kidney podocytes, tubular epithelial cells, and endothelial cells endowed with differentiated features and created from iPSCs generated from control and patients with monogenic diseases affecting the kidney.  2)Design, construct, and characterize a kidney microphysiological analysis platform (MAP) to evaluate the function of hPSC-derived kidney podocytes, endothelial and epithelial cells, and kidney organoids.  3)Design, bioprint, and characterize a vascularized kidney model. |
| 2017-2020 | Resequencing and functional analyses of two candidate genes contributing to progression to ESRD in Type 1 diabetes |
|  | 3-SRA-2018-529-M-B Joslin Diabetes Center |
|  | PI |
|  | Specific Aims: Bonventre's laboratory will conduct cellular studies to test hypotheses about the function of the HSD17B14 protein in Year 1 and similar studies regarding the FHAD1 protein will be conducted in Year 2. |
| 2017-2021 | Role of SMOC2 in Kidney Fibrosis |
|  | R01ES017543 NIH-NIEHS |
|  | Co PI |
|  | The objective is to investigate how induction of SMOC2 in fibroblasts and epithelial cells regulate initiation and the progression of kidney fibrosis. |

**Report of Local Teaching and Training**

Teaching of Students in Courses

|  |  |  |
| --- | --- | --- |
| Year(s) | Course Title | Location |
|  | Type of student/audience | Level of Effort |

|  |  |  |
| --- | --- | --- |
| 1988-1992 | Organize and deliver series of lectures on Renal Physiology to Renal Fellows and Medical Students at MGH | 1 hr/wk contact time and 4hr/wk preparation time for 6 wk/year. |
| 1992-1993 | Faculty Trainer in Scientific Integrity, MGH | 4 hr/year contact time, 2 fellows |
| 1984-98 | HST 110-Renal pathophysiology | Co-director 1986-98 50 contact hrs/per yr  1998 – 4 hrs/year |
| 1996-2005 | Co-Director, HST Division | 10 contact hrs/wk, 52 wks/yr |

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

|  |  |  |
| --- | --- | --- |
| Year(s) | Title | Location |
| Type of student/audience | Level of Effort |

|  |  |  |
| --- | --- | --- |
| 1979 | Didactic sessions in Clinical Nephrology and Renal Physiology for Harvard Medical students in clerkship in Nephrology as well as for Renal Fellows. | 2 hr/month contact and 2 hr/month preparation time, 3 students, 1 resident, 6 fellows |
| 2002-07 | Program Director, BWH-MGH Nephrology Training Program | Responsible for 32 fellows, clinical and research training over 4year training program |

Clinical Supervisory and Training Responsibilities

|  |  |  |
| --- | --- | --- |
| Year(s) | Type of responsibility | Level of Effort |

|  |  |  |
| --- | --- | --- |
| 1980-1996 | Clinical teaching as Attending Physician during core clerkship in Medicine at Massachusetts General Hospital. | 36 hr/week contact time, 5 hr preparation time, for one month, 4 students, 4 residents |
| 1980-2002 | Attending Physician in Nephrology, Massachusetts General Hospital. Clinical teaching for Harvard Medical students during Nephrology clerkship | 20 hr/wk contact time, 5 hr/wk preparation time for 4.5 weeks/year, 2 medical students, 2 fellows, 1 medical resident. |
| 1980-2002 | Dialysis Attending, Massachusetts General Hospital | 16 hr/wk contact time for 10 weeks/year: 1 nephrology fellow |
| 2002- | Consultation Attending, BWH | 2 wks/year |

Laboratory and Other Research Supervisory and Training Responsibilities

|  |  |  |
| --- | --- | --- |
| Year(s) | Type of responsibility | Level of Effort |

|  |  |  |
| --- | --- | --- |
| 1980- | Research Supervisor for more than 120 postdoctoral trainees, medical students and undergraduates |  |
| 1993 | Mentor for the NIH/MGH Minority High School Student Research Apprentice Program | 3 hr/wk for 8 wks, 1 high school student |
| 1996 | Undergraduate Research Opportunity Program | 2 hr/wk contact time for 10 wks, 2 MIT undergraduates |

Formally Supervised Trainees

|  |  |
| --- | --- |
| Year(s) | Name and degrees/ Current position |
| Describe the type of supervision and the specific accomplishments of your trainee that occurred as a direct result of your supervision (maximum one sentence) |

|  |  |
| --- | --- |
| 80-83 | Joseph Y. Cheung, M.D., Ph.D./ Richard Laylord & Dorothy L. Evans Professor & Chair, Medicine, Lewis Katz School of Medicine at Temple University, Professor, Center of Translational Medicine, Lewis Katz School of Medicine at Temple University, Pennsylvania |
| 82-89 | Charles Malis, M.D./ Private Practice, Concord Clinic, Concord, MA |
| 83 | Jonathan Diamond, M.D./ Private Practice, Harrisburg Hospital, Medical Director, Fresenius Medical Care hemodialysis and peritoneal dialysis programs |
| 84-87 | Mark Swidler, M.D./ Associate Professor; Director, Outpatient Palliative Care, Smilow Cancer Hospital, Palliative Care Program, Yale School of Medicine |
| 85-89 | Joseph H. Gronich, M.D./ Private Practice, Philadelphia, PA |
| 86-88 | Mark Pettus, M.D./ Director Medical Education and Population Health, Berkshire Health Systems Pittsfield, Massachusetts |
| 87-88 | Catherine Kim/ unknown |
| 87-88 | Rajan Varadarajan, Ph.D./ Assistant Professor Plant Biotechnology Unit, Tuskegee University, AL |
| 87-89 | Andrey Cybulsky, MD/ Director, Division of Nephrology, McGill University Health Centre, Royal Victoria Hospital Canada |
| 88- | Harumasa Nakamura, M.D./ Assistant Professor, Anesthesia, Nagasaki University, Japan |
| 88-90 | Alois Sellmayer, M.D./ Physician, Medizinische Poliklinik Klinikum der Universität München, Munich |
| 89 | John Chen/unknown |
| 89 | Veronique Emmenegger, MD/Medical Director, Clinic Lemanic, Lausanne, Switzerland |
| 89-91 | Gary Hyman, M.D./ Deceased |
| 89-92 | Steven Guest, MD/ Renal Director, Baxter Healthcare, Deerfield, IL |
| 89-90 | Mitchell Bamberger, MD/ Private Practice, Milford, MA |
| 90 | Mark Beinke/unknown |
| 90 | Reinhard Gessner, MD, PhD/Assistant Professor, Freie Universitat, Berlin |
| 90 | Roger Hajjar, MD/ Professor of Medicine, Cardiology, Professor of Gene and Cell Medicine, Mount Sinai School of Medicine |
| 90 | Yves Donati, MD/ Department of Pediatrics and Pathology-Immunology, School of Medicine and University Hospital, Geneva, Switzerland |
| 90-91 | Guy Rordorf, MD/Assistant Professor in Neurology, Harvard Medical School, Massachusetts General Hospital |
| 90-91 | Sam Lee/Unknown |
| 90-91 | Craig Surman, MD/Assistant Professor of Psychiatry, Harvard Medical School, Massachusetts General Hospital |
| 91 | Amy Chang/Unknown |
| 92 | David Newbower/unknown |
| 92 | Frank Lornz, PhD/unknown |
| 92 | Liliana Ercole, PhD/ Assistant Professor of Medicine, Jewish Hospital, Buenos Aires |
| 92-93 | Rudiger Volk, PhD/ Adjunct Professor, Roxbury Community College, Owner, Dr. Volk Real Estate Management |
| 93 | Dilek Onaldi, MD/ Physician, pediatrics, Munich, Germany |
| 93 | Jin Chen Yu/unknown |
| 89-94 | Ralph Witzgall, M.D./ Professor and Chair, Department of Anatomy and Cell Biology, University of Regensburg, Germany |
| 92-94 | Taeko Fukuda, PhD/Assistant Professor of Anaestesia, Hyogo College of Medicine, Hyogo, Japan |
| 93-94 | Hee-Won Moon, MD/ Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea |
| 91-94 | Dae Kyong Kim, PhD/Vice Dean, Associate Professor, Cardiology, School of Pharmacy, Seoul, Korea |
| 92-94 | Richard Spech, MD/ Assistant Professor of Medicine, Case Western Reserve University |
| 93-95 | Hiroaki Morooka, MD, PhD/Assistant Professor of Anaesthesia, Nagasaki University, Japan |
| 94-95 | Sung-Su Kim, Department of Pharmacology of Medicine, Seoul National University |
| 91-96 | Katrina Kelly, MD/ Assistant Professor of Medicine, University of Indiana |
| 94-96 | Steven Hau/President and CEO, Shareable Ink |
| 93-96 | Celia Pombo, PhD/Professor of Physiology, University of Santiago de Compostela, Spain |
| 95-96 | Yung-Ming Chen, MD, PhD/ Associate Professor of Medicine, National Taiwan University College of Medicine, Chief, Blood Purification, National Taiwan University Hospital |
| 95-99 | Gabriel Choukroun MD, PhD/ Professor of Pharmacology, Centre Hospitalier Universitaire d’Amiens, France |
| 95-99 | Patricio Downey MD/ Assistant Professor, Catholic University, Chile |
| 96-98 | Stephen Hsu MD PhD/University of Florida |
| 96-98 | Toshiya Tsujita MD/ Assistant Professor, Nagasaki U. Japan |
| 98-99 | Yoshiaki Taero, MD/ Assistant Professor, Nagasaki U. Japan |
| 98-99 | Hideyuki Saito, PhD/ Professor, Kyoto University, Japan |
| 98-99 | Rekha Abichandani MD/Senior Medical Director, Clinical Research, Genzyme Corporation |
| 96-99 | Takaharu Ichimura, PhD/Instructor in Medicine, Harvard Medical school |
| 98-99 | Peter Linde, MD/Physician, San Francisco General Hospital, San Francisco, CA |
| 89-02 | Thomas Force, MD/ James C. Wilson Professor of Medicine, Clinical Director, Center for Translational Medicine, Jefferson University School of Medicine |
| 93-98 | Alice Sheridan, MD/Assistant Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital |
| 97-2000 | Eckhard Schulze-Lohoff, MD/ Chief of Nephrology, HELIOS Marien Clinic, Duisburg, Germany |
| 97-99 | Ang Chen, MD/ Physician, Arizona Kidney Disease & Hypertension Center, Tuscon, Arizona |
| 99-02 | Hyung-Jin Yoon MD/ Assistant Professor of Medicine Seoul National University, Seoul, Korea |
| 99-00 | Young-Joo Kwon, MD/Assistant Professor of Medicine, Division of Cardiology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Seoul, Korea |
| 98-01 | Muriel Vayssier-Taussat, MD/ Director of Research, French National Institute for Agricultural Research, Maisons-Alfort, France |
| 98-01 | Won Han, MD/ Assistant Professor, Jefferson Medical School |
| 99-00 | Zhiwei Zhang, PhD/ Assistant Professor, St. Louis University |
| 99-02 | Wolfgang Kuehn, MD/ Deputy Chief, Department of Medicine IV  Nephrology and Primary Care, University Medical Center Freiburg, Germany |
| 96 | Kwon Moo Park, PhD/Assistant Professor, Kyungpook National University, Korea |
| 00-02 | Cornelius Kramers, MD PhD/ Associate Professor, University of Nijmegen, The Netherlands |
| 00-01 | Tilman Matthaeus/ faculty and Physician, University of Cologne, Germany |
| 00-03 | Chieng-Cheh Hung, MD, PhD/Assistant Professor, ChangGung University, Taiwan |
| 00-03 | Michele Andreucci, MD, PhD/ University of Catanzaro, Italy |
| 01-02 | Shiro Kurusu/Assosciate Professor, Kitasato University, Japan |
| 01-02 | Yiming Zhao-Lit, MD/Assistant Professor, Stanford University, Medical Director, Dialysis Unit, Palo Alto VA Medical Center |
| 00-04 | Hae Sook Shin, PhD/ Instructor in Anaesthesia, Massachusetts General Hospital |
| 98-04 | Amy Schuerman-Gen, MD/ Assistant Professor, University of California at Davis |
| 00-05 | Benjamin Humphreys, MD, PhD/ Assistant Professor of Medicine, BWH/Harvard Medical School |
| 03-05 | Vishal Vaidya, PhD/ Assistant Professor of Medicine, BWH/Harvard Medical School |
| 03-06 | Rohan Samarakoon, PhD/ Instructor in Medicine, Albany Medical School, Albany, NY |
| 98-05 | Dirk Hentshel, MD, PhD/ Instructor in Medicine, BWH/Harvard Medical School |
| 04 | Li-Li Hsiao, MD, PhD/ Assistant Professor of Medicine, BWH/Harvard Medical School |
| 04-06 | Jeremy Duffield, MD, PhD/ Associate Professor of Medicine, Division of Nephrology, and Lung Biology, Institute for Stem Cell & Regenerative Medicine, University of Washington |
| 05-07 | Edwin van Asseldonk, MD/ Research Fellow, Radboud University of Nijmegen, The Netherlands |
| 05 | Kenneth Christopher, MD/ Instructor in Medicine, BWH/Harvard Medical School |
| 05-06 | Kai Liu, MD, PhD/Research Fellow, Children’s Hospital Boston |
| 05-06 | Masashi Mizuno, MD/ Nagoya City University Hospital |
| 06-08 | Michael Ferguson, MD/ Instructor in Pediatrics, Children’s Hospital, Boston/Harvard Medical School |
| 05-09 | Lakshman Gunaratnam, MD/ Assistant Professor of Medicine and Microbiology & Immunology, London Health Sciences Centre, University Hospital, Ontario, Canada |
| 06-07 | Marcela Gonzales del Vecchio/ Universidad Central de Venezuela, Escuela de Medicina José María Vargas |
| 05-06 | Amy Tang /Graduate Student, MIT |
| 06-07 | Carmen de Lucas Collantes, MD/Gregorio Maranon Hospital, Madrid, Spain |
| 07-08 | Ali Hilal-Alnaqbi, PhD/ Assistant Professor, United Arab Emirates University, Dubai |
| 07-08 | Satohiro Masuda, PhD/ Professor & Director, Department of Pharmacy, Kyusyu University Hospital |
| 07-08 | Wirasat Hasnain/ Physician, Milford Regional Medical Center |
| 08 | Juan Torras-Ambros, PhD/Fundacio Privada Institut D’investigacio Biomedica De Bellvitge, Barcelona, Spain |
| 07-08 | Shan Mou/ Assistant Professor, Renji Hospital/Shanghai JiaoTong University School of Medicine, Shanghai,China |
| 07-08 | Junne-Ming Sung/National Cheng Kung University Hospital, Tainan, Taiwan |
| 07-10 | Li Yang / Associate Professor, Beijing Medical University, Beijing, China |
| 07-09 | Guochun Chen/2nd Xiangya Hospital, Central South University, Changsha, Hunan, China |
| 07-09 | Abhishek Maan/ Fellow, University of Massachusetts, Boston |
| 08-09 | Anna Greening, PhD/ Jr. Product Manager, MEDA Pharma GmbH |
| 08-09 | Heung–Myong Woo DVM, PhD /Associate Professor Section of Veterinary Surgical Sciences, School of Veterinary Medicine,Kangwon National University, South Korea |
| 08-10 | Richard Wei/ CHUM Hotel Dieu, Montreal, Canada |
| 08-10 | Letian Zhou, PhD/ Postdoctoral Fellow, 2nd Xiangya Hospital, Central South University, Changsha, Hunan, China |
| 08-10 | Huiping Zhao, PhD/ Associate Professor, Department of Nephrology, Peking University People’s Hospital |
| 08-09 | Salaheldin Elhamamsy/ Resident, Brown University, Rhode Island Memorial Hospital |
| 08-10 | Venkata Sabbisetti, PhD/ Instructor in Medicine, Harvard Medical School, Brigham and Women’s Hospital |
| 08-10 | Suetonia Palmer, MD/ Senior Lecturer in Medicine, University of Otago Christchurch, New Zealand |
| 09-11 | Gabriela Campanholle, PhD/ |
| 09-10 | Roohi Khan, MD/ Research Fellow, Baylor University school of Medicine |
| 09-10 | Jessica Kaufeld, MD/Postdoctoral Fellow, Medizinischen Hochschule Hannover, Germany |
| 09-11 | Ningning Wang, PhD/ Associate Professor, First Affiliated Hospital of Nanjing Medical University |
| 10 | Daniel Antoine, PhD/ Lecturer in Pharmacology, Wellome Trust Research Fellow, MRC Centre for Drug Safety Science, Molecular & Clinical Pharmacology, University of Liverpool |
| 10 | Kurinji Singaravelu, PhD/Unknown |
| 10-11 | Dhruti Patel/ Medical Student, University of North Carolina School of Medicine |
| 10-11 | Ushashi Dadwal/ Doctoral Student, Vanderbilt University Medical Center |
| 10-11 | Harmeen Goraya/Medical Student |
| 10-11 | Liangying Gan, MD, PhD/ Associate Professor, Division of Nephrology, People’s Hospital, Peking University |
| 10-11 | Kazumi Ito/ Toxicologist, Daiichi Sankyo CO., LTD |
| 10-11 | Chang Wang/Postdoctoral Fellow, 2nd Xiangya Hospital, Central South University, Changsha, Hunan, China |
| 08-11 | Albert Lam, MD/ Instructor in Medicine, BWH/Harvard Medical School |
| 08-12 | Ivica Grgic, PhD/ Attending, Zentrum für Innere Medizin und Nephrologie, Klinikum der Philipps-Universität Marburg |
| 10-12 | Rosella Iatrino, MD/ Clinical Trainee, University Hospital of Modena |
| 11-12 | Alberto Lazaro Fernandez, PhD/ Postdoctoral Fellow, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid |
| 11-12 | Hong Liu, MD/ Professor, Division of Nephrology, Department of Medicine, 2nd Xiangya Hospital, Central South University, Hunan, China |
| 12-13 | Guillaume Canaud, MD, PhD/Research and Clinical Fellow, Université Paris Descartes, Paris, France; Renal Transplant Unit, Necker Hospital, Paris, France |
| 2013 | Tao Su, Beijing Medical University |
| 08-14 | Craig Brooks, MD/ Instructor in Medicine, BWH/Harvard Medical School |
| 10-13 | Ashok Kumar, PhD/Visiting Professor, currently in lab |
| 10-14 | Benjamin Freedman, PhD/Assistant Professor, University of Washington |
| 11-15 | Yumin Liu, MD/ Research Associate, Montreal Neurological Institute and Hospital |
| 12-15 | Jae Chang, MD/Assistant Professor, Columbia University |
| 13-15 | Takehiro Suzuki, MD, PhD/ Assistant Professor, Tohoku University Graduate School of  Medicine, Sendai, Japan |
| 12-15 | Ryuji Morizane, MD, PhD/ Assistant Professor of Medicine, Mass General Hospital/Harvard Medical School |
| 12-15 | Weiqi Yao, MS/ |
| 12-15 | Seiji Kishi, MD, PhD/ assistant Professor, Department of Nephrology, Graduate School of Medicine, Institute of Health-Bio-Science, University of Tokushima, Tokushima, Japan |
| 12-15 | Florian Toegel, MD, PhD/ Physician, Colorado Kidney Care |
| 11-19 | Wenqing Yin, MD, PhD/ Nephrology Fellow, Boston Medical Center |
| 14-19 | David Ferenbach, PhD/ Wellcome Trust Intermediate Clinical Fellow, Edinburgh University |
| 12-18 | Amrendra Ajay/ Instructor in Medicine, Renal Division, Department of Medicine, Brigham and Women's Hospital |
| 15-19 | Akinwande Akinfolarin, MD/ Physician, Dallas Nephrology Associates |
| 15-19 | Juia Wilflingseder, PhD/ Medical University of Vienna |
| 15-18 | Hannes Olauson, MD, PhD/ Postdoctoral fellow, Uppsala University, Sweden |
| 15-18 | Takahisa Yano/ Associate Professor, Department of Pharmacy, Shimane University  Hospital, Japan |
| 15-19 | Navin Gupta/ Clinical Fellow, Mass General Hospital |
| 15- | Cuiyan Xin/ Postdoctoral fellow, currently in lab |
| 15- | Tomohisa Suzuki/ Postdoctoral fellow, currently in lab |
| 15- | Yutaro Mori, PhD, Research Fellow in Medicine, currently in lab |
| 16- | Nathan Lee, Research Fellow in Medicine, currently in lab |
| 18- | Ankit Patel, MD, PhD, Postdoctoral Fellow, currently in lab |
| 18- | Kyle McCracken, MD, Clinical Fellow in Pediatrics, Children’s Hospital Boston, currently in lab |
| 18- | Guillermo Ruiz Esparza Herrera, Research Fellow in Medicine, currently in lab |
| 19- | JIahua Li, MD, Clinical Fellow in Medicine, currently in lab |

Formal Teaching of Peers (e.g., CME and other continuing education courses)

|  |  |  |
| --- | --- | --- |
| Year(s) | Title(s) or topic(s) or talks | Number of talks in a single course |
| Course Name (Sponsor, if any) | Location(s) (city or country) |

|  |  |  |
| --- | --- | --- |
| 2004 | *Current Progress in Tissue Engineering* |  |
|  | HMS CME | Cambridge, MA |
| 2004 | *Pathogensis of Acute Renal Failure* |  |
|  | Harvard Medical School Department of Continuing Education Course, Nephrology: A Case Based Approach for the Nephrologist | Naples, FL |
| 2004 | *Renal Repair Mechanism* |  |
|  | HMS CME Course Current Progress in Tissue Engineering | Cambridge, MA |
| 2005 | *Pathogenesis of ARF* |  |
|  | Harvard Medical School Department of Continuing Education Course, Nephrology: A Case Based Approach for the Nephrologist | Naples, FL |
| 2007 | *Acute Kidney Injury* |  |
|  | Harvard Medical School Department of Continuing Education Course, Nephrology: A Case Based Approach for the Nephrologist | Naples, Florida |
| 2007 | *State of the Art Lecture – Pathophysiology of AKI* |  |
|  | Harvard Medical School Department of Continuing Education Course, The Brigham Renal Board Review Course | Boston, MA |
| 2011 | State of the Art Lecture – Pathophysiology of AKI |  |
|  | Harvard Medical School Department of Continuing Education Course, The Brigham Renal Board Review Course | Boston, MA |
| 2019 | *Promoting Regeneration as Opposed to Scarring in Wound Repair -* Regenerative Biomedicine (AISC 602.0), Harvard Medical School Department of Stem Cell and Regenerative Biology | Boston, MA |

Local Invited Presentations

|  |  |
| --- | --- |
| Year(s) | Title of presentation/ Type of presentation |
| Department and Institution where presented (Sponsor, if any) |

|  |  |
| --- | --- |
| 1997 | Medical Grand Rounds, *Acute Renal Failure* |
|  | Massachusetts General Hospital, Boston, MA |
| 1999 | *Cytosolic PLA2: Lessons learned from a Knockout mouse* |
|  | Tufts University School of Medicine, Somerville, MA |
| 1999 | Renal Rounds, *Perspectives on Acute Renal Failure* |
|  | National Kidney Foundation of MA, RI, NH and Vermont, Norwood, MA |
| 1999 | Medical Grand Rounds, Ischemic *Acute Renal Failure* |
|  | Massachusetts General Hospital, Boston, MA |
| 1999 | Physiology Grand Rounds, *A cPLA2 Knockout: Physiological and pathophysiological consequences* |
|  | University of Massachusetts, Boston, MA |
| 2000 | Invited Speaker: *What we Learn from the Cytosolic Phospholipase A2 Knockout Mouse* |
|  | International Meeting on Eicosanoids, Boston, MA |
| 2000 | Surgical Grand Rounds, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | Beth Israel Deaconess Medical Center, Boston, MA |
| 2002 | *Is there life after MIT Engineering?* |
|  | MIT Society of Women Engineers, MIT, Cambridge, MA |
| 2004 | *Renal Repair Mechanism* |
|  | Current Progress in Tissue Engineering, Cambridge, MA |
| 2005 | *Biomarkers of Nephropathy* |
|  | Laboratory Medicine Extreme Makeover 19th Annual Northeast Region Conference Exhibition, Boxborough, MA |
| 2005 | Keynote Speaker at *A Life in Academics: Its Opportunities and Rewards* |
|  | 2005 Clinical Fellows Celebration, Brigham and Women’s Hospital, Boston, MA |
| 2007 | *Acute Kidney Injury (AKA Acute Renal Failure)* |
|  | Medical Grand Rounds, Faulkner Hospital, Boston, MA |
| 2009 | *Ethics: Managing Conflict of Interest in Medicine, Academia, Industry & Government – Academic Research perspective* |
|  | HST Biomatrix, Cambridge, MA |
| 2011 | *Kim-1 in diabetic nephropathy: more than a biomarker* |
|  | Longwood Area Diabetes and Metabolism Seminar Series, Joslin Diabetes Center, Boston, MA |
| 2011 | *Acute kidney injury and repair* |
|  | Seventh Annual Barry M. Brenner, M.D. Lecture, Brigham and Women’s Hospital, Boston, MA |
| 2011 | *Normal and Abnormal Kidney Repair* |
|  | Boston University, Boston, MA |
| 2011 | Plenary Talk: *Detecting Kidney Injury* |
|  | BWH BRI Regenerative Therapeutics Research Center Inaugural Symposium, Brigham and Women’s Hospital, Boston, MA |
| 2012 | *Kidney Normal and Abnormal Repair after Injury* |
|  | Beth Israel Deaconness Hospital Renal Grand Rounds, Boston, MA |
| 2012 | “*Acute Kidney Disease: Past. Present, Future”*  *“Insights into the Hospital-based healthcare: View from the American Society of Nephrology”* |
|  | Boston Biotech Network Series, Boston, MA |
| 2013 | *Pathophysiology of AKI* |
|  | Brigham Renal Board Review, Boston, MA |
| 2014 | *Pathophysiology of AKI* |
|  | Brigham Renal Board Review, Boston, MA |
| 2015 | *Adaptive and Maladaptive Kidney Repair and the Potential for Kidney Regeneration* |
|  | Cardiovascular Institute, Beth Israel Deaconess Medical Center |
| 2016 | *Directed Differentiation of Human Stem Cells to Kidney Organoids and Disease Modeling* |
|  | Keynote Lecture, Broad Institute MUC1 Kidney Team Annual Meeting, Cambridge, MA |
|  | *Directed differentiation of human stem cells to kidney organoids and disease modeling* |
|  | Selectbio Second Annual Tissue Engineering, Biofabrication and 3D-Bioprinting Conference, Boston, MA |
| 2016 | *Generation of kidney organoids and use for disease modeling* |
|  | Society for Developmental Biology/International Society of Differentiation 75th Annual Meeting, Boston, MA |
| 2016 | *Pathophysiology of AKI* |
|  | The Brigham Renal Board Review Course, Boston, MA |
| 2017 | *Pathophysiology of AKI* |
|  | The Brigham Renal Board Review Course, Boston, MA |
| 2018 | *Acute Kidney Injury and Maladaptive Repair* |
|  | St. Vincent’s Hospital Renal Rounds, Worcester, MA |
| 2018 | *Kidney organoids: a human model system for precision medicine?* |
|  | 4th Annual Kidney NEXT Symposium, The Broad Institute, Cambridge, MA |
| 2018 | *Pathophysiology of AKI* |
|  | The Brigham Renal Board Review Course, Boston, MA |
| 2018 | Keynote Presentation: *From Stem Cells to Kidney Organoids to Disease Modeling* |
|  | World Preclinical Conference, Boston, MA |
| 2019 | *Pathophysiology of AKI* |
|  | The Brigham Renal Board Review Course, Boston, MA |
| 2020 | *Acute Kidney Injury and Maladaptive Repair* |
|  | St. Vincent’s Hospital Renal Rounds, Worcester, MA |

**Report of Regional, National and International Invited Teaching and**

**Presentations**

Invited Presentations and Courses

Regional

|  |  |
| --- | --- |
| Year(s) | Title of presentation or name of course/ Type of presentation/role(s) (note if presentation the result of a selected abstract) |
| Location (Sponsor, if any) |

|  |  |
| --- | --- |
| 1987 | Invited speaker, *Vasopressin signaling processes in mesangial cells* |
|  | Second International Vasopressin Conference, Smuggler’s Notch, Vermont |
| 1988 | *The role of phospholipases in ischemic injury* |
|  | International Society of Nephrology Forefronts in Nephrology Symposium on “Signal Transduction”, Chatham Bars Inn, Chatham, MA |
| 1989 | *Protein kinases and calcium signaling in the mesangial cell* |
|  | FASEB Summer Conference: Renal Hemodynamics: Integrative and Cellular Mechanisms, Vermont |
| 1991 | Invited Speaker, *Phospholipase A2 and acute renal injury* |
|  | Forefronts in Nephrology Symposium on Acute Renal Failure, Chatham, MA |
| 1998 | *The Role of MAP kinases in mesangial cell function.* |
|  | FASEB Conference on Renal Hemodynamics, Saxton’s River, VT |
| 1998 | *The cPLA2 Knockout Mouse* |
|  | FASEB Conference on Phospholipases Saxton’s River, VT |
| 2000 | Renal Grand Rounds, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | Brown University School of Medicine, Providence, RI |
|  | *Cytosolic Phospholipase A2 and its interacting proteins in physiology and pathophysiology* |
|  | Cardiovascular Research Center Seminar |
| 2005 | *Acute Renal Failure in Zebrafish: A Novel System to Study a Complex Disease* |
|  | Mount Desert Island Stem Cell Symposium, Salisbury Cove, ME |
| 2005 | Renal Grand Rounds, *Biomarkers of Acute Kidney Injury: From Bench to Bedside* |
|  | Brown University, Providence, RI |
| 2006 | *What’s New in Acute Kidney Injury (AKA Acute Renal Failure)* |
|  | Renal Grand Rounds, University of Vermont, Burlington, VT |
| 2006 | Grand Rounds in Pharmacogenetics, *Clinical applications of KIM-1 as a biomarker of kidney injury* |
|  | Symposium on Preclinical and Clinical Applications of Genomic Biomarkers of Nephrotoxicity, FDA, Silver Spring, MD |
| 2006 | *The Roles of Cystolic Phospholipase A2 (cPLA2) Orthologues in Zebrafish in Cardiac, Brain, and Kidney Functional Development* |
|  | FASEB Conference on Phospholipases, Saxton’s River, VT |
| 2008 | *Cell Types, Their Roles and Interactions in Acute Kidney Injury* |
|  | Acute Kidney Injury Network Conference, Bethesda, MD |
| 2017 | *From stem cells to nephrons to disease modeling* |
|  | Keynote Lecture, Graduate School of Biomedical Engineering, University of Maine at Orono |

National

|  |  |
| --- | --- |
| Year(s) | Title of presentation or name of course/ Type of presentation/role(s) (note if presentation the result of a selected abstract) |
| Location (Sponsor, if any) |

|  |  |
| --- | --- |
| 1985 | Invited Lecture: *Measurement of Intracellular Free Ca2+ Concentration* |
|  | 18th Annual Meeting of the American Society of Nephrology |
| 1988 | *Calcium signaling in mesangial cells* |
|  | National Institute of Environmental Health Sciences’ Calcium Research Workshop, Research Triangle, NC |
| 1988 | *Mechanisms of kidney mitochondrial injury with ischemia* |
|  | Symposium on Clinical Ischemic Syndromes, U. of Michigan |
| 1988 | *Calcium and phospholipase activation in the mesangial cell* |
|  | FASEB Annual Meeting, Scientific Session: “Molecular and Immune Mechanisms of Kidney Disease”, Las Vegas, NV |
| 1990 | Invited Lecture, *Phospholipase A2 and Signal Transduction* |
|  | Annual Meeting of the American Society of Nephrology |
| 1991 | Invited Speaker, *Transcription factors and acute renal failure* |
|  | International Congress on Acute Renal Failure, North Carolina |
| 1992 | Visiting Professor, Renal Grand Rounds, *Cellular aspects of the pathophysiology of acute renal failure* |
|  | University of Colorado Medical Center |
| 1994 | Visiting Professor, Renal Grand Rounds, *Kid-1, KRAB, and a KRAB interacting protein in the regulation of transcription* |
|  | University of Pennsylvania |
| 1994 | Invited Speaker, *Phospholipase A2 and cell injury* |
|  | Annual Meeting of the Society of Toxicology, Dallas, TX |
| 1994 | Annual Renal Alumni Professorship, Renal Grand Rounds, *Pathophysiology of Acute Renal Failure* |
|  | Washington University and Barnes Hospital |
| 1994 | Eckel Lecturer and Visiting Professor  Medical Grand Rounds: *Acute Renal Failure*  Nephrology Grand Rounds: *Phospholipase A2s* |
|  | Case Western Reserve University, Cleveland, OH |
| 1994 | Invited Speaker, Symposium on Acute Renal Failure, *Role of leukocyte-endothelial adhesion molecules in acute renal failure* |
|  | National Kidney Foundation Annual Meeting, Orlando FL |
| 1995 | Visiting Professor, Renal Grand Rounds, *Adhesion molecules and acute renal failure* |
|  | Vanderbilt University, Nashville, TN |
| 1995 | Visiting Professor, Renal Grand Rounds, *Cellular pathophysiology of acute renal failure* |
|  | University of Texas at Galveston |
| 1996 | Invited speaker, *Acute renal failure: Role of integrins and adhesion factors* |
|  | 5th Annual Clinical Nephrology Meetings, Anaheim, CA |
| 1996 | Visiting Professor, *New Concepts in Pathophysiology of Ischemic Injury* |
|  | Columbia University College of Physicians and Surgeons, New York |
| 1996 | Visiting Professor,  *Acute Renal Failure*  *Zinc Fingers, KRAB, and KRIP, an evolving perspective on transcriptional repression* |
|  | Indiana University School of Medicine |
| 1997 | Visiting Professor: Medical Grand Rounds, *Ischemic Acute Renal Failure*  *Vascular and cellular foundations for future therapies in acute renal failure* |
|  | University of Rochester School of Medicine, Rochester, NY |
| 1997 | Invited Lecture, *Growth Factors and MAP Kinases* |
|  | Workshop on Vascular Biology and Hypertension, Ann. Meeting of American Heart Association-Hypertension |
| 1997 | Invited Speaker, *Kinases and Transcriptional Responses in Renal Injury and Repair* |
|  | American Society of Nephrology Basic Science Symposium |
| 1998 | Invited Speaker, *The cPLA2 Knockout Mouse* |
|  | Keystone Symposium on Lipid Mediators, Keystone, CO |
| 1998 | Medical Grand Rounds, *Acute Renal Failure*  Renal Grand Rounds, *The cPLA2 Knockout Mouse* |
|  | University of South Carolina, Columbia, SC |
| 1998 | Renal Grand Rounds, *The cPLA2 Knockout Mouse* |
|  | Mount Sinai School of Medicine, NY, NY |
| 1998 | Invited Minilecture, *The Cytosolic PLA2 Knockout Mouse* |
|  | American Society of Nephrology Annual Meeting, Philadelphia, PA |
| 1998 | *Pathophysiology of Acute Renal Failure* |
|  | ICU Nephrology Course of the American Society of Nephrology |
| 1999 | Renal Grand Rounds, *Ischemic Acute Renal Failure*  Renal Research Conference, *The Phospholipase A2 Knockout Mouse; Physiological and Pathophysiological Consequences* |
|  | University of California Los Angeles, Los Angeles, CA |
| 1999 | Renal Rounds, *A New Way to Bind Phosphorus* |
|  | National Kidney Foundation of Southern California, Sherman Oaks, CA |
| 2000 | Medical Grand Rounds, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | University of Iowa College of Medicine |
| 2001 | Renal Grand Rounds, *Early Fallout from a Genomic Approach to Acute Renal Failure* |
|  | Hennepin Medical Center, University of Minnesota, Minneapolis, MN |
| 2001 | CME Lecture, *Cellular and Physiological roles of group IVA cytosolic PLA2: Insight from the knockout mouse* |
|  | University of Texas, Southwestern, Dallas, TX |
| 2001 | Keynote speaker, *HST: A 30-year experiment in training of physician scientists and biomedical engineers. A model for the 21st century* |
|  | Case Western Reserve Annual Medical Education Retreat, Cleveland, OH |
| 2001 | Keynote speaker, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | 12th Congress of the International Pediatric Nephrology Association, Seattle WA |
| 2001 | Nephrology Grand Rounds, *The Pathophysiology of Acute Renal Failure: What do we know in 2001?*  Nephrology Research Forum, *The Genomic Approach to Acute Renal Failure: A Tale of Two Proteins* |
|  | Mayo Medical School, Rochester, Minnesota |
| 2002 | Medical Grand Rounds, *Pathophysiology of Ischemic Acute Renal Failure*  Invited Speaker, Weis Center, *A Genomic Approach to Acute Renal Failure: A tale of two proteins* |
|  | Geisinger Health Care System, Danville, PA |
| 2002 | Renal Grand Rounds,: *Kidney Injury Molecule 1: From Bench to Bedside* |
|  | Duke Medical Center, Raleigh, NC |
| 2002 | Biochemistry and Molecular Biology Grand Rounds, *Kidney Injury Molecule-1: Cellular and molecular features and clinical applications in acute kidney injury and proliferative disorders* |
|  | University of Central Florida, Orlando, FL |
| 2002 | *Pathophysiology of ischemic Acute Renal Failure: Setting the Stage* |
|  | American Society of Nephrology Symposium on Hypoxia-Induced Gene Expression: Clues to the Pathogenesis of Ischemic ATN, Philadelphia, PA |
| 2002 | Nephrology Grand Rounds, *Kidney Injury Molecule-1 (Kim-1): Potential Roles in Ischemic, Cystic, and Proliferative Renal Disorders*  Research Lecture, *Cytosolic Phospholipase A2: Lessons Learned from a Knockout Mouse* |
|  | Harbor-UCLA Medical Center, Los Angeles, CA |
| 2002 | Nephrology Grand Rounds, *Kidney Injury Molecule-1 (Kim-1): Potential Roles in Ischemic, Cystic, and Proliferative Renal Disorders* |
|  | Cedars-Sinai Medical Center, Los angeles, CA |
| 2002 | Medical Grand Rounds, *Pathophysiology of Ischemic Acute Renal Failure*  Renal Grand Rounds, *Kidney Injury Molecule-1 (Kim-1): Potential Roles in Ischemic, Cystic, and Proliferative Renal Disorders* |
|  | King/Drew Medical Center UCLA, Los Angeles, CA |
| 2002 | Research Lecture, *Cytosolic Phospholipase A2: Lessons Learned from a Knockout Mouse* |
|  | UCLA-CHS, Los Angeles, CA |
| 2002 | UCLA Combined Renal Grand Rounds, *Kidney Injury Molecule-1 (Kim-1): Potential Roles in Ischemic, Cystic, and Proliferative Renal Disorders* |
|  | Wadsworth VA Medical Center, Los Angeles, CA |
| 2002 | Medical Grand Rounds, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | Sepulveda VA Medical Center UCLA, Sepulveda, CA |
| 2002 | Research Lecture, *Cytosolic Phospholipase A2: Lessons Learned from a Knockout Mouse* |
|  | Wadsworth VA Medical Center, Los Angeles, CA |
| 2002 | *Acute Renal Failure: from Bench to Bedside and Back* |
|  | National Kidney Foundation Clinical Nephrology Meeting, Chicago Illinois |
| 2002 | *Genetics and preconditioning of acute renal failure* |
|  | Nephrology Update, Cleveland Clinic Foundation |
| 2003 | Renal Grand Rounds, *Kidney Injury Molecule-1 (Kim-1): Potential Roles in Ischemic and Proliferative Renal Disorders* |
|  | University of Utah School of Medicine, Salt Lake City, Utah |
| 2003 | Edward Everett Anderson Visiting Professor, *Pathophysiology of Ischemic Acute Renal Failure*  The Whitney Lecture, *The Kidney: From Fish to Philosopher*  Physiology Grand Rounds*, Kidney injury molecule-1: A marker of epithelial cell injury* |
|  | University of Arkansas for Medical Sciences, Little Rock, AR |
| 2003 | The Kline Memorial Lecture, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | Northwestern University School of Medicine, Evanston, IL |
| 2003 | Medical Grand Rounds, *Pathophysiology of Acute Renal Failure*  Renal Grand Rounds, *Kidney Injury Molecule-1* |
|  | University of Pittsburgh, Pittsburgh, PA |
| 2003 | Medical Grand Rounds, Medical Center*, Pathophysiology of Acute Renal Failure* |
|  | State University of New York at Stony Brook, Stony Brook, NY |
| 2004 | *Potential Biomarkers of Injury: Overview of Currently Studied Proposed Markers* |
|  | ASN Annual Meeting, Washington DC |
| 2004 | *The Identification and Validation of Safety and Efficacy Biomarkers* |
|  | The Inaugural Safety and Efficacy Biomarkers, Princeton, NJ |
| 2004 | *Acute Renal Failure: Targets for Intervention*  *Early Diagnosis of ARF: Emerging Techniques* |
|  | Ninth International Conference on Continuous Renal Replacement Therapies, San Diego, CA |
| 2004 | *Pharmacological Prevention of ARH* 2004 & *Ischemic ARF* |
|  | NKF National Clinical Meeting; Chicago, IL |
| 2004 | *KIM-1, a Biomarker of Renal Toxicity in Animals and Man* |
|  | Safety Biomarkers: Using Advances in Toxicogenomics and Toxicoproteomics to Predict Drug Safety and Toxicity, American Conference Institute’s Washington, DC |
| 2004 | Phospholipases: *In Vivo and Ex-Vivo Studies using cPLA2 Knockout Mice* |
|  | FASEB, Summer Research Conferences, Pine Mountain, GA |
| 2004 | *Progress Towards Early Diagnosis of Kidney Disease: Urinary and Other Biomarkers* |
|  | American Society of Nephrology, 37th Annual Meeting & Scientific Exposition, St. Louis, MO |
| 2005 | *Acute Kidney Injury: Mechanisms and Adaptations*  *Repair Mechanisms: the Role of Stem Cells* |
|  | International Conference on Continuous Renal Replacement Therapies, San Diego, CA |
| 2005 | Medical Grand Rounds, *Pathophysiology of Acute Kidney Injury*  Physiology Rounds, *Kidney Injury Molecule-1: From Bench to Bedside* |
|  | Pennsylvania State University College of Medicine, Pittsburgh, PA |
| 2005 | Medical Grand Rounds, *Acute Renal Failure* |
|  | New York University, New York, NY |
| 2005 | Visiting Professor, *Acute Kidney Injury: From Zebrafish to the Patient* |
|  | Department of Medicine, University Of Minnesota, Minneapolis, MN |
| 2005 | Medical Grand Rounds, *Pathophysiology of Acute Kidney Injury (aka Acute Renal Failure)* Renal Grand Rounds, *KIM-1, A Biomarker of Acute Proximal Tubular Injury* Renal Research Conference, *Acute Kidney Injury in Zebrafish: a Novel System to Study a Complex Disease* |
|  | Vanderbilt University, Nashville, TN |
| 2005 | *Markers of Early Injury and Prediction Models in ARF* |
|  | National Kidney Foundation Clinical Nephrology Meeting, Chicago Illinois |
| 2005 | *Kidney Injury Molecule-1: from Bench to Bedside* |
|  | Nephrology Research Conference, Mount Sinai School of Medicine, NY, NY |
| 2006 | *Role of Stem Cells in Ischemic Tubular Injury* |
|  | 1st Scientific Symposium on Technological Advances in Kidney Disease Research, Keck School of Medicine, Los Angeles, CA |
| 2006 | Women in Nephrology Professional Development Seminar, *Fostering Research*  *Renal Regeneration Mediated by the Tubule Epithelial Cell* |
|  | Annual Meeting of the American Society of Nephrology, San Diego, California |
| 2006 | *Kidney Injury Molecule-1: from Bench to Bedside* |
|  | Nephrology Renal Grand Rounds, Albert Einstein College of Medicine, Bronx, NY |
| 2007 | *Kidney Injury Molecule-1: From Bench to Bedside* |
|  | Invited Speaker, Cincinnati Children’s Hospital, Cincinnati, Ohio |
| 2007 | *Models and Mechanisms of Kidney Injury and Repair* |
|  | Society of Toxicology Annual Meeting, Charlotte, North Carolina |
| 2007 | *Promising Proteomic Discoveries in Kidney Disease* |
|  | National Kidney Foundation Clinical Nephrology Meeting, Orlando, Florida |
| 2007 | *Kidney Injury Molecule-1 (KIM-1): From Bench to Bedside* |
|  | Renal Grand Rounds, Drexel University, Philadelphia, Pennsylvania |
| 2007 | *Early and Predictive Markers of Renal Function in Man* |
|  | 43rd Annual Meeting of the Drug Information Association, Atlanta, GA |
| 2007 | Scribner Society Lecture: *Urinary Biomarkers of Kidney Injury*  Renal Grand Rounds: *Renal Repair: Is there a Role for Stem Cells* |
|  | University of Washington, Seattle, WA |
| 2007 | *Acute Kidney Injury – More Than Just a Change in Name!* |
|  | Internal Medicine Grand Rounds, University of Texas MD Anderson Cancer Center |
| 2007 | *Fostering Research* |
|  | Annual Meeting of the American Society of Nephrology, Women in Nephrology Professional Development Seminar, San Diego, California |
| 2007 | Invited Speaker, *Kidney Injury Molecule-1: From Bench to Bedside and Back* |
|  | College of Pharmacy, Medical University of South Carolina, Charleston, SC |
| 2007 | Cardiovascular Forum Seminar, *Kidney Injury Molecule-1 (KIM-1): From Bench to Bedside and Back* |
|  | Texas A&M University, College Station, Texas |
| 2008 | Renal Grand Rounds, *Kidney Injury Biomarkers: an Update* |
|  | Drexel University, Philadephia, PA |
| 2008 | *Integrating Animal with Clinical Data to Best Understand Kim-1 as a Kidney Safety Biomarker* |
|  | 33rd Annual Meeting of the Toxicology Forum, Washington, DC |
| 2008 | Medicine Grand Rounds, *Acute Kidney Injury (aka Acute Renal Failure): More than just a change in name*  Inter-City Renal Rounds, *Biomarkers of Kidney Injury: A look into the future*  Renal Division Research Conference: *The search for an adult renal stem cell involved in repair* |
|  | Thomas Jefferson University, Philadelphia, PA |
| 2008 | *Biomarkers of Kidney Injury: Dawn of a New Era?* |
|  | Northwestern University, Chicago, IL |
| 2008 | *Biomarkers of Kidney Injury: Dawn of a New Era?* |
|  | University of Texas Southwest, Dallas, TX |
| 2008 | Nephrology Conference *Biomarkers of Kidney Injury: a Bench to Bedside Odyssey and Dawn of a New Era?* |
|  | University of North Carolina, Chapel Hill, NC |
| 2008 | Invited Speaker, *Diagnosis and Monitoring of Acute Kidney Injury with New Biomarkers: Opportunities and Pitfalls* |
|  | Stanford University, Palo Alto, CA |
| 2008 | Charles Austin Lecturer, *Biomarkers of Kidney Injury: from Bench to Bedside* |
|  | Baylor University Medical Center, Dallas, TX |
| 2008 | Women in Nephrology Professional Development Seminar, *Hot Topics in Nephrology Research* |
|  | Annual Meeting of the American Society of Nephrology, Philadelphia, PA |
| 2009 | Visiting Professor, Renal Grand Rounds, *Repair of the Kidney Epithelium* |
|  | Hahnemann University Hospital, Drexel University, Philadelphia, PA |
| 2009 | *Biomarkers of Kidney Injury: Dawn of a New Era* |
|  | Institute Of Medicine Biomarkers for Drug safety Workshop, Washington, DC |
| 2009 | Rogosin Institute Annual Professorship, *Acute Kidney Injury and Repair*  *Diagnosis and Monitoring of Kidney Injury with Biomarkers: Opportunities and Pitfalls* |
|  | Weill Cornell Medical College, New York, NY |
| 2010 | Invited speaker*, Biomarkers of Ischemia Reperfusion Injury* |
|  | American Transplant Congress, San Diego, CA |
| 2010 | Keynote Address, *Biomarkers of Nephrotoxicity: Uses and Challenges in Pre-Clinical and Clinical Studies* |
|  | World Pharmaceutical Congress, Philadelphia, PA |
| 2010 | Visiting Professor, Renal Grand Rounds, *Acute Kidney Injury – from Bench to Bedside* |
|  | Baylor College of Medicine, Houston, TX |
| 2011 | Roscoe Robinson Visiting Professorship  Medicine Grand Rounds, *Acute Kidney Injury and Repair*  Nephrology Friday Morning Conference, *Normal and Abnormal Repair after Kidney Injury* |
|  | Duke University, Durham, NC |
| 2011 | Medical Grand Rounds: *Acute Kidney Injury and Repair*  Cell Biology Seminar: *Normal and Abnormal Repair after Kidney Injury* |
|  | Medical College of Georgia, Atlanta, GA |
| 2011 | *Training at the Health Science-Technology Interface* |
|  | AAAS Annual Meeting, Washington, DC |
| 2011 | *Preconditioning: can it be modulated?*  Special Lecture: *AKI to CKD progression: mechanisms, pathways and targets* |
|  | Sixteenth International Conference on Continuous Renal Replacement Therapies, San Diego, CA |
| 2011 | *Do stem cells exist in the adult kidney?* |
|  | Organogenesis Forum, Washington University, St. Louis, MO |
| 2011 | Kleeman Visiting Professorship:  *Mechanisms of normal and abnormal kidney repair* |
|  | Harbor/UCLA Medical Center, Los Angeles, CA |
|  | Nephrology Ground Rounds: *Acute kidney Injury* |
|  | Cedars-Sinai Hospital, Los Angeles, CA |
|  | *Biomarkers of kidney injury* |
|  | VA Greater Los Angeles Healthcare System, Los Angeles, CA |
|  | General Nephrology Conference: *Acute kidney injury* |
|  | UCLA Medical Center, Los Angeles, CA |
|  | *Biomarkers of kidney injury* |
|  | Olive View Medical Center, Los Angeles, CA |
| 2011 | Medical Grand Rounds: *Acute Kidney Injury and Repair* |
|  | Indiana University, Indianapolis, IN |
| 2011 | *Beyond the Glomerulus: Tubular Dysfunction in Diabetic Nephropathy* |
|  | 71st Scientific Sessions of the American Diabetes Assoctiation, San Diego, CA |
| 2011 | Medical Grand Rounds: *Acute Kidney Injury and Repair*  Basic Research Seminar: *Mechanisms of normal and abnormal kidney tubular repair after injury* |
|  | Case Western University, Cleveland, OH |
| 2012 | Medical Grand Rounds: *Acute Kidney Injury and Repair*  Renal Grand Rounds: *Normal and Abnormal Repair after Kidney Injury* |
|  | University of Louisville, Louisville, KY |
| 2012 | *KIM-1: A translational journey* |
|  | Drexel University College of Medicine, Philadelphia, PA |
| 2012 | *Acute Kidney Injury and Repair* |
|  | Phillip C. Liverman Visiting Professorship, University of Virginia, Charlottesville, VA |
| 2012 | *Maladaptive Kidney Repair and Its Mechanisms* |
|  | Annual Meeting of the American Society of Nephrology, San Diego, CA |
| 2013 | *KIM-1: A Translational Journey* |
|  | Annual Meeting of the American Clinical and Climatological Association, Charleston, SC |
| 2013 | Keynote lecture: *The role of acute kidney injury in development and progression of chronic kidney disease* |
|  | 3rd Annual Acute Kidney Injury Symposium, University of Pittburgh, Pittsburgh, PA |
| 2013 | Invited lecture: *Overview of Current Biomarkers in Kidney Disease* |
|  | 30th Beckman Conference, Atlanta, GA |
| 2013 | Invited lecture: *Highly Efficient Differentiation of Human Pluripotent Stem Cells into Targeted Mesendoderm* |
|  | American Society of Nephrology Kidney Week, Atlanta, GA |
| 2013 | State of the Art Lecture: *Adaptive and Maladaptive Repair after Acute Kidney Injury* |
|  | Houston Methodist J.C. Walter Jr. Transplant Center Conference Series, Houston, TX |
| 2014 | *Adaptive and maladaptive innate immune responses and repair processes* |

American Society of Transplantation Cutting Edge of Transplantation Meeting, Chandler, AZ

2014 Renal Grand Rounds: *KIM-1: A Translational Journey*

Additional invited lecture: *The Future is Now: Induced Pluripotent Stem Cells and Directed Differentiation of Human Stem Cells into Kidney Precursors*

Visiting Professorship, University of Pennsylvania Renal Electrolyte and Hypertension Division, Philadelphia, PA

2014Charles D. Swartz, M.D. Memorial Lecturer**:**

Renal Grand Rounds *KIM-1: a Biomarker and Much More*

2014 Medicine Grand Rounds – Charles Swartz, MD Memorial Lecture: *Acute Kidney Injury and Healing*

Drexel University College of Medicine, Philadelphia, PA

2014 Renal Rounds: *KIM-1: A biomarker and much more*

Northwestern University, Chicago, IL

2015 Vanderbilt Harrison Society Lecture: *Acute Kidney Injury and Repair*

Vanderbilt University, Nashville, TN

2015 Renal Grand Rounds: *Acute Kidney Injury Markers*

Winthrop University Hospital, Mineola, NY

2015 Medicine Grand Rounds: *Acute Kidney Injury and Repair*

Temple University School of Medicine, Philadelphia, PA

2015 *Biomarkers in Acute Kidney Injury*

American Society of Hypertension Annual Meeting, NY, NY

|  |  |
| --- | --- |
| 2015 | *Modeling PKD Using iPS Cells* |
|  | Advances in Research Conference, American Society of Nephrology Annual Kidney Week, San Diego, CA |
| 2016 | *Making "Mini-Kidneys" in a*  *Dish: The Path from Stem Cell to Nephron* |
|  | Ernest Just Scientific Symposium, Medical University of South Carolina, Charleston, SC |
| 2016 | *Directed Differentiation of Stem Cells to Kidney and Applications to*  *Disease Modeling* |
|  | Symposium on Cystic Kidney Disease and Acute Kidney Injury, Univeristy of Alabama at Birmingham, Birmingham, AL |
| 2016 | Role of Epithelium in CKD Progression |
|  | CKD-MBD: past, present and future, Celebrating the Career of Eduardo Slatopolsky, MD, Washington University St. Louis, St Louis, MI |
| 2016 | Renal Grand Rounds: *Generation of kidney organoids and use for disease modeling* |
|  | Vanderbilt University, Nashville, TN |
| 2016 | *Acute Kidney Injury: Adaptive and Maladaptive Repair and Regeneration* |
|  | Cade Visiting Professorship, Univesity of Florida, Gainesville, FL |
| 2016 | *Nephron Organoids to Model Kidney Development and Injury* |
|  | American Society of Nephrology Annual Kidney Week, Chicago, IL |
| 2017 | Renal Grand Rounds: *From stem cells to kidney organoids to disease modeling*  Medical Grand Rounds: *Acute Kidney Injury: Adaptive and Maladaptive Repair* |
|  | Cunio Richardson Lectureship, University of Miami, Miami, FL |
| 2017 | *Human Kidney Organoids and Their Use in Modeling Diseases* |
|  | 22nd International AKI & CRRT Conference, Minneapolis, MN |
| 2017 | *Maladaptive Proximal Tubule Repair: KIM‐1 and Epithelial Cell*  *Cycle Arrest and Senescence* |
|  | Keystone Symposia: Injury, Inflammation and Fibrosis, Snowbird, Utah |
| 2018 | *Autophagy in AKI and Aging* |
|  | NIDDK Workshop:Autophagy as a Common Pathway in Diseases, National Institutes of Health, Bethesda, MD |
| 2018 | *Human Kidney Organoids as Models for Injury and Fibrosis* |
|  | Advances in Translational Models to Study Fibrosis, The New York Academy of Sciences, New York, New York |
| 2018 | *Acute Kidney Injury: Novel Risk Markers and Prophylaxis* |
|  | American College of Physicians 2018 Internal Medicine Meeting, New Orleans, LA |
| 2018 | Grand Rounds Presentation: *Acute Kidney Injury: Adaptive and Maladaptive Repair* |
|  | Research Forum: *The Future of Regenerative Nephrology:* *Stem Cells, Organoids, Bioengineering and a Roadmap to Replacement of Renal Function* |
|  | Mayo Clinic, Rochester MN |
| 2018 | Sullivan Conference: *The Future of Regenerative Nephrology: Stem Cells, Organoids, Bioengineering and a Roadmap to Replacement of Renal Function* |
|  | University of Kansas, Kansas City, KS |
| 2018 | *From Cells to Clinical Trial: Roadmap for Innovative RRT: A Catalyst for Change* |
|  | American Society of Nephrology Annual Meeting, San Diego, CA |
| 2019 | Panel Participant: *Are we entering the golden age of Precision Medicine in Kidney Disease?* |
|  | Renalytix AI Kidney Summit, NY, NY |
| 2019 | *From Stem Cells to Kidney Organoids to Disease Modeling* |
|  | 3rd Annual Comprehensive Kidney Symposium, Advocate Christ Medical Center, Chicago, IL |
| 2019 | *From Stem Cells to Kidney Organoids to Disease Modeling* |
|  | 4th Kidney Disease Clinical Trialists Workshop, Washington, DC |
| 2019 | Pirani Lectureship: *AKI & Adaptive and Maladaptive Repair* |
|  | 32nd Annual Conrad L. Pirani Lectureship Columbia University College of Physicians and Surgeons, NY, NY |
| 2019 | Keynote Lecture: *Epithelial Cell Cycle Arrest and Mediators of Fibrosis after Kidney Injury* |
|  | FASEB Acute Kidney Injury Science Research Conference, Pacific Grove, CA |
| 2019 | Keynote Lecture: *Kidney Organoids* |
|  | APS 9th Annual International Conference of Aldosterone and ENaC in Health and Disease: The Kidney and Beyond, Estes Park, Colorado |
| 2019 | *Innovations of Dialysis Delivery: Looking into the Future* |
|  | American Society of Nephrology Kidney Week, Washington, DC |
| 2020 | *Acute Kidney Injury and Maladaptive Fibrotic Repair* |
|  | Consortium for Fibrosis Research & Translation (CFReT) at the University of Colorado Anschutz Medical Campus |

International

|  |  |
| --- | --- |
| Year(s) | Title of presentation or name of course/ Type of presentation/role(s) (note if presentation the result of a selected abstract) |
| Location (Sponsor, if any) |

|  |  |
| --- | --- |
| 1986 | Visiting Professor, *Calcium and phospholipase A2 signaling in the mesangial cell* |
|  | University of Toronto, Toronto, Canada |
| 1987 | Invited speaker, *Calcium and reactive oxygen species in mitochondrial injury* |
|  | 12th International Conference on Biological Membranes, Crans-sur-sierre, Switzerland: |
| 1989 | Invited speaker, *Calcium signaling in the mesangial cell* |
|  | Symposium on “Glomerular Function” at the International Congress of Physiology, Helsinki, Finland |
| 1989 | Visiting Professor, *Signal transduction in the mesangial cell* |
|  | Geneva University Hospital, University of Geneva, Geneva, Switzerland |
| 1992 | Invited Speaker, *Phospholipase A2 and the brain* |
|  | International Conference on Prostaglandins and Related Compounds, Montreal, Canada |
| 1994 | Centennial Year Visiting Professor, *Phospholipase A2 and signal transduction* |
|  | McGill University, Quebec, Canada |
| 1994 | Invited Speaker, *Phospholipases A2 and renal cell injury* |
|  | 6th International Congress on Nephrotoxicity and Nephrocarcinogenesis, Leiden, Holland |
| 1995 | *Adhesion molecules in acute renal failure* |
|  | Necker Seminar in Nephrology, Hopital Necker, Paris, France |
| 1995 | Invited Speaker, *Phospholipases A2 and injury to the nervous system* |
|  | International meeting on Lipid Messengers in the Nervous System, Tokyo, Japan |
| 1995 | Symposium on Growth Factors and Recovery from Acute Renal Failure, Invited lecture: *Growth factors and ischemic injury and repair* |
|  | Int. Congress of Nephrology, Madrid, Spain |
| 1997 | Invited Featured State of the Art Lecturer, *Acute Renal Failure, integrins and adhesion molecules* |
|  | International Congress of Nephrology, Sydney, Australia |
| 1997 | Invited Lecture, *Stress and oxidant regulated protein kinases* |
|  | Satellite Symposium of the International Society of Nephrology, Cairns, Australia |
| 1997 | Keynote Speaker, *Acute Renal Failure: Perspectives* |
|  | VIIIth Brazilian Congress of Intensive Care, Salvador, Bahia, Brazil |
| 1997 | Invited Speaker and Panel Participant, *Update on Acute Renal Failure* |
|  | Panel on Role for Integrins in Acute Renal Failure, 6th Paulista Meeting on Nephrology, Guarujá, Brazil |
| 1998 | Renal Grand Rounds, *Ischemic Acute Renal Failure* |
|  | University of Alberta, Alberta, Canada |
| 1998 | Invited Speaker, *Adhesion Molecules and Acute Renal Failure* |
|  | Alberta Nephrology Days, University of Alberta, Alberta, Canada |
| 1999 | Invited Speaker, *Pathophysiology of Acute Renal Failure, A Genomic Approach*  Invited Speaker, *The role of Kinases in Kidney Injury and Repair* |
|  | International Conference on Acute Renal Failure, Santiago, Chile |
| 1999 | Invited Speaker, *A Cytosolic Phospholipase A2 Knockout Mouse* |
|  | International Congress on Phospholipases, Berlin, Germany |
| 2000 | Conference on Medical Technology, *Education and Research in Medical Technology* |
|  | Trondheim, Norway |
| 2000 | Keynote speaker  *Pathophysiology of Ischemic Acute Renal Failure*  *Genomic Approach to Understanding the Pathophysiology of Acute Renal Failure*  *Ischemic Preconditioning of the Kidney* |
|  | Second Latin American Conference on Acute Renal Failure, Rio de Janeiro |
| 2001 | *Pathophysiology of Acute Renal Failure* |
|  | Second International Course on Critical Care Nephrology, Vincenza, Italy |
| 2001 | Master in Nephrology, *Pathophysiology of Ischemic Acute Renal Failure* |
|  | Naples, Italy |
| 2001 | Invited speaker, *A Genomic Approach to Renal Injury and Repair* |
|  | Conference on Ischemia/reperfusion injury, Antwerp, Belgium |
| 2001 | *Pathophysiology of Acute Renal Failure* |
|  | Second International Course on Critical Care Nephrology, Vicenza, Italy |
| 2001 | Honorary Doctorate Guest Lecture: *Bringing Medicine and Technology together in Research and Education* |
|  | Seminar in Medical Technology, Norwegian University of Science and Technology, Trondheim, Norway |
| 2002 | *De-differentiation, migration and proliferation of surviving epithelial cells in acute renal failure* |
|  | Journées Gabriel Richet, Renal epithelial cells: differentiation and plasticity, Le Coudray Montceaux, France |
| 2002 | *Ischemic Tissue Injury* |
|  | ISN Forefronts in Nephrology, Antwerp, Belgium |
| 2002 | *Genomics of Acute Renal Failure* |
|  | ISN Forefronts in Nephrology, Post Graduate Course, Antwerp, Belgium |
| 2002 | Invited speaker *New mechanisms in the pathophysiology of acute tubular necrosis* |
|  | Satellite Symposium on Acute Renal Failure of the World Congress of Nephrology, Ghent, Belgium |
| 2002 | Osler Oration, *The Pathophysiology of Ischemic Acute Renal Failure* |
|  | Joint Conference, Royal College of Physicians, London, England |
| 2004 | *Pathogenesis of Acute Renal Failure* and *Does Prior Injury Protect the Kidney Against Ischemia?* |
|  | NephroAsia 2004, Singapore |
| 2004 | *Pathophysiology of ARF* |
|  | Acute Dialysis Quality Initiative Conference, Vicenza, Italy |
| 2004 | *Acute Renal Failure* |
|  | International Society of Nephrology Department of Medicine Nephrology Course, Mexico City |
| 2004 | *Pathobiology of Acute Kidney Injury (AKI) and Repair: Roles of Organ Crosstalk, Intrinsic Protective Processes, Stem Cells and Biomarkers* |
|  | The 13th Congress of the International Pediatric Nephrology Association, Adelaide, Australia |
| 2004 | *Pathogenesis of Acute Tubular Necrosis* |
|  | Nefro 2004 XXII Brazilian Nephrology Congress, Salvador-Bahia, Brazil |
| 2004 | *Kidney Ischemic Preconditioning* |
|  | Institut Pasteur Euroconferences, Paris, France |
| 2004 | *Pathophysiology of ARF* |
|  | 3rd International Course on Critical Care Nephrology Acute Dialysis Quality Initiative, Vicenza, Italy |
| 2004 | *Acute Tubular Necrosis: Mechanisms, Animal Models* |
|  | 2nd European Nephropathology and Nephrology Workshop, Vienna, Austria |
| 2004 | *Pathophysiology of Ischemic Acute Renal Failure Diagnosis and Treatment of Acute Kidney Injury: What are future Directions?* |
|  | Annual Update Course in Nephrology, Mexico City, Mexico |
| 2005 | *Bone Marrow Stem Cells Differentiate into Endothelial but not Tubular Epithelial Cells During Repair of the Ischemically Injured Kidney* |
|  | International Society of Nephrology Forefronts in Nephrology, Karuizawa, Japan |
| 2005 | *Kidney Ischemic Preconditioning* |
|  | Institut Pasteur Euroconferences, Paris, France |
| 2005 | *Novel Biomarkers of Acute Renal Tubular Injury* |
|  | 18th Congress of the International Society of Nephrology, Singapore |
| 2005 | *Ischemic Preconditioning and Physiological Changes in ARF* and *Secondary prevention (Post-injury)* |
|  | Satellite Symposium, 18th Congress of the International Society of Nephrology, Penang, Malaysia |
| 2005 | *Training of the Physician Scientist: the Harvard-MIT Model* |
|  | Day of Education, Karolinska University Hospital, Stockholm, Sweden |
| 2006 | *New Insights into the Pathophysiology of Acute Renal Failure* |
|  | British Renal Society/Renal Association Integrated Conference, Harrogate, UK |
| 2006 | *Mechanistic Basis and Biomarkers for Cytotoxic Renal Injury* |
|  | Keystone Symposia on Molecular and Cellular Biology, Victoria, B.C. |
| 2006 | Nephrology Grand Rounds, *Biomarkers in Acute Kidney Injury* |
|  | Renji Hospital, Shanghai Jiao Tong University Medical School, Shanghai, China |
| 2006 | *Bridging the Research Between Bedside and Bench*  *Biomarkers in Kidney Injury* |
|  | International Nephrology Forum, Beijing University First Hospital, Beijing, China |
| 2006 | *Restoration of kidney tubular epithelium* |
|  | Nephrology CME Course, Xinjiang Medical University First Hospital, Urumqi, China |
| 2006 | *Acute Kidney Injury: Early diagnosis and prevention of a secondary injury* |
|  | Nephroprevention Conference, Toronto, Canada |
| 2006 | *Biomarkers of acute Kidney Injury*  *Pathophysiology of acute kidney injury* |
|  | Brazilian Congress of Nephrology, Gramado, Brazil |
| 2006 | *Basic approaches to acute renal failure* |
|  | Krescent Workshop, Montreal, Canada |
| 2006 | *Mechanisms of kidney injury and repair* |
|  | Annual Meeting of the Swiss Society of Nephrology, Solothurn, Switzerland |
| 2007 | *Kidney Injury Molecule-1: From Bench to Bedside* |
|  | Multidisciplinary Research Conference, McGill University, Montreal, Canada |
| 2007 | Rapoport Visiting Professor, Renal City Wide Rounds,: *Kidney Injury and Repair: Role of Kim-1 and Stem Cells* |
|  | University of Toronto, Toronto, Canada |
| 2007 | *Biomarkers* |
|  | World Congress of Nephrology, Rio de Janeiro, Brazil |
| 2007 | *Therapies for Prevention, Extension and Repair*  *Mechanisms of Kidney Injury* |
|  | World Congress of Nephrology, Satellite Symposium on Acute Kidney Injury, Salvador, Bahia, Brazil |
| 2007 | *Renal Ischemic Preconditioning* |
|  | Pediatric Academic Societies’ Annual Meeting, Toronto, Canada |
| 2007 | Session on Epidemiology and Pathogenesis of ARF, Sepsis and MOF, *Pathophysiology of Acute Renal Failure*  Session on Diagnosis and Evaluation of Severity of Illness, *Diagnosis of AKI: from Classic Parameters to New Biomarkers* |
|  | 16th International Course on Critical Care Nephrology, Vicenza, Italy |
| 2007 | *Diabetic Nephropathy*  *Dysnatremia and Water Homeostasis*  *Acute Kidney Injury* |
|  | 2007 Board Review CME and Contemporary Issues in Nephrology, Peking University, Beijing, China |
| 2008 | *Kidney injury molecule-1 (KIM-1)* |
|  | 11th Bergmeyer Conference, Grainau, Garmisch-Partenkirchen, Germany |
| 2008 | Invited speaker, *Biomarkers of Kidney Injury* |
|  | Kyoungpook National University, Daegu, Korea |
| 2008 | Invited speaker, *Biomarkers of Kidney Injury: Dawn of a New Era?* |
|  | Korea University Guro Hospital, Seoul, Korea |
| 2008 | Keynote Presenter, *Biomarkers of Acute Kidney Injury*  *Progress in Understanding How the Kidney Repairs after Acute Injury* |
|  | Korean Society of Nephrology Annual Meeting, Seoul, Korea |
| 2008 | Plenary Lecture, *Pathogenisis and Repair in Acute Kidney Injury*  *New Markers of Acute Kidney Injury* |
|  | Latin American Congress on Acute Renal Failure, Lima, Peru |
| 2008 | *Acute injury and renal regeneration: role of resident versus circulating cells* |
|  | Renal Symposium, Barcelona, Spain |
| 2008 | *Diagnostic markers of early kidney injury* |
|  | 40th Course on Advances in Nephrology and Dialysis, Milan, Italy |
| 2008 | *Early markers of acute kidney injury* |
|  | Workshop Nefrologie 2008, Arnhem, The Netherlands |
| 2008 | *Repair processes following ischemic renal failure: a tubular process*  *Preconditioning: a potential therapeutic target?* |
|  | 5th Symposium ERTIC, Paris, France |
| 2009 | *New Markers in Acute Renal Failure* |
|  | Actualités Néphrologiques – Jean Hamburger, Hôpital Necker, Paris, France |
| 2009 | *Biomarkers as windows into the pathogenesis of AKI – KIM-1* |
|  | World Congress of Nephrology 2009, Milan, Italy |
| 2009 | *New Concepts and Management of Diabetic Nephropathy.*  *New Biomarkers of Kidney Injury*  *Biomarkers of AKI: Technical Considerations* |
|  | International Society of Nephrology Renal CME course, Shandong, China |
| 2009 | Invited speaker, *Mechanisms of Repair after Ischemic Injury to the Tubule,*  *New Biomarkers of Kidney Injury* |
|  | Shanghai Renji Hospital/Shanghai Jiatong University School of Medicine, Shanghai, China |
| 2009 | Invited speaker, *Acute Kidney Injury: Pathophysiology and State of the Art*  *Acute Kidney Injury: How the Kidney Repairs Itself* |
|  | Congress of the Panamanian Society of Nephrology, Panama City, Panama |
| 2009 | *Which biomarkers are ready for use in daily clinical practice?* |
|  | Annual Congress of the European Society of Intensive Care, Vienna, Austria |
| 2009 | Invited speaker, *Biomarkers of injury* |
|  | National Congress of the Italian Society of Urgency Surgery, Palermo, Italy |
| 2010 | Invited speaker, *Role of new biomarkers and novel tools to predict and prevent renal disease* |
|  | Congress on Early Disease Detection and Prevention, Munich, Germany |
| 2010 | Invited speaker, *Renal injury in Heart Failure: How to Manage it* |
|  | 2nd Congress on Water and Sodium Management in Heart Failure, Palermo, Italy |
| 2010 | Invited Speaker, *Pathophysiology of AKI: the classic interpretation* |
|  | 19th International Vicenza Course on Critical Care Nephrology, Vicenza, Italy |
| 2010 | *Characteristics of an Outstanding Renal Division*  *Chronic Kidney Disease After Acute Renal Injury*  *Biomarkers in Acute Renal Failure* |
|  | International Society of Nephrology Renal CME Course, Beijing and Chendgu, China |
| 2010 | Invited speaker, *Biomarkers of Acute Kidney Injury* |
|  | 2nd Xiangya Hospital, Central South University, Changsha, China |
| 2010 | Invited Speaker, *Biomarkers of Kidney Injury: A Rapidly Changing Landscape* |
|  | Sun Yat-Sen University, Guangzhou, China |
| 2010 | Invited Speaker, *Tissue Inflammation and Repair* |
|  | XXIII International Congress of the Transplantation Society, Vancouver, Canada |
| 2010 | Plenary Lecture: *Biomarkers of Acute Kidney Injury*  Invited Speaker: *AKI as Risk and Progression Factor for Chronic Kidney Disease* |
|  | XXV Meeting of the Brazilian Society of Nephrology, Vitoria, Brazil |
| 2010 | Invited Speaker, *Renal Replacement Therapy in the United States: ASN Perspectives* |
|  | 3rd International Hemodyalisis Course, Mansoura University, Mansoura, Egypt |
| 2010 | Invited Speaker, *Stem Cells and Kidney Disease* |
|  | 2nd MERC Conference on Nanotechnology and Stem Cell Transplantation in Regenerative Medicine, Mansoura University, Mansoura, Egypt |
| 2010 | Keynote Lecture, *State of the Art: Mechanisms of tubular damage and repair* |
|  | 3rd International Symposium on Molecular Targets in Renal Disease, Bamberg, Germany |
| 2010 | Distinguished Lecture, *Biomarkers of kidney injury* |
|  | 31st Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, Kyoto, Japan |
| 2011 | *Effects of deranged recovery processes* |
|  | Round Table Conference “Controversies in acute Kidney injury”, Brussels, Belgium |
| 2011 | AKI Biomarkers |
|  | Dutch Nephrology Days, Veldhoven, The Netherlands |
| 2011 | *Tubular damage and survival in heart failure: athophysiology, diagnosis and approach* |
|  | 3rd Congress on Water and Sodium Management in Heart Failure, Palermo, Italy |
| 2011 | *The career of a Physician Scientist* |
|  | Yang Ming Medical School, Taipei, Taiwan |
| 2011 | *Normal and maladaptive repair after kidney injury* |
|  | Taipei Veteran’s General Hospital, Taipei, Taiwan |
| 2011 | *Kim-1, a translational journey* |
|  | National Cheng-King University |
| 2011 | *Kim-1, a translational journey* |
|  | Taiwan Society of Nephrology Annual meeting, Taipei, Taiwan |
| 2012 | *Biomarkers for predicting renal injury in heart failure* |
|  | 4th Congress on Water and Sodium Management in Heart Failure, Palermo, Italy |
| 2012 | *Kim-1: a translational journey*  *The contribution of acute kidney injury to chronic kidney disease* |
|  | International Society of Nephrology Renal CME Course, Beijing and Shanxi, China |
| 2012 | Opening Plenary Talk: *Mechanisms of Progression of AKI to CKD*  Additional talks:  *Primary proximal tubule injury leads to interstitial fibrosis and glomerulosclerosis*  *Future Perspectives on AKI Diagnosis: What is the status of biomarkers for AKI?* |
|  | 26th Brazilian Congress of Nephrology, Sao Paolo, Brazil |
| 2012 | Plenary talk: *AKI and biomarkers* |
|  | 4th Jahrestagung der Deutschen Gesellschaft für Nephrologie, Hamburg, Germany |
| 2013 | *Mechanisms of cellular repair after AKI* |
|  | World Congress of Nephrology Annual Meeting, Hong Kong |
| 2013 | *Tubular injury causes fibrosis* |
|  | WCN Sattellite Meeting on Fibrosis, Guangzhou, China |
| 2013 | *Biomarkers in acute kidney injury* |
|  | WCN Sattellite Meeting on Acute Kidney Injury, Shanghai, China |
| 2013 | *Reduced Ciliary Polycystin-2 in iPS Cells from Individuals with PKD1 Mutations* |
|  | 5th Sun Yat-sen International Forum on Nephrology, Guangzhou, China |
| 2013 | *Cell cycle arrest and maladaptive repair in AKI* |
|  | 31st International Vicenza Course on Critical Care Nephrology |
| 2013 | Magisterial talk: *Pathophysiology of Acute Renal Failure*  Additional talk: *Biomarkers of Acute Kidney Injury* |
|  | PRNS Annual Meeting, San Juan, Puerto Rico |
| 2013 | *Non-invasive methods to detect renal pathology* |
|  | International Forum of Renal Pathology, Beijing, China |
| 2013 | *Directed Differentiation Of Embryonic Stem Cells To Intermediate Mesoderm* |
|  | ISN Forefronts of Nephrology, Florence, Italy |
| 2013 | *Biomarkers for the diagnosis of acute kidney injury*  *Mechanism and clinical trials to accelerate recovery from AKI* |
|  | Symposium on Critical Care Nephrology, Dubai, UAE |
| 2014 | *Biomarkers of Kidney Injury* |
|  | 2014 International Forum of Renal Pathology & The 9th National Renal Pathology Conference, Beijing, China |
| 2014 | *Biomarkers in Kidney Disease* |
|  | ISN Board Review CME and Contemporary Issues in Nephrology, Zhengzhou, China |
| 2014 | Plenary talk: *Current status of molecular pathology of toxicity/clinical biomarkers* |
|  | Kidney Toxicity Workshop, University of Liverpool Medical Research Council |
| 2015 | Keynote Lecture: *Stem Cells in the Kidney: A look into the future*  *Clinical-pathological correlation: 3 AKI cases*  *Nephrology for Medical Students: Arousing Interest in the Area*  *Relationships between AKI and CKD* |
|  | Brazilian Congress of Nephrology, Curitiba, Brazil |
| 2015 | "Mechanisms of repair after acute kidney injury" |
|  | ERA/EDTA Congress, London, UK |
| 2015 | *Acute Kidney Injury and Repair* |
|  | ISN GO CME, Beijing and Zhengzhou, China |
| 2015 | *State of the BWH Renal Division Clinical-pathological correlation: 3 AKI cases* |
|  | International Forum of Renal Pathology & The 10th National Renal Pathology Conference, Beijing, China |
| 2015 | *Kidney injury and repair and nephrogenesis from iPS cells* |
|  | Kyoto University, Kyoto, Japan |
| 2015 | *Kidney injury and repair and nephrogenesis from iPS cells* |
|  | 45th Eastern Regional Meeting of the Japanese Society of Nephrology, Tokyo, Japan |
|  | *Kidney injury and repair and nephrogenesis from iPS cells* |
|  | Keio University, Tokyo, Japan |
| 2016 | *The Kidney Repair and Regeneration Shop* |
|  | City Wide Rounds, University of Toronto/St. Michael's Hospital, Toronto, Canada |
| 2016 | *How might we be preventing acute kidney injury in 2025?* |
|  | Cardiology, Diabetes & Nephrology at the Limits Symposium, Royal College of Physicians, London, UK |
| 2016 | *From AKI to CKD* |
|  | Actualités Néphrologiques Hôpital Necker, Paris, France |
| 2016 | *From AKI to CKD* |
|  | Consensus Meeting on Renal Progenitors and Kidney Regeneration, Florence, Italy |
| 2016 | *Kidney tubules, intertubular, vascular and glomerular cross-talks* |
|  | International Renal Pathology Meeting, 2016 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Beijing, China |
| 2016 | *Kidney tubules, intertubular, vascular and glomerular cross-talks* |
|  | 2016 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Nephrology Institute Zhengzhou University, Zhengzhou, China |
| 2016 | Chan Woo Cheung Visiting Professorship: *Regenerating the nephron with human pluripotent stem cells* |
|  | Hong Kong Society of Nephrology Annual Scientific Meeting |
| 2016 | Chan Woo Cheung Visiting Professorship, Keynote lecture: *Urinary and Blood Biomarkers for AKI and CKD* |
|  | Hong Kong Society of Nephrology Annual Scientific Meeting |
| 2017 | *Acute Kidney Injury*  *To Heal or Not to Heal - Longterm Consequences of AKI* |
|  | International Society of Nephrology Annual Meeting, Mexico City, Mexico |
| 2017 | *Use of renal progenitor cells for kidney regeneration, organoid creation and disease modeling*  *Repair after nephron ablation reveals limitations of neonatal neo-nephrogenesis* |
|  | 54th Congress of ERA-EDTA |
| 2017 | *An Academic Renal Division: Brigham and Women’s Hospital*  *Pathophysiology of Acute Kidney Injury* |
|  | International Renal Pathology Meeting, 2016 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Beijing, China |
| 2017 | *Pathophysiology of Acute Kidney Injury* |
|  | 2017 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Nephrology Institute Zhengzhou University, Zhengzhou, China |
| 2018 | *AKI: From the laboratory to the clinic* |
|  | International Society of Nephrology Frontiers Symposium on Kidney Disease and Cardiovascular Disease, Tokyo, Japan |
| 2018 | Plenary Lecture: *From Stem Cells to Kidney Organoids to Disease Modeling* |
|  | *Maladaptive repair in progression of AKI to CKD* |
|  | *A roadmap to innovative alternative solutions to renal replacement therapy* |
|  | 16th Asian Pacific Congress of nephrology and 2018 Annual Congress of the Chinese Society of Nephrology |
| 2018 | *From Stem Cells to Kidney Organoids to Disease Modeling* |
|  | International Renal Pathology Meeting, 2018 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Beijing, China |
| 2018 | *Stem Cells, Kidney Organoids and a Roadmap to Innovation in Renal Replacement Therapy* |
|  | 2018 Xiangya Kidney Disease Forum, Changsha, China |
| 2018 | *The Status of Kidney Organoids and their utility* |
|  | International Renal Pathology Meeting, 2018 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Beijing, China |
| 2018 | *Acute Kidney Injury and Maladaptive Repair* |
|  | International Renal Pathology Meeting, 2018 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Beijing, China |
| 2018 | *Acute Kidney Injury and Maladaptive Repair* |
|  | Division of Nephrology, Nanfang Hospital , Southern Medical University  Guangzhou, Guangdong, China |
| 2019 | *The Status of Kidney Organoids and their Utility* |
|  | *Acute Kidney Injury and Maladaptive Repair* |
|  | 2019 International Society of Nephrology Board Review and CME in Contemporary Issues in Nephrology, Beijing and Zhengzhou, China |
| 2019 | Plenary Lecture*: From Stem Cells to Kidney Organoids to Disease Modeling* |
|  | XLVII IMIN Update in Nephrology Course, Mexico City, Mexico |
| 2019 | *From stem cells to organoids to disease modeling* |
|  | 35th Ernst Klenk Symposium in Molecular Medicine , Cologne, Germany |
| 2019 | *From Stem Cells to Human Kidney Organoids to Disease Modeling* |
|  | 7th International Stem Cell Meeting, Tel Aviv, Israel |

**Report of Clinical Activities and Innovations**

Current Licensure and Certification

|  |  |
| --- | --- |
| Year | Type of License or Certification |

|  |  |
| --- | --- |
| 1977- | Massachusetts Medical License |
| 1980 | Diplomate, American Board of Internal Medicine |
| 1984 | Diplomate, American Board of Nephrology |

**Report of Education of Patients and Service to the Community**

Recognition

|  |  |  |
| --- | --- | --- |
| Year(s) | Name of award/recognition | Organization conferring recognition |

|  |  |  |
| --- | --- | --- |
| 1984 | Who’s Who in Frontier Science and Technology |  |
| 1987- | Who’s Who in the East |  |
| 1988- | Who’s Who in America |  |
| 1989- | Who’s Who in the World |  |
| 2004 | Voted one of 3 top mentors in the US by Postdoctoral Fellows | Science Magazine |

**Report of Scholarship**

Publications

|  |
| --- |
| Include only manuscripts that are published or accepted for publication (forthcoming) in print or other media; do not include manuscripts that have been submitted but not accepted for publication or those that are in preparation; Please use bold-faced type for your name in the authorship list. Numbering of contributions should start with "1" in each new section. |

Peer reviewed publications in print or other media

|  |
| --- |
| Group peer reviewed publications in three categories under the following headings:  -Research investigations  -Other peer-reviewed publications (e.g., case reports, proceedings of meetings which are full-length manuscripts)  -Research publications without named authorship |

1. **Bonventre JV** and Lechene C. A method for electron probe microanalysis of organic components in picoliter samples. Proceeding of the Microbeam Analysis Society, 9th Annual Conference (Ottawa) 8A-8D, 1974.
2. Beeuwkes R and **Bonventre JV**. Tubular organization and vascular-tubular relations in the dog kidney. American Journal of Physiology 229: 695-713, 1975.
3. Lechene C and **Bonventre JV**. Electron probe study of the urinary concentrating mechanism. Elemental cortico-papillary gradient in frozen hydrated rat kidney. Proceedings of the Microbeam Analysis Society, 11th Annual Conference (Miami) 6lA-6lG, 1976.
4. **Bonventre JV**, Karnovsky MJ and Lechene CP. Renal papillary epithelial morphology in antidiuresis and water diuresis. American Journal of Physiology 235: F69-F76, 1978.
5. **Bonventre JV**. Renal concentration mechanism: Role of papillary epithelium and pelvic urine; corticomedullary gradient by electron probe analysis; a passive model with functional heterogeneity in the outer medulla. Ph. D. Thesis, Harvard University 1979.
6. Roman RJ, **Bonventre JV** and Lechene C. Fluorometric assay for urea in urine, plasma, and tubular fluid. Analytical Biochemistry 98: 136-141, 1979.
7. **Bonventre JV** and Lechene C. Renal medullary concentration process: An integrative hypothesis. American Journal of Physiology 239: F578-F588, 1980.
8. **Bonventre JV**, Roman R and Lechene C. Effect of the urea concentration of pelvic fluid on renal concentrating ability. American Journal of Physiology 239: F609-F618, 1980.
9. **Bonventre JV** and Rabito CA. Electron microprobe analysis of cultured (LLC-PK1) renal epithelial cells. Proc Microbeam Analysis Society, 16th Annual Conference, 213-214, 1981.
10. Roman RR, **Bonventre JV**, Silva P and Lechene C. Sodium orthovanadate diuresis in rats. J Pharm ExpTher 218: 168-174, 1981.
11. **Bonventre JV** and Leaf A. Sodium homeostasis. Steady states without a set point. Kidney International 21: 880-885, 1982.
12. Cheung JY, Thompson IG and **Bonventre JV**. Effects of extracellular calcium removal and anoxia on isolated rat myocytes. Am. J. Physiol. 243 (Cell Physiol. 12): C184—C190, 1982.
13. Jensen SR, Novelline RA, Brewster DC and **Bonventre JV**. Transient renal artery stenosis produced by a pheochromocytoma. Radiology 144: 767-768, 1982.
14. Lebowitz PQ, Cote ME, Daniels AL and **Bonventre JV**. Comparative renal effects of midazolam and thiopental in humans. Anesthesiology 59: 381-384, 1983.
15. Malis CD, Cheung JY, Leaf A and **Bonventre JV**. Effects of verapamil in models of ischemic acute renal failure in the rat. Am. J. Physiol. 245 (Renal Fluid Electrolyte Physiol. 14): F735-F742, 1983.
16. Blackshear PJ, Nemenoff RA, **Bonventre JV**, Cheung JY and Avruch LA. Hormonal regulation of protein phosphorylation in isolated rat heart cells. Am. J. Physiol. 246 (Cell Physiol. 15): C439-C449, 1984.
17. Cheung JY, Leaf A and **Bonventre JV**. Mechanism of protection by verapamil and nifedipine from anoxic injury in isolated cardiac myocytes. Am. J. Physiol. 246 (Cell Physiol. 15): C323-329, 1984.
18. Corwin and **Bonventre JV**. Renal insufficiency associated with nonsteroidal anti-inflammatory agents. Am. J. Kidney Diseases 4: 147-152, 1984.
19. **Bonventre JV** and Cheung JY. Effects of metabolic acidosis on viability of cells exposed to anoxia. Am. J. Physiol. 250 (Cell Physiol. 18): C149- C159, 1985.
20. Cheung JY, Leaf A and **Bonventre JV**. Determination of isolated myocyte viability. Staining methods and functional criteria. Basic Res. Cardiol. 80, Suppl. 1: 23—30, 1985.
21. **Bonventre JV** and Cheung JY. Cytosolic free calcium in cultured renal epithelial cells. Am. J. Physiol. 250 (Renal Fluid Electrolyte Physiol. 19): F329-F338, 1986.
22. **Bonventre JV**, Skorecki EL, Kreisberg JI and Cheung JY. Vasopressin increases cytosolic free calcium concentration in glomerular mesangial cells. Am. J. Physiology 251 (Renal Fluid Electrolyte Physiol. 20): F94- F102, 1986.
23. Cheung JY, Constantine JM and **Bonventre JV**. Regulation of cytosolic free calcium in cultured renal epithelial cells. Am. J. Physiol. 251(Renal, Fluid Electrolyte Physiol. 20): F690-F701, 1986.
24. Cheung JY, Leaf A and **Bonventre JV**. Mitochondrial function and intracellular calcium in anoxic cardiac myocytes. Am. J. Physiol. 250 (Cell Physiol. 19): C18-C25, 1986.
25. Diamond J, **Bonventre JV** and Karnovsky M. Oxygen free radicals and aminonucleoside nephrosis. Kidney International. 29: 478-483, 1986.
26. Malis CD and **Bonventre JV**. Mechanism of calcium potentiation of oxygen free radical injury to renal mitochondria. A model for post-ischemic and toxic mitochondrial damage. J. Biol. Chem. 261: 14201-14208, 1986.
27. Ara G, Aprille JR, Malis CO, Kane SB, Cincotta L, Foley J, **Bonventre JV** and Oseroff AR. Mechanisms of mitochondrial photosensitization by a kryptocyanine dye: EDKC preferentially inactivates complex I in the electron transport chain. Cancer Res. 47: 6580-6585, 1987.
28. Ausiello DA, Skorecki, Verkman AS and **Bonventre JV**. Vasopressin signaling in kidney cells. Kidney Int. 31: 521-529, 1987.
29. Cheung JY, Constantine JM and **Bonventre JV**. Cytosolic free calcium concentration and glucose transport in isolated cardiac myocytes. Am. J.Physiol. 252 (Cell Physiol. 21): C163-172, 1987.
30. Corwin HL, Schreiber MJ, Teplick R, Fang LST, **Bonventre JV** and Coggins CC. Prediction of outcome in acute renal failure. Am. J. Nephrology. 7: 8-12, 1987.
31. Malis CD and **Bonventre JV**. Susceptibility of mitochondrial membranes to calcium and oxygen free radical damage. Potential modulation of injury by dietary n-3 fatty acids. Proceedings of the American Oil Chemists’ Society. Edited by W.E.M. Lands, American Oil Chemists’ Society, 1987, pp 430-434.
32. **Bonventre JV**, Weber P and Gronich J. PAF and PDGF increase cytosolic [Ca2+] and phospholipase activity in mesangial cells. Am. J. Physiol. 254 (Renal Fluid Electrolyte Physiol. 23): F87-F94, 1988.
33. Margolis BL, **Bonventre JV**, Kremer S, Kudlow JE and Skorecki KL. Epidermal growth factor is synergistic with phorbol esters and vasopressin in stimulating arachidonate release and prostaglandin production in renal glomerular mesangial cells. Biochemical Journal 249: 587-592, 1988.
34. Polla BS, Ohara J, Paul WE, Nabavi N, Myer A, Liou H-C, Shen F-W, Gillis 5, **Bonventre JV** and Glimcher LH. Differential induction of class II gene expression in murine pre-B-cell lines by B-ceIl stimulatory factor-I and antibodies to B-cell surface antigens. J. Mol. Cell. Immunol. 3: 363-373, 1988.
35. **Bonventre JV** and Swidler M. Calcium dependency of prostaglandin E2 production in rat mesangial cells. Evidence that protein kinase C modulates the Ca2+-dependent activation of phospholipase A2. J. Clin. Invest. 82: 168-176, 1988.
36. Polla BS, **Bonventre JV** and Krane SM. 1,25-dihydroxyvitamin D3 increases the toxicity of hydrogen peroxide in the human monocyte line U937: role of calcium and heat shock. J. Cell Biol. 107: 373-380, 1988.
37. Gronich JH, **Bonventre JV** and Nemenoff RA. Identification and characterization of a hormonally-regulated form of phospholipase A2 in rat renal mesangial cells. J. Biol. Chem. 263: 16645-16651, 1988.
38. Force T, Malis CD, Guerrero JL, Varadarajan GS, **Bonventre JV**, Weber PC and Leaf A. n-3 Fatty acids increase postischemic blood flow but do not reduce myocardial necrosis. Am. J. Physiol.257(Heart Circ. Physiol.26): H1204-H1210, 1989.
39. Cybulsky AV, Salant DJ, Quigg RJ, Badalamenti J and **Bonventre JV**. Complement C5b-9 complex activates phospholipases in glomerular epithelial cells. Am. J. Physiol. 257(Renal Fluid Electrolyte Physiol.26): F826-F836, 1989.
40. Stafford-Brady F, Sugiyama E, Robinson DR, Sy M-S, **Bonventre JV** and Yeh ETH. Defective signal transduction in CD4-, CD8- T cells of *lpr* mice. Cellular Immunology 123: 396-404, 1989.
41. Bloch DB, **Bonventre JV**, Neer E and Seidman J. The G protein αo subunit alters morphology, growth kinetics and phospholipid metabolism of somatic cells. Mol. Cell. Biol. 9: 5434-5439, 1989.
42. Ouellette AJ, Malt RA, Sukhatme VP and **Bonventre JV**. Expression of two “Immediate Early” genes, *Egr-1* and *c-fos*, in response to renal ischemia and during compensatory renal hypertrophy in mice. J. Clin. Invest. 85: 766-771, 1990.
43. **Bonventre JV**. Calcium in renal cells. Modulation of calcium dependent activation of phospholipase A2. Env. Health Persp. 84: 155-162, 1990.
44. Krane SM, Polla BS, and **Bonventre JV**. 1,25-dihydroxyvitamin D3 increases the toxicity of hydrogen peroxide: The role of calcium and heat shock. Experimental Gerontology. 25: 239-245, 1990.
45. Cybulsky AV, **Bonventre JV**, Quigg RJ, Wolfe IS and Salant DJ. Extracellular matrix regulates proliferation and oleculess turnover in glomerular epithelial cells. Am. J. Physiol. 259(Renal Fluid Electrolyte Physiol. 28): F326-F337, 1990.
46. **Bonventre JV**, Gronich JH, and Nemenoff RA. Epidermal growth factor enhances glomerular mesangial cell soluble phospholipase A2 activity. J. Biol. Chem. 265: 4934-4938, 1990.
47. Kantengwa S, Capponi AM, **Bonventre JV**, and Polla BS. Calcium and the heat shock response in the human monocyte line U937: Effects of l,25-diydroxyvitamin D3. Am. J. Physiol. 259(Cell Physiol.28): C77-C83, 1990.
48. Reno TA, Ley S, Sugiyama E, Cantagrel A, Blumberg R, **Bonventre JV**, Terhorst C and Yeh ETH. Generalized defects in signal transduction caused by a T-cell receptor b chain substitution. Eur. J. Immunol. 20: 1417-1422, 1990.
49. Gronich JH, **Bonventre JV** and Nemenoff RA. Purification of a high- molecular-mass form of phospholipase A2 from rat kidney activated at physiological calcium concentration. Biochem J. 271: 37-43, 1990.
50. Cybulsky AV, **Bonventre JV**, Quigg RJ, Lieberthal W, and Salant DJ. Cytosolic calcium and protein kinase C modulate complement-mediated glomerular epithelial cell injury. Kidney Int. 38: 803-811, 1990.
51. Malis CD, Weber PC, Leaf A and **Bonventre JV**. Incorporation of marine lipids into mitochondrial membranes increases susceptibility to damage by calcium and reactive oxygen species. Evidence for enhanced activation of phospholipase A2 in mitochondria enriched with n-3 fatty acids Proc. Natl. Acad. Sci. 87: 8845-8849, 1990.
52. Sugiyama E, Yeh ETH, Stafford-Brady F, Cantagrel A, Reno T and **Bonventre JV**. Characterization of T-cell receptor expression mutants derived by functional selection through T-cell activating protein. Cellular Immunology. 130: 271-280, 1990.
53. Sellmayer A, Uedelhoven WM, Weber PC and **Bonventre JV**. Endogenous non-cyclooxygenase metabolites of arachidonic acid modulate growth and mRNA levels of immediate-early response genes in rat mesangial cells. J. Biol. Chem. 266: 3800-3807, 1991.
54. Force T, Hyman G, Hajjar R, Sellmayer A and **Bonventre JV**. Non-cyclooxygenase molecules of arachidonate amplify the vasopressin-induced Ca2+ signal in glomerular mesangial cells by releasing Ca2+ from intracellular stores. J. Biol. Chem. 266: 4295-4302, 1991.
55. Force T, Kyriakis JM, Avruch J, and **Bonventre JV**. Endothelin, vasopressin, and angiotensin II enhance tyrosine phosphorylation by protein kinase C-dependent and-independent pathways in glomerular mesangial cells. J. Biol. Chem. 266: 6650-6656, 1991.
56. **Bonventre JV**, Sukhatme VP, Bamberger M, Ouellette A and Brown D. Localization of the protein product of the immediate early growth response gene, Egr-1, in the kidney after ischemia and reperfusion. Cell Regulation, 2: 251-260, 1991.
57. Nakamura H, Nemenoff RA, Gronich JH and **Bonventre JV**. Subcellular characteristics of phospholipase A2 activity in rat kidney. Enhanced cytosolic, mitochondrial, and microsomal phospholipase A2 enzymatic activity after renal ischemia and reperfusion. J. Clin. Invest. 87: 1810-1818, 1991.
58. Rordorf G, Uemura Y and **Bonventre JV**. Characterization of phospholipase A2 (PLA2) activity in gerbil brain. Enhanced activities of cytosolic, mitochondrial and microsomal forms after ischemia and reperfusion. J. Neurosciences. 11: 1829-1836, 1991.
59. Malis CD, Varadarajan GS, Force T, Weber PC, Leaf A and **Bonventre JV**. Effects of dietary fish oils on vascular contractility subsequent to anoxia. Circulation 84: 1393-1401, 1991.
60. Polla BS, Mili N, and **Bonventre JV**. Les proteines de stress: quelles implications en nephrologie. Nephrologie 12: 119-123, 1991.
61. Hajjar RJ and **Bonventre JV**. Oscillations of intracellular calcium induced by vasopressin in individual fura-2-loaded mesangial cells. Frequency dependency on basal calcium concentration, agonist concentration and temperature. J. Biol. Chem. 266: 21589-21594, 1991.
62. Rordorf G, Koroshetz WJ, and **Bonventre JV**. Heat shock protects cultured neurons from glutamate toxicity. Neuron. 7: 1043-1051, 1991.
63. Sellmayer A, Krane SM, Ouellette AJ, and **Bonventre JV**. 1,25-(OH)2 Vitamin D3 induces expression of the genes encoding for two myeloid cell–specific calcium binding proteins, MRP-8 and MRP-14, in U937 cells. Am. J. Physiol. (Cell Physiol.) 262: C235-C242, 1992.
64. Abou-Samra A-B, Jueppner H, Force T, Freeman MW, Kong X-F, Schipani E, Urena P, Richards J, **Bonventre JV**, Potts Jr JT, Kronenberg HM, and Segre GV. Expression cloning of a PTH/PTHrP receptor from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both ole and inositol trisphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. USA. 89: 2732-2736, 1992.
65. Force T, **Bonventre JV**, Flannery MR, Gorn AH, Yamin M, and Goldring SR. A cloned porcine renal calcitonin receptor couples to adenylyl cyclase and phospholipase C. Am. J. Physiol. (Renal Fluid and Electrolyte Physiol.) 262: F1110-F1115, 1992.
66. Wong, JT, **Bonventre JV**, Dunn, S, and Colvin, RB. Comparative studies of isolated CD3:CD8, CD3:CD3, and monovalent CD3 binding on CD8+ T-cell activation: Model of progressive T-cell receptor aggregation synergism. Human Immunol. 35: 200-208, 1992.
67. Segre GV, Abou-Samra A-B, Jüppner H, Schipani E, Force T, Urena P, Freeman M, Kong X-F, Kolakowski Jr. LF, Hock J, **Bonventre JV**, Potts JT, and Kronenberg HM. Characterization of cloned PTH/PTHrP receptors. J. Endocrinological Inv. 15, Suppl 6: 11-17, 1992.
68. Cantiello HF, Prat AG, **Bonventre JV**, Cunningham CC, Hartwig JH, and Ausiello DA. Actin-binding protein contributes to cell volume regulatory ion channel activation in melanoma cells. J. Biol. Chem. 268: 4596-4599, 1993.
69. Witzgall R, O’Leary E, Gessner R, Ouellette AJ, and **Bonventre JV**. Kid-1, a putative renal transcription factor: regulation during growth, ontogeny, and in response to ischemia and toxic injury. Mol. Cell. Biol. 13: 1933-1942, 1993.
70. **Bonventre, JV** and Koroshetz WJ. Phospholipase A2 activity in Gerbil brain: Characterization of cytosolic and membrane-associated forms and effects of ischemia and reperfusion on enzymatic activity. J. Lipid Mediators. 6: 457-471, 1993.
71. Kim DK and **Bonventre JV**. Purification of a 100 kDa phospholipase A2 from spleen, lung and kidney. Antiserum raised to porcine spleen phospholipase A2 recognizes a similar form in bovine lung, kidney and platelets and immunoprecipitates phospholipase A2 activity. Biochemical J. 294: 261-270, 1993.
72. Kyriakis JM, Force T, Rapp UR, **Bonventre JV**, and Avruch J. Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase kinase. J. Biol. Chem. 268: 16009-16019, 1993.
73. Kelly KJ, Williams Jr WW, Colvin RB, and **Bonventre JV**. Antibody to intercellular adhesion molecule-1 protects the kidney against ischemic injury Proc. Natl. Acad. Sci. USA. 91: 812-816, 1994.
74. Force T, **Bonventre JV**, Heidecker G, Rapp U, Avruch J, and Kyriakis JM. Enzymatic characteristics of the c-Raf-1 protein kinase. Proc. Natl. Acad. Sci. USA. 91: 1270-1274, 1994.
75. Witzgall R, Volk R, Yeung RS, and **Bonventre JV**. Genomic structure and chromosomal localization of the gene encoding the zinc finger transcription factor Kid-1. Genomics 20: 203-209, 1994.
76. Witzgall R, Brown D, Schwarz C, and **Bonventre JV**. Localization of proliferating cell nuclear antigen, vimentin, c-Fos and clusterin in the postischemic kidney. Evidence for a heterogeneous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J. Clin. Invest. 93: 2175-2188, 1994.
77. Witzgall R, O’Leary E, Leaf A, Önaldi D, and **Bonventre JV**. The KRAB-A domain of zinc finger proteins mediates transcriptional repression. Proc. Natl. Acad. Sci. USA. 91: 4514-4518, 1994.
78. Sohn UD, Kim DK, **Bonventre JV**, Behar J, and Biancani P. Role of 100-kDa cytosolic PLA2 in Ach-induced contraction of cat esophageal circular muscle. Am. J. Physiol. 267 (Gastrointest. Liver Physiol. 30): G433-G441, 1994.
79. Rabb HA, Mendiola CC, Dietz J, Saba SR, Issekutz TB, Ananilla F, **Bonventre JV**, and Ramirez G. Role of CD11a & CD11b in ischemic acute renal failure in rats. Am. J. Physiol. 267 (Renal, Fluid and Electrolyte Physiol. 36): F1052-F1058, 1994.
80. Abbate M, **Bonventre JV**, and Brown D. The microtubule network of renal epithelial cells is disrupted by ischemia and reperfusion. Am. J. Physiol. 267 (Renal, Fluid and Electrolyte Physiol. 36) : F971-F978, 1994.
81. Pombo CM, **Bonventre JV**, Avruch J, Woodgett JR, Kyriakis JM, and Force T. The stress-activated protein kinases (SAPKs) are major c-jun amino-terminal kinases activated by ischemia and reperfusion. J. Biol. Chem. 269: 26546-26551, 1994.
82. Witzgall R, O’Leary E, and **Bonventre JV**. A mammalian expression vector for the expression of GAL4-fusion proteins with an epitope tag and histidine tail. Anal. Biochem. 223: 291-298, 1994.
83. Koroshetz WJ and **Bonventre JV**. Heat-shock response in the central nervous system. Experientia. 50: 1085-1091, 1994.
84. Nakamura H, Kim DK, Philbin DM, Peterson MB, Debros F, Koski G and **Bonventre JV**. Heparin-enhanced plasma phospholipase A2 activity and prostacyclin levels in patients undergoing cardiac surgery. J. Clin. Invest. 95: 1062-1070, 1995.
85. **Bonventre JV**, Kyriakis JM, Spech R, Witzgall R, Avruch J, and Force T. Phospholipase A2 and lipids as potential modulators of c-Raf-1 kinase. Amer. J. Therapeutics, 2: 1-8, 1995.
86. **Bonventre JV** and Witzgall R. Kid-1, a kidney transcription factor. Exp. Nephrol. 3: 159-164, 1995.
87. Ross BM, Kim DK, **Bonventre JV**, and Kish SJ. Characterization of a novel phospholipase A2 activity in human brain. J. Neurochemistry 64: 2213-2221, 1995.
88. Kleinman JG, Worcester EM, Beshensky AM, Sheridan AM, **Bonventre JV** and Brown D. Upregulation of osteopontin expression by ischemia in rat kidney. Ann. NY Acad. Sci. 760: 321-323, 1995.
89. Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, and **Bonventre JV**. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am. J. Physiol. 269 (Lung Cellular and Molecular Physiol. 13). L109-L118, 1995.
90. Kim DK, Rordorf G, Nemenoff RA, Koroshetz WJ, and **Bonventre JV**. Glutamate stably enhances the activity of two cytosolic forms of phospholipase A2 in brain cortical neurons. Biochem. J. 310: 83-90, 1995.
91. Rabb H, Mendiola CC, Saba SR, Dietz JR, Smith CW, **Bonventre JV**, Ramirez G. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochem. Biophys. Res. Comm. 211: 67-73, 1995.
92. Silverman ES, Thompson BT, Quinn DA, Kinane TB, **Bonventre JV**, and Hales CA. Na+/H+ exchange in pulmonary artery smooth muscle from spontaneously hypertensive rats and Wistar Kyoto rats. Am. J. Physiol. (Lung Cellular and Molecular Physiol.) 269 (5 Pt 1): L673-280, 1995.
93. Morooka H, **Bonventre JV**, Pombo CM, Kyriakis JM, and Force T. Ischemia and reperfusion enhance ATF-2 and c-Jun binding to ole response elements and to an AP-1 binding site from the c-*jun* promoter. J. Biol. Chem. 270:30084-30092, 1995.
94. Quinn DA, Dahlberg CGW, **Bonventre JV**, Scheid CR, Honeyman T, Joseph PM, Thompson BT, and Hales CA. The role of Na+/H+ exchange and growth factors in pulmonary artery smooth muscle proliferation. Am. J. Resp. Cell and Mol. Biol. 14: 139-145, 1996.
95. Dahlberg CGW, Thompson BT, Joseph PM, Garg HG, Spence CR, Quinn DA, **Bonventre JV**, and Hales CA. The differential effect of three commercial heparins on Na+/H+ exchange and growth of pulmonary artery smooth muscle cells. Am. J. Physiol. (Lung Cellular and Molecular Physiol.) 270: L260-L265, 1996.
96. Kelly KJ, Williams Jr. WW, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos J-C, and **Bonventre JV**. Intercellular adhesion molecule-1 deficient mice are protected against ischemic renal injury. J. Clin. Invest. 97: 1056-1063, 1996.
97. **Bonventre JV**. Calcium and calcium-related olecules pathways in glomerular mesangial cells. Clin. Exp. Pharmacol. Physiol. 23: 65-70, 1996.
98. Rothenberg ME, Ownbey R, Mehlhop PD, Loiselle PM, van de Rijn M, **Bonventre JV**, Oettgen HC, Leder P, and Luster AD. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Molecular Medicine 2: 334-348, 1996.
99. Sapirstein A, Spech RA, Witzgall R, and **Bonventre JV**. Cytosolic PLA2 (cPLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J. Biol. Chem. 271: 21505-21513, 1996.
100. Pombo C, **Bonventre JV**, Molnar A, Kyriakis J, Force T. Activation of a human Ste20-like by oxidant stress defines a novel stress response pathway. EMBO J. 15: 4537-4546, 1996.
101. Kelly KJ, Tolkoff-Rubin NE, Rubin RH, Williams Jr. W, Meehan SM, Meschter CL, Christenson J, and **Bonventre JV**. An oral platelet activating factor antagonist, RO-24-4736, protects the rat kidney from ischemic injury. Amer. J. Physiol. 271: F1061-F1067, 1996.
102. Kim S-S, Chen Y-M, O’Leary E, Witzgall R, Vidal M, and **Bonventre JV**. A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc. Natl. Acad. Sci. USA. 93:15299-15304, 1996.
103. **Bonventre JV**. Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity. J. Lipid Med. Cell Signalling 16: 199-208, 1997.
104. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, **Bonventre JV**, Slatopolsky EA. Poly[allylamine hydrochloride] (RenaGelTM ): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kid. Diseases. 29: 66-71, 1997.
105. DuBose Jr TD, Warnock DG, Mehta RL, **Bonventre JV**, Hammerman MR, Molitoris BA, Paller MS, Siegel NJ, Scherbenske MJ, and Sriker GE. Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am J. Kid. Diseases 29: 793-799, 1997.
106. Pombo CM, Tsujita T, Kyriakis JM, **Bonventre JV**, Force T. Activation of the Ste-20-like oxidant stress response kinase-1 during initial stages of chemical anoxia-induced necrotic cell death. Requirement for dual inputs of oxidant stress and increased cytosolic [Ca2+]. J. Biol. Chem. 272: 29372-29379, 1997.
107. Elser B., Kriz W, **Bonventre JV**, Englert C, Witzgall R. The Krüppel-associated box (KRAB)-zinc finger protein Kid-1 and the Wilms’ tumor protein WT1, two transcriptional repressor proteins, bind to heteroduplex DNA. J. Biol. Chem. 272: 27908-27912, 1997.
108. Brown D, Lee R, **Bonventre JV**. Redistribution of villin to proximal tubule basolateral membranes after ischemia and reperfusion. Am. J. Physiol. 273:F1003-F1012, 1997.
109. **Bonventre JV**, Huang Z, Taheri MR, O’Leary E, Li E, Moskowitz MA, and Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390:622-625, 1997.
110. Ichimura T, **Bonventre JV**, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273:4235-4142, 1998.
111. Zuk A, **Bonventre JV**, Brown D, Matlin KS. Polarity, integrin and extracellular matrix dynamics in the postischemic rat kidney. Am. J. Physiol. (Cell Physiol.) 275: C711-C731, 1998.
112. **Bonventre JV**. Pathogenetic and regenerative mechanisms in acute tubular necrosis. Kidney and Blood Pressure Research 21: 226-229, 1998.
113. Choukroun G, Hajjar R, Kyriakis JM, **Bonventre JV**, Rosenzweig A, and Force T. Role of stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J. Clin. Invest. 102: 1311-1320, 1998.
114. **Bonventre JV**, Brezis M, Siegel N, Rosen S, Portilla D and Venkatachalam M. Acute renal failure. I. Relative importance of proximal vs distal tubular injury. Am. J. Physiol. 275: F623-F632, 1998.
115. Witzgall R, Obermüller N, Bölitz U, Calvet JP, Cowley Jr BD, Walker C, Kriz W, Gretz N, and **Bonventre JV**. Kid-1 expression is high in differentiated renal proximal tubule cells and suppressed in cyst epithelia. Am. J. Physiol: 275 (Renal Physiol. 44): F928-F937, 1998.
116. Rabb H, **Bonventre JV**. Experimental strategies for acute renal failure: the future. In: Therapy in Nephrology and Hypertension; A Companion to Brenner and Rector’s The Kidney. Edited by Hugh R. Brady and Christopher S. Wilcox, W.B. Saunders Co. 12 : 71-80. 1998.
117. Klivenyi P, Beal MF, Ferrante R, Andreassen O, Wermer M, Chin M-R, and **Bonventre JV**. Mice deficient in cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J. Neurochem. 71:2634-2637, 1999.
118. Huang Z, Philippin B, O’Leary E, **Bonventre JV**, Kriz W, and Witzgall R. Expression of the transcriptional repressor Kid-1 leads to the disintegration of the nucleolus. J. Biol. Chem. 274:7640-7648, 1999.
119. Fujishima H, Sanchez RO, Bingham III CO, Lam BK, Sapirstein A, **Bonventre JV**, Austen KF, Arm JP. Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in bone marrow-derived mast cells. Proc. Natl. Acad. Sci. USA. 96: 4803-4807, 1999.
120. Fukuda T, Kim DK, Chin M-R, Hales CA and **Bonventre JV**. Increased group IV cytosolic phospholipase A2 activity in lungs of sheep after smoke inhalation injury. Am. J. Physiol. 277(Lung Cell. Mol. Physiol. 21.): L533-L542, 1999.
121. Abbate M , Brown D, and **Bonventre JV**. Expression of neural adhesion molecule recapitulates tubulogenic developmental pattern in kidneys recovering from acute ischemic injury. Am. J. Physiol. (Renal) 277: F971-F978, 1999.
122. Kelly KJ, Meehan SM, Colvin RB, Williams Jr WW, and **Bonventre JV**. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 56: 922-931, 1999.
123. Alessandrini A, Namura S, Moskowitz MA, and **Bonventre JV**. MEK1 inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 96:12866-12869, 1999.
124. Tekki-Kessaris N, **Bonventre JV**, and Boulter CA. Characterization of the mouse Kid-1 gene and identification of a highly related gene, Kid-2. Gene 240: 13-22, 1999.
125. Faccio L, Fusco C, Chen A, Martinotti S, **Bonventre JV**, and Zervos AS. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J. Biol. Chem. 275: 2581-2588, 2000.
126. Faccio L, Chen A, Fusco C, Marinotti S, **Bonventre JV** and Zervos AS. Mxi2, a splice variant of p38 stress-activated kinase, is a distal nephron protein regulated with kidney ischemia. Am. J. Physiol. (Cell) 278: C781-C790, 2000.
127. Welch DR, Sakamaki T, Pioquinto R, Leonard TO, Goldberg SF, Hon Q, Erikson RL, Hicks DJ, **Bonventre JV**, and Alessandrini A. Transfection of constitutively active Mek1 confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res. 60: 1552-1556, 2000.
128. Makkinje A, Quinn DA, Chen A, Cadilla C, Force T, **Bonventre JV** and Kyriakis JM. Gene 33/Mig-6; a transcriptionally-inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in response to persistent stress. J. Biol. Chem. 275: 17838-17847, 2000.
129. Gijon M, Spencer D, Siddiqu A, **Bonventre JV**, Leslie C. Cytosolic phospholipase A2 is required for machrophage arachidonic acid release by agonists that do and do not mobilize calcium. J. Biol. Chem. 275: 20146-56, 2000.
130. Choukroun GJ, Marshansky V, Gustafson CE, McKee M, , Hajjar RJ, Rosenzweig A, Brown D, and **Bonventre JV**. Cytosolic phospholipase A2 regulates golgi structure and modulates intracellular trafficking of membrane proteins. J. Clin. Invest. 106: 983-993, 2000.
131. Samad TA, Moore KA, Sapirstein A, Billet S, Allchrome A, Poole S, **Bonventre JV**, and Woolf CJ. An interleukin-1-mediated induction of Cox-2 in the central nervous system contributes to inflammatory pain hypersensitivity. Nature, 410: 471-475, 2001.
132. Park K-M, Chen A, and **Bonventre JV**. Prevention of kidney ischemia/reperfusion-induced functional injury, and JNK, p38, and MAP kinase kinase activation by remote ischemic pretreatment. J. Biol. Chem. 276:11870-11876, 2001.
133. Downey P, Sapirstein A, O’Leary E, Brown D, and **Bonventre JV**. Renal with an abnormality in proximal tubule aquaporin 1. Am. J. Physiol. Renal Physiol 280:F607-F618, 2001.
134. Hong KH, Bonventre JC, O’Leary E, **Bonventre JV** and Lander ES. Deletion of cytosolic phospholipase A2 suppresses ApcMin-induced tumorigenesis. Proc. Natl. Acad. Sci. USA. 98: 3935-3939, 2001.
135. Hsu SI-H, Hentschel D, O’Leary E, and **Bonventre JV**. TRIP-Br: A Novel Family of PHD Finger and bromodomain interacting proteins that regulate the activation function of E2F-1/DP-1. EMBO J. 20:2273-85, 2001.
136. Zuk A, **Bonventre JV**, Matlin K. Expression of fibronectin splice variants in the post-ischemic rat kidney. Am J Physiol Renal Physiol. 280:F1037-53, 2001.
137. Sheridan AM, Force T, Yoon H.-J., Choukroun G, O’Leary E, Taheri MR, and **Bonventre JV**. PLIP, a nuclear protein, interacts with group IV cytosolic phospholipase A2, induces apoptosis and potentiates prostaglandin production. Mol Cell Biol. 21:4470-81, 2001.
138. Das A, Asatryan L, Reddy MA, Wass CA, Stins MF, Joshi S, **Bonventre JV**, and Kim KS. Differential role of cytosolic phospholipase A2 in the invasion of brain microvascular endothelial cells by *Escherichia coli* and *Listeria monocytogenes*‡. J. Infectious Dis. 184:732-737, 2001.
139. Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, Moskowitz MA, **Bonventre JV** & Alessandrini A. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc. Natl. Acad. Sci. USA. 98: 11569-11574, 2001.
140. Panini S, Yang L, Rusinol A, Sinensky MS, **Bonventre JV** and Leslie CC. Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized LDL /oxysterol. J. Lipid Res. 42:1678-1686, 2001.
141. Sheridan AM, Sapirstein A, Lemieux N, Martin BD, Kim DK, Bonventre JV. Nuclear translocation of cytosolic phospholipase A2 is induced by ATP depletion. J Biol Chem. 276:29899-905, 2001.
142. Park K-M, Kramers C, Vayssier-Taussat M, Chen A, and **Bonventre JV**. Prevention of kidney ischemia/reperfusion functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J. Biol Chem. 277:2040-2049,2002.
143. Kim S-S, Chae H-S, Bach J-H, Lee MW, Kim KY, Lee WB, Jung Y-M, **Bonventre JV**, and Suh YH. P53 mediates ceramide-induced apoptosis in SKN-SH cells. Oncogene. 21:2020-8, 2002.
144. Han WK, Bailly V, Abichandani R, Thadhani R, and **Bonventre JV**. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62:237-44, 2002.
145. Song H, Lim H, Paria BC, Matsumoto H, Morrow J, **Bonventre JV**, Dey SK. Cytosolic phospholipase A2 deficiency is crucial for ‘on-time’ embryo implantation that directs subsequent development. Development. 129:2879-2889, 2002.
146. Ichinose F, Ullrich R, Sapirstein A, Jones RC, **Bonventre JV**, Serhan CN, Bloch KD, Zapol WM. A role of cytosolic phospholipase A2 in hypoxic pulmonary vasoconstriction – a study of cPLA2-deficient mice. J. Clin. Invest. 109:1493-500, 2002.
147. Goruppi S, **Bonventre JV**, Kyriakis JM. Signaling pathways and late onset gene induction associated with renal mesangial cell hypertrophy. EMBO J. 21:5427-5436, 2002.
148. Kuehn EW, Park K-M, Somlo S, **Bonventre JV**. Kidney Injury molecule-1 (Kim-1) expression in murine polycystic kidney disease. Am. J. Physiol. Renal. 283: F1326-F1336, 2002.
149. Bailly V, Meier W, Sanicola M, Ding J, and **Bonventre JV**. Shedding of KIM-1, a putative adhesion protein involved in renal regeneration. J. Biol. Chem. 277:39739-48, 2002.
150. Diaz BL, Fujishima H, Sapirstein A, **Bonventre JV**, Arm JP. Participation of cytosolic phospholipase A2 in eicosanoid generation by mouse bone marrow-derived mast cells. Adv Exp Med Biol 507:41-6, 2002.
151. **Bonventre JV**, Sapirstein A. Group IV cytosolic phospholipase A2 (PLA2) function: insights from the knockout mouse. Adv Exp Med Biol 507:25-31, 2002.
152. Rosenberger TA, Villacreses NE, Contreras MA, **Bonventre JV**, Rapoport SI. Brain lipid metabolism in the cPLA(2) knockout mouse. J Lipid Res. 44:109-17, 2003.
153. Cilenti L, Lee Y, Hess S, Srinivasula S, Park KM, Junqueira D, Davis H, **Bonventre JV**, Alnemri ES, Zervos AS. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem. 278:11489-11494, 2003.
154. Choi WI, Quinn DA, Park KM, Moufarrej RK, Jafari B, Syrkina O, **Bonventre JV**, Hales CA. Systemic Microvascular Leak in an In vivo Rat Model of Ventilator-Induced Lung Injury. Am J Respir Crit Care Med. 167:1627-32, 2003.
155. Li LF, Ouyang B, Choukroun G, Matyal R, Mascarenhas M, Jafari B, **Bonventre JV**, Force T, Quinn DA. Stretch-induced IL-8 depends on c-Jun NH2-terminal and nuclear factor-kB-inducing kinases. Am J Physiol Lung Cell Mol Physiol. 285:L464-L475, 2003.
156. Park KM, Byun JY, Kramers C, Kim JI, Huang PL, **Bonventre JV**. Inducible nitric oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem. 278:27256-27266, 2003.
157. Han WK, Sapirstein A, Hung CC, Alessandrini A, **Bonventre JV**. Cross-talk between cPLA2a and sPLA2 in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells. SPLA2 regulates cPLA2\_ activity which is responsible for arachidonic acid release. J Biol Chem. 278:24153-63, 2003.
158. Munoz NM, Kim YJ, Meliton AY, Kim KP, Han SK, Boetticher E, O’Leary E, Myou S, Xu X, **Bonventre JV**, Leff AR, Cho W. Human group V phospholipase A2 induces group IVA phospholipase A2-independent cysteinyl leukotriene synthesis in human Eosinophils. J Biol Chem. 278:38813-20, 2003.
159. Hung CC, Ichimura T, Stevens JL, **Bonventre JV**. Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem. 278:29317-26, 2003.
160. Haq S, Kilter H, Michael A, Tao J, O’Leary E, Sun XM, Walters B, Bhattacharya K, Chen X, Guerrero JL, Andreucci M, Cui L, Rosenzweig A, Molkentin J, Liao R, Patten R, Picard M, **Bonventre JV**, Force T: Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat. Med. 9:944-51, 2003.
161. Andreucci M, Michael A, Kramers C, Park KM, Chen A, Matthaeus T, Alessandrini A, Haq S, Force T, **Bonventre JV**. Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1. Kidney Int. 64:1189-98, 2003.
162. Ghosh M, Stewart A, Tucker DE, **Bonventre JV**, Murphy RC, Leslie CC. Role of cytosolic phospholipase A2 in prostaglandin E2 production by lung fibroblasts. Am J Respir Cell Mol Biol. 30: 91-100, 2004.
163. Ichimura T, Hung CC, Yang SA, Stevens JL, **Bonventre JV**. Kidney Injury Molecule –1 (Kim-1): A Tissue and Urinary Biomarker for Nephrotoxicant-Induced Renal Injury. Am J Physiol Renal Physiol. 286: F552-63, 2004.
164. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O’Leary E. You M, **Bonventre JV**, Nemenoff RA, Malkinson AM. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 25: 1517-1524, 2004.
165. Thio SS, **Bonventre JV**, Hsu SI. The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain. Nucleic Acids. Res. 32:1836-47, 2004.
166. **Bonventre JV.** Cytosolic phospholipase A2α reigns supreme in arthritis and bone resorption. Trends Immunol 25:116-119, 2004.
167. **Bonventre JV**, Zuk A. Ischemic Acute Renal Failure: An Inflammatory Disease? Kidney Int 66: 480-485, 2004.
168. De Broe ME, **Bonventre JV**, Molitoris BA, Haller H. Evolving basic concepts in ischemic injury, Kidney Int 66:479, 2004.
169. **Bonventre, JV**. Pathophysiology of Ischemic Acute Renal Failure: Inflammation, Lung-Kidney Cross-talk, and Biomarkers. Contrib Nephrol. 144:19-30, 2004.
170. Jaber BL, Pereira BJ, **Bonventre JV**, Balakrishnan VS. Polymorphism of host response genes: Implications in the pathogenesis and treatment of acute renal failure. Kidney International. 67(1):14-33, 2005.
171. Cilenti L, Kyriazis GA, Soundarapandian MM, Stratico V, Yerkes A, Park KM, Sheridan AM, Alnemri ES, **Bonventre JV**, Zervos AS. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 288:F371-9, 2005
172. Sim KG, Zang Z, Yang CM, **Bonventre JV**, Hsu SI. TRIP-Br Links E2F to Novel Functions in the Regulation of Cyclin E Expression During Cell Cycle Progression and in the Maintenance of Genomic Stability. Cell Cycle 3:1296-304, 2004.
173. Cilenti L, Soundarapandian MM, Kyriazis GA, Stratico V, Singh S, Gupta S, **Bonventre JV**, Alnemri ES, Zervos AS. Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem. 279:50295-301, 2004.
174. Park KM, Kim JI, Ahn Y, Bonventre AJ, **Bonventre JV.** Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem .279:52282-92, 2004.
175. Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, Thadhani R, **Bonventre JV**. Human Kidney Injury Molecule-1 Is a Tissue and Urinary Tumor Marker of Renal Cell Carcinoma. J Am Soc Nephrol. 16:1126-34, 2005.
176. Hentschel DM, Park KM, Cilenti L, Zervos AS, Drummond I, **Bonventre JV**. Acute Renal Failure in Zebrafish: A Novel System to Study a Complex Disease. Am J Physiol Renal Physiol. 288:F923-9, 2004.
177. Sapirstein A, Saito H, Texel S, Samad T, O’Leary E, **Bonventre JV**. Cytosolic Phospholipase A2α Regulates Induction Of Brain Cyclooxygenase-2 In a Mouse Model of Inflammation. Am J Physiol Regul Integr Comp Physiol. 288(6):R1774-82, 2005.
178. Park KM, Cho HJ, **Bonventre JV**. Orchiectomy reduces susceptibility to renal ischemic injury: a role for heat shock proteins. Biochem Biophys Res Commun. 328:312-7, 2005.
179. Jaber BL, Pereira BJ, **Bonventre JV**, Balakrishnan VS. Polymorphism of host response genes: implications in the pathogenesis and treatment of acute renal failure. Kidney Int. 67:14-33, 2005.
180. Duffield JS, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, **Bonventre JV**. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest. 115(7):1743-55, 2005.
181. Muckova K, Duffield JS, Held KD, **Bonventre JV**, Sheridan AM. CPLA2-interacting protein, PLIP, causes apoptosis and decreases G1 phase in mesangial cells. Am J Physiol Renal Physiol. 290(1):F70-9, 2006.
182. Duffield JS, Bonventre JV. Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int. 68(5):1956-61, 2005.
183. Chertow GM, Burdick E, Honour M, **Bonventre JV**, Bates DW: Acute kidney injury mortality length of stay and costs in hospitalized patients. J. Am. Soc. Nephrol. 16(11):3365-70, 2005.
184. Vaidya V, Ramirez V, Ichimura T, Bobadilla N, and **Bonventre JV**: Urinary kidney injury molecule-1 (Kim-1): a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 290(2):F517-29, 2006.
185. Duffield JS, Tipping PG, Kipari T, Cailhier JF, Clay S, Lang R, **Bonventre JV**, Hughes J. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol. 167(5):1207-19, 2005.
186. Bellomo R, **Bonventre J**, Macias W, Pinsky M. Management of early acute renal failure: focus on post-injury prevention. Curr Opin Crit Care. 11(6):542-547, 2005.
187. Stafforini DM, Sheller JR, Blackwell TS, Sapirstein A, Yull FE, McIntyre TM, **Bonventre JV**, Prescott SM, Roberts LJ 2nd. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem. 24;281(8):4616-23, 2006.
188. Balestrieri B, Hsu VW, Gilbert H, Leslie CC, Han WK, **Bonventre JV**, Arm JP.Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis. J Biol Chem. 281(10):6691-8, 2006.
189. Meyer AM, Dwyer-Nield LD, Hurteau G, Keith RL, Ouyang Y, Freed BM, Kisley LR, Geraci MW, **Bonventre JV**, Nemenoff RA, Malkinson AM. Attenuation of the pulmonary inflammatory response following butylated hydroxytoluene (BHT) treatment of cytosolic phospholipase A2 (cPLA2) null mice. Am J Physiol Lung Cell Mol Physiol. 290: 1260-1266, 2006.
190. van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J, Stegeman CA, **Bonventre JV**, van Goor H. Tubular Kidney Injury Molecule-1 (Kim-1) In Protein-Overload Nephropathy. Am J Physiol Renal Physiol. 291(2):F456-64, 2006.
191. Kim J, Kil IS, Seok YM, Yang ES, Kim DK, Lim DG, Park JW, **Bonventre JV**, Park KM. Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem. 281(29):20349-56, 2006.
192. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, **Bonventre JV**, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 292(1):F131-9, 2007.
193. Kang MS, Jeong JY, Seo JH, Jeon HJ, Jung KM, Chin MR, Moon CK, **Bonventre JV**, Jung SY, Kim DK. Methylmercury-induced toxicity is mediated by enhanced intracellular calcium through activation of phosphatidylcholine-specific phospholipase C. Toxicol Appl Pharmacol. 216(2):206-15, 2006.
194. De Borst MH, van Timmeren MM, Vaidya VS, Van Dalen MB, Kramer AB, Schuurs TA, **Bonventre JV**, Navis G, van Goor H. Induction of Kidney injury molecule-1 (Kim-1) in homozygous Ren2 rats is attenuated by blockade of the olecu-angiotensin system or p38 MAP kinase. Am J Physiol Renal Physiol. 292(1):F313-20, 2007.
195. Lin F, Zhang P, Yang XJ, Blasick TM, Han WK, Shen SS, **Bonventre JV**. Human Kidney Injury Molecule-1 (hKIM-1): A Useful Immunohistochemical Marker for Diagnosing Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma. Am J Surg Pathol. 31(3):371-81, 2007.
196. Lechene CP, Hillion F, McMahon G, Benson DM, Kleinfeld AM, Kampf JP, Distel DL, Luyten YA, **Bonventre JV**, Hentschel DM, Park KM, Ito S, Schwartz MA, Benichou GA, Slodzian G. High-resolution quantitative imaging of mammalian and bacterial cells using stable isotope mass spectrometry. J Biol. 5(6):20, 2006.
197. Rennert PD, Ichimura T, Sizing ID, Bailly V, Li Z, Rennard R, McCoon P, Pablo L, Miklasz S, Tarilonte L, **Bonventre JV**. T cell, Ig domain, mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of th2 immune responses and airway inflammation. J Immunol. 177(7):4311-21, 2006.
198. Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, **Bonventre JV**. Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury. J Immunol. 177(9):5902-5911, 2006.
199. Liu L, Zhao R, Bai Y, Stanish L, Evans JE, Sanderson M, **Bonventre JV**, and Rittenhouse AR: M1 muscarinic receptors inhibit L-type Ca2+ current and M-current by divergent signal transduction cascades. J Neurosci. 26(45):11588-98, 2006.
200. van de Weyer PS, Muehlfeit M, Klose C, **Bonventre JV**, Walz G, Kuehn EW. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun. 351(2):571-6, 2006.
201. Perianayagam MC, Liangos O, Kolyada AY, Wald R, Mackinnon RW, Li L, Rao M, Balakrishnan VS, **Bonventre JV**, Pereira BJ, Jaber BL.NADPH Oxidase p22phox and Catalase Gene Variants Are Associated with Biomarkers of Oxidative Stress and Adverse Outcomes in Acute Renal Failure. J Am Soc Nephrol. 18(1):255-263, 2007. PMID: 17151330
202. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, **Bonventre JV**, Jaber BL. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 18(3):904-12, 2007. PMID: 17267747
203. Kikawada E, **Bonventre JV**, Arm JP. Group V secretory PLA2 regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA2{alpha} activation. Blood. 15;110(2):561-7, 2007. PMCID: PMC1924482
204. Ghosh M, Loper R, Ghomashchi F, Tucker DE, **Bonventre JV**, Gelb MH, Leslie CC. Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts. J Biol Chem. 20;282(16):11676-86, 2007. PMCID: PMC2678067
205. Chen G, Bridenbaugh EA, Akintola AD, Catania JM, Vaidya VS, **Bonventre JV**, Dearman AC, Sampson HW, Zawieja DC, Burghardt RC, Parrish AR. Increased Susceptibility of Aging Kidney to Ischemic Injury: Identification of Candidate Genes Changed During Aging, but Corrected by Caloric Restriction.
206. Am J Physiol Renal Physiol. 293(4):F1272-81, 2007. PMCID: PMC2758575
207. Prozialeck WC, Vaidya VS, Liu J, Waalkes MP, Edwards JR, Lamar PC, Bernard AM, Dumont X, **Bonventre JV**. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int. 72(8):985-93, 2007. PMCID: PMC2747605
208. Hentschel DM, Mengel M, Boehme L, Liebsch F, Albertin C, **Bonventre JV**, Haller H, Schiffer M. Rapid screening of glomerular slit diaphragm integrity in larval zebrafish. Am J Physiol Renal Physiol. 293(5):F1746-50, 2007. PMID: 17699558
209. Espandiari P, Zhang J, Rosenzweig BA, Vaidya VS, Sun J, Schnackenberg L, Herman EH, Knapton A, **Bonventre JV**, Beger RD, Thompson KL, Hanig J. The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol Sci. 99(2):637-48, 2007. PMCID: PMC2729403
210. Munoz NM, Meliton AY, Arm JP, **Bonventre JV**, Cho W, Leff AR. Deletion of secretory group v phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J Immunol. 179(7):4800-7, 2007. PMID: 17878379
211. Zhang Z, Humphreys BD, **Bonventre JV**. Shedding of the Urinary Biomarker Kidney Injury Molecule-1 (KIM-1) Is Regulated by MAP Kinases and Juxtamembrane Region. J Am Soc Nephrol. 18(10):2704-14, 2007. PMID: 17898236
212. Han WK, Waikar S, Johnson A, Betensky R, Dent C, Devarajan P, **Bonventre JV**. Urinary Biomarkers for Detection of Acute Kidney Injury. Kidney Int. 73(7):863-9, 2007. PMCID: PMC2586909
213. Zhou Y, Vaidya VS, Brown RP, Zhang J, Rosenzweig BA, Thompson KL, Miller TJ, **Bonventre JV** and Goering PL. Comparison of Kidney Injury Molecule-1 and Other Nephrotoxicity Biomarkers in Urine and Kidney FollowingAcute Exposure to Gentamicin, Mercury, and Chromium. Toxicol. Sci. 101(1):159-70, 2008.
214. Noor S, Goldfine H, Tucker DE, Suram S, Lenz LL, Akira S, Uematsu S, Girotti M, **Bonventre JV**, Breuel K, Williams DL, Leslie CC. Activation of cytosolic phospholipase A2alpha in resident peritoneal macrophages by Listeria monocytogenes involves listeriolysin O and TLR2. J Biol Chem. 283(8):4744-55, 2007. PMID: 18083708
215. van Timmeren MM, Vaidya VS, van Ree RM, Oterdoom LH, de Vries AP, Gans RO, van Goor H, Stegeman CA, **Bonventre JV**, Bakker SJ. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 84(12):1625-30, 2007. PMCID: PMC2745062
216. Cubells L, Vilà de Muga S, Tebar F, **Bonventre JV**, Balsinde J, Pol A, Grewal T, Enrich C. Annexin A6-induced inhibition of cPLA2 is linked to CAV-1 export from the golgi. J Biol Chem. 283(15):10174-83, 2008. PMID: 18245088
217. Murray PT, Devarajan P, Levey AS, Eckardt KU, **Bonventre JV**, Lombardi R, Herget-Rosenthal S, Levin A. A Framework and Key Research Questions in AKI Diagnosis and Staging in Different Environments. Clin J Am Soc Nephrol. 3(3):864-8, 2008. PMID: 18287251
218. Humphreys BD, Valerius MT, Kobayashi A, Mugford JW, Soeung S, Duffield JS, McMahon AP, **Bonventre JV**. Intrinsic Epithelial Cells Repair the Kidney after Injury. Cell Stem Cell. 2: 284-291, 2008. PMID: 18371453
219. Zhang PL, Rothblum LI, Han WK, Blasick TM, Potdar S, **Bonventre JV**. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 73(5):608-14, 2008. PMCID: PMC2915578
220. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules, C, Bradwin G, Matsouaka R, Betensky R, Curhan GC, **Bonventre JV**. Urinary Biomarkers for Sensitive and Specific Detection of Acute Kidney Injury in Humans. Clin. and Transl. Sci. 1(3):200-208, 2008. PMCID: PMC2638059
221. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, **Bonventre JV**. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 118(5):1657-68, 2008. PMCID: PMC2293335
222. Zhang J, Brown RP, Shaw M, Vaidya VS, Zhou Y, Espandiari P, Sadrieh N, Stratmeyer M, Keenan J, Kilty CG, **Bonventre JV**, Goering PL. Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine. Toxicol Pathol. 36(3):397-409, 2008. PMCID: PMC2745064
223. Taylor AL, **Bonventre JV**, Uliasz TF, Hewett JA, Hewett SJ. Cytosolic Phospholipase A(2)alpha Inhibition Prevents Neuronal NMDA Receptor-Stimulated Arachidonic Acid Mobilization and Prostaglandin Production but not Subsequent Cell Death. J Neurochem. 106: 1828-1840, 2008. PMCID: PMC2582587
224. Trujillo J, Cruz C, Tovar AR, Vaidya VS, Zambrano E, **Bonventre JV**, Gamba G, Torres N, Bobadilla NA. Renoprotective Mechanisms of Soy Protein Intake in the Obese Zucker Rat. Am J Physiol Renal Physiol. 295(5):F1574-82, 2008. PMID: 18815216
225. Waanders F, Vaidya VS, Goor HV, Leuvenink H, Damman K, Hamming I, **Bonventre JV**, Vogt L, Navis G. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Am J Kidney Dis. 53(1):16-25, 2008. PMCID: PMC3298772
226. Chagnon F, Vaidya VS, Plante GE, **Bonventre JV**, Bernard A, Guindi C, Lesur O. Modulation of aquaporin-2/V2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge. Crit Care Med. 36(11):3054-61, 2008. PMCID: PMC2745282
227. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cissé M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, **Bonventre JV**, Mucke L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 11(11):1311-8, 2008. PMCID: PMC2597064
228. Zhang ZJ, Gunaratnam L, Cheong JK, Lai LY, Hsiao LL, O'Leary E, Sun X, Salto-Tellez M, **Bonventre JV**, Hsu SI. Identification of PP2A as a novel interactor and regulator of TRIP-Br1. Cell Signal. 21(1):34-42, 2009. PMID: 18940248
229. Kim J, Kim KY, Jang HS, Yoshida T, Tsuchiya K, Nitta K, Park JW, **Bonventre JV**, Park KM. Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia/reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 296(3):F622-33, 2009. PMCID: PMC2660191
230. Cheong JK, Gunaratnam L, Zang ZJ, Yang CM, Sun X, Nasr SL, Sim KG, Peh BK, Rashid SB, **Bonventre JV**, Salto-Tellez M, Hsu SI. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. J Transl Med. 20;7(1):8, 2009. PMCID: PMC2671481
231. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin G, Matsouaka R, Betensky RA, Curhan GC, **Bonventre JV**. Urinary Biomarkers for Sensitive and Specific Detection of Acute Kidney Injury in Humans. Clin Transl Sci. 1(3):200-208, 2008. PMCID: PMC2638059
232. Kramer AB, van Timmeren MM, Schuurs TA, Vaidya VS, **Bonventre JV**, van Goor H, Navis G. Reduction of proteinuria in adriamycin-induced nephropathy is associated with reduction of renal Kidney injury molecule-1 (Kim-1) over time. Am J Physiol Renal Physiol. 296(5):F1136-45, 2009. PMCID: PMC2681357
233. Takakura A, Contrino L, Zhou X, **Bonventre JV**, Sun Y, Humphreys BD, Zhou J. Renal Injury is a Third Hit Promoting Rapid Development of Adult Polycystic Kidney Disease. Hum Mol Genet. 18(14):2523-31, 2009. PMCID: PMC2701325
234. Sieber M, Hoffmann D, Adler M, Vaidya V, Clement M, **Bonventre J**, Zidek N, Rached E, Amberg A, Callanan J, Dekant W, Mally A.Comparative analysis of novel non-invasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol Sci. 109(2):336-49, 2009. PMID:19349640
235. Prozialeck WC, Edwards JR, Lamar PC, Liu J, Vaidya VS, **Bonventre JV**. Expression of kidney injury molecule-1 (Kim-1) in relation to necrosis and apoptosis during the early stages of Cd-induced proximal tubule injury. Toxicol Appl Pharmacol. 238(3):306-14, 2009. PMCID: PMC2709705
236. Prozialeck WC, Edwards JR, Vaidya VS, **Bonventre JV**. Preclinical Evaluation of Novel Urinary Biomarkers of Cadmium Nephrotoxicity. Toxicol Appl Pharmacol. 238(3):301-5, 2009. PMCID: PMC2709709
237. Stokes JB, Haupt A, Molitoris BA, Kokemueller P, Ibrahim T; ASN Committee on Corporate Relations; ASN Council. J Am Soc Nephrol. 20(9):1853-9, 2009. PMID: 19713305
238. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, Ramirez V, Glaab WE, Troth SP, Sistare FD, Prozialeck WC, Edwards JR, Bobadilla NA, Mefferd SC, **Bonventre JV**. A rapid urine test for early detection of kidney injury. Kidney Int. 76(1):108-14, 2009. PMCID: PMC2737345
239. Parti RP, Loper R, Brown GD, Gordon S, Taylor PR, **Bonventre JV**, Murphy RC, Williams DL, Leslie CC. Cytosolic Phospholipase A2 Activation by Candida albicans in Alveolar Macrophages: Role of Dectin-1. Am J Respir Cell Mol Biol. 42(4):415-23, 2009. PMCID: PMC2848735
240. Nijboer WN, Schuurs TA, Damman J, van Goor H, Vaidya VS, van der Heide JJ, Leuvenink HG, **Bonventre JV**, Ploeg RJ. Kidney Injury Molecule-1 is an Early Noninvasive Indicator for Donor Brain Death-Induced Injury Prior to Kidney Transplantation. Am J Transplant. 9(8):1752-9, 2009. PMCID: PMC2747608
241. Zhang J, Goering PL, Espandiari P, Shaw M, **Bonventre JV**, Vaidya VS, Brown RP, Keenan J, Kilty CG, Sadrieh N, Hanig JP. Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and Nitrotyrosine. Toxicol Pathol. 37(5):629-43, 2009. PMCID: PMC2733219
242. Liangos O, Tighiouart H, Perianayagam MC, Kolyada A, Han WK, Wald R, **Bonventre JV**, Jaber BL. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers. 14(6):423-31, 2009. PMCID: PMC2743298
243. Lamour NF, Subramanian P, Wijesinghe DS, Robert V. Stahelin RV, **Bonventre JV** and Chalfant CE. Ceramide-1-phosphate is required for the translocation of group IVA cytosolic phospholipase A2 and prostaglandin synthesis. J. Biol. Chem. 284(39):26897-907, 2009. PMCID: PMC2785377
244. Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, Vaidya VS, Goering PL, Brown RP, **Bonventre JV**, Mahjoob K, Holland RD, Beger RD, Thompson K, Hanig J, Sadrieh N. Age-related differences in susceptibility to cisplatin-induced renal toxicity. J Appl Toxicol. 30(2):172-82, 2009. PMCID: PMC2829343
245. Ferguson MA, Vaidya VS, Waikar SS, Collings FB, Sunderland KE, Gioules CJ, **Bonventre JV**.Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 77(8):708-14, 2009. PMCID: PMC2880954
246. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, **Bonventre JV**, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 176(1):85-97, 2010. PMCID: PMC2797872
247. Schröppel B, Krüger B, Walsh L, Harris S, Garrison K, Himmelfarb J, Lerner SM, Bromberg JS, Zhang PL, **Bonventre JV**, Wang Z, Farris AB, Colvin RB, Murphy BT, Vella JP. Tubular Expression of KIM-1 Does not Predict Delayed Function After Transplantation. J Am Soc Nephrol. 21(3):536-42, 2010. PMCID: PMC2831861
248. Nishihara K, Masuda S, Nakagawa S, Yonezawa A, Ichimura T, **Bonventre JV**, Inui KI. Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. Am J Physiol Renal Physiol. 298(4):F923-34, 2010. PMID: 20071461
249. Hoffmann D, Adler M, Vaidya V, Rached E, Mulrane L, Gallagher WM, Callanan JJ, Gautier JC, Matheis K, Staedtler F, Dieterle F, Brandenburg A, Sposny A, Hewitt P, Ellinger-Ziegelbauer H, **Bonventre JV**, Dekant W, Mally A. Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci. 116(1):8-22, 2010. PMCID: PMC2886853
250. Kim J, Kim DS, Park M, Cho HJ, Zervos AS, **Bonventre JV**, Park KM. Omi/HtrA2 protease is associated with tubular cell apoptosis and fibrosis induced by unilateral ureteral obstruction. Am J Physiol Renal Physiol. 298(6):F1332-40, 2010. PMCID: PMC2886814
251. Yang L, Besschetnova TY, Brooks CR, Shah JV, **Bonventre JV**. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nature Medicine. 16(5):535-43, 2010. PMCID: PMC3928013
252. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, **Bonventre JV**. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotechnology. 28(5):478-85, 2010. PMCID: PMC2885849
253. Waikar SS, Sabbisetti VS, **Bonventre JV**. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 78(5):486-94, 2010. PMCID: PMC3025699
254. Suram S, Gangelhoff TA, Taylor PR, Rosas M, Brown GD, **Bonventre JV**, Akira S, Uematsu S, Williams DL, Murphy RC, Leslie CC.Pathways Regulating Cytosolic Phospholipase A2 Activation and Eicosanoid Production in Macrophages by *Candida albicans*. J Biol Chem. 285(40):30676-85, 2010. PMCID: PMC2945562
255. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, **Bonventre JV**, Voors AA, Hillege HL. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 96(16):1297-302, 2010. PMCID: PMC3480323
256. Krishnamoorthy A, Clement ME, O'leary E, **Bonventre JV**, Vaidya VS. TIM2 gene deletion results in susceptibility to cisplatin induced kidney toxicity. Toxicol Sci. 118(1):298-306, 2010. PMCID: PMC2955214
257. Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, **Bonventre JV**, Swanson KD, Duffield JS. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J. 24(12):4767-81, 2010. PMCID: PMC2992370
258. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester EM, Akhter SA, Raman J, Jeevanandam V, O'Connor MF, Devarajan P, **Bonventre JV**, Murray PT. Urinary Biomarkers in the Clinical Prognosis and Early Detection of Acute Kidney Injury. Clin J Am Soc Nephrol. 5(12):2154-65, 2010. PMCID: PMC2745082
259. Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, **Bonventre JV**.Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int 79(4):464-70,2010. PMCID: PMC3033751
260. **Bonventre JV**, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol. 28(5):436-40, 2010. PMCID: PMC3033582
261. Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, **Bonventre JV**, Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, Quaggin SE. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol. 22(1):113-23, 2011. PMCID: PMC3014040
262. Lee HJ, Park J, Yoon OJ, Kim HW, Lee do Y, Kim do H, Lee WB, Lee NE, **Bonventre JV**, Kim SS. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat Nanotechnol. 6(2):121-5, 2011. PMID: 21278749
263. Endre ZH, Pickering JW, Walker RJ, Devarajan P, Edelstein CL, **Bonventre JV**, Frampton CM, Bennett MR, Ma Q, Sabbisetti VS, Vaidya VS, Walcher AM, Shaw GM, Henderson SJ, Nejat M, Schollum JB, George PM. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int. 79(10):1119-30, 2011. PMCID: PMC3884688
264. Frasch SC, Fernandez-Boyanapalli RF, Zemski Berry K, Leslie CC, **Bonventre JV**, Murphy RC, Henson PM, Bratton DL. Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. J Biol Chem. 286(14):12108-22, 2011. PMCID: PMC3069415
265. Sangoi AR, McKenney JK, Brooks JD, **Bonventre JV**, Higgins JP. Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors: A Tissue Microarray Study of 100 Cases. Appl Immunohistochem Mol Morphol. 20(5):451-3, 2012. PMCID: PMC4124747
266. Humphreys BD, Czerniak S, DiRocco D, Hasnain W, Cheema R, **Bonventre JV**. Repair of Injured Proximal Tubule Does not Involve Specialized Progenitors. Proc. Natl. Acad. Sci. 108(22):9226-31, 2011. PMCID: PMC3107336
267. Kurusu S, Sapirstein A, Sawada H, Kawaminami M, **Bonventre JV**. Group IVA phospholipase A2 regulates testosterone biosynthesis by murine Leydig cells and is required for timely sexual maturation. Biochem J. 439(3):403-11, 2011. PMID: 21762109
268. Jeong EM, Ahn KH, Jeon HJ, Kim HD, Lee HS, Jung SY, Jung KM, Kim SK, **Bonventre JV**, Kim DK. Purification and characterization of a cytosolic Ca(2+)-independent phospholipase A(2) from bovine brain. Mol Cells. 32(5):405-13, 2011. PMCID: PMC3887695
269. Kerkelä R, Boucher M, Zaka R, Gao E, Harris D, Piuhola J, Song J, Serpi R, Woulfe KC, Cheung JY, O'Leary E, **Bonventre JV**, Force T. Cytosolic Phospholipase A(2) α Protects against Ischemia/Reperfusion Injury in the Heart. Clin Transl Sci. 4(4):236-42, 2011. PMCID: PMC3107336
270. Qin Y, Alderliesten MC, Stokman G, Pennekamp P, **Bonventre JV**, de Heer E, Ichimura T, de Graauw M, Price LS, Water BV. Focal Adhesion Kinase Signaling Mediates Acute Renal Injury Induced by Ischemia/Reperfusion. Am J Pathol. 179(6):2766-78, 2011. PMCID: PMC3260828
271. Waikar SS, Betensky RA, Emerson SC, **Bonventre JV**. Imperfect gold standards for kidney injury biomarker evaluation J Am Soc Nephrol. 23(1):13-21, 2012. PMCID: PMC3695762
272. Ralib A, Pickering JW, Shaw GM, Devarajan P, Edelstein CL, **Bonventre JV**, Endre ZH. Test Characteristics of Urinary Biomarkers Depend on Quantitation Method in Acute Kidney Injury. J Am Soc Nephrol. 23(2):322-33, 2011. PMCID: PMC3269182
273. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, **Bonventre JV**, Shen J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener. 7:2, 2012. PMCID: PMC3296570
274. Gardiner L, Akintola A, Chen G, Catania JM, Vaidya V, Burghardt RC, **Bonventre JV**, Trzeciakowski J, Parrish AR. Structural equation modeling highlights the potential of kim-1 as a biomarker for chronic kidney disease.Am J Nephrol. 35(2):152-63, 2012. PMCID: PMC3326283
275. Roy-Chaudhury P, Yevzlin A, **Bonventre JV**, Agarwal A, Almehmi A, Besarab A, Dwyer A, Hentschel DM, Kraus M, Maya I, Pflederer T, Schon D, Wu S, Work J. Academic interventional nephrology: a model for training, research, and patient care.Clin J Am Soc Nephrol. 7(3):521-4, 2012. PMID: 22344507, PMC journal, in process
276. Grgic I, Brooks CR, Hofmeister AF, Bijol V, **Bonventre JV**, Humphreys BD. Imaging of Podocyte Foot Processes by Fluorescence Microscopy.J Am Soc Nephrol. 23(5):785-91, 2012. PMCID: PMC3338299
277. Nejat M, Pickering JW, Devarajan P, **Bonventre JV**, Edelstein CL, Walker RJ, Endre ZH. Some biomarkers of acute kidney injury are increased in pre-renal acute injury.Kidney Int. 81(12):1254-62, 2012. PMCID: PMC3365288
278. Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti VS, Ichimura T, Humphreys BD, **Bonventre JV.** Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int. 82(2):172-83, 2012. PMCID: PMC3480325
279. Sangoi AR, McKenney JK, Brooks JD, **Bonventre JV**, Higgins JP. Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors: A Tissue Microarray Study of 100 Cases. Appl Immunohistochem Mol Morphol. 20(5):451-3, 2012. PMCID: PMC4077160
280. Ichimura T, Brooks CR, **Bonventre JV**. Kim-1/Tim-1 and immune cells: shifting sands. Kidney Int. 81(9):809-11, 2012. PMCID: PMC3339439.
281. Mizuguchi KA, Mitani A, Waikar SS, Ireland P, Panizales C, Deluke G, Sugarbaker DJ, **Bonventre JV**, Frendl G. Use of Postoperative Creatinine to Predict Sustained Kidney Injury in Patients Undergoing Mesothelioma Surgery. Clin J Am Soc Nephrol. 7(7):1071-1078, 2012. PMCID: PMC3386676
282. Vermeulen R, Zhang L, Spierenburg A, Tang X, **Bonventre JV**, Reiss B, Min S, Smith M, Qiu C, Chen G, Ji Z, Xiong J, He J, Hao Z, Liu S, Xie Y, Fei Y, Guo W, Purdue M, Beane Freeman LE, Sabbisetti V, Li L, Huang H, Rothman N, Lan Q. Carcinogenesis. 33(8):1538-41, 2012. PMCID: PMC3499056
283. Kurusu S, Sapirstein A, **Bonventre JV**. Group IVA phospholipase A2 optimizes ovulation and fertilization in rodents through induction of and metabolic coupling with prostaglandin endoperoxide synthase 2. FASEB J. 26(9):3800-10, 2012. PMCID: PMC3425826
284. Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kopparam J, Kulkarni A, Muto K, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, **Bonventre JV**, Mashelkar RA, Sengupta S. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A. 109(28):11294-9, 2012. PMCID: PMC3396529
285. Peralta CA, Katz R, **Bonventre JV**, Sabbisetti V, Siscovick D, Sarnak M, Shlipak MG. Associations of Urinary Levels of Kidney Injury Molecule 1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) With Kidney Function Decline in the Multi-Ethnic Study of Atherosclerosis (MESA).Am J Kidney Dis. 60(6):904-11, 2012. PMCID: PMC3690926
286. Xiao S, Brooks CR, Zhu C, Wu C, Sweere JM, Petecka S, Yeste A, Quintana FJ, Ichimura T, Sobel RA, **Bonventre JV**, Kuchroo VK. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc Natl Acad Sci U S A. 109(30):12105-10, 2012. PMCID: PMC3409739
287. McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, **Bonventre JV**, Park BK, Smyth RL, Pirmohamed M.Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One. 7(8), 2012. PMCID:PMC3427159
288. **Bonventre JV**, Basile D, Liu KD, McKay D, Molitoris BA, Nath KA, Nickolas TL, Okusa MD, Palevsky PM, Schnellmann R, Rys-Sikora K, Kimmel PL, Star RA; on behalf of the Kidney Research National Dialogue (KRND).Clin J Am Soc Nephrol. 8(9):1606-8.2013. PMCID: PMC3805072
289. Sabbisetti VS, Ito K, Wang C, Yang L, Mefferd SC, **Bonventre JV**. Novel assays for detection of urinary Kim-1 in mouse models of kidney injury. Toxicol Sci. 131(1):13-25, 2013. PMCID: PMC3621351
290. Nishihara K, Masuda S, Shinke H, Ozawa A, Ichimura T, Yonezawa A, Nakagawa S, Inui K, **Bonventre JV**, Matsubara K. Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity**.** Biochem Pharmacol. 85(4):570-82, 2013. PMCID: PMC4077184
291. Milwid JM, Ichimura T, Li M, Jiao Y, Lee J, Yarmush JS, Parekkadan B, Tilles AW, **Bonventre JV**, Yarmush ML. Secreted factors from bone marrow stromal cells upregulate IL-10 and reverse acute kidney injury. Stem Cells Int. 2012:392050, 2012. PMCID: PMC3539665
292. Greenberg JO, Vakharia N, Szent-Gyorgyi LE, Desai SP, Turchin A, Forman J, **Bonventre JV**, Kachalia A. Meaningful measurement: developing a measurement system to improve blood pressure control in patients with chronic kidney disease. J Am Med Inform Assoc. 20(e1):e97-e101, 2013. PMCID: PMC3715343
293. Tögel FE, **Bonventre JV**. Multipotent mesenchymal stromal cells protect against kidney injury. Cytotherapy.15(6):629-31, 2013. PMCID: PMC4077161
294. Susantitaphong P, Perianayagam MC, Tighiouart H, Liangos O, **Bonventre JV**, Jaber BL.Tumor Necrosis Factor Alpha Promoter Polymorphism and Severity of Acute Kidney Injury. Nephron Clin Pract. 123(1-2):67-73. PMCID: PMC4959276
295. **Bonventre JV**, Basile D, Liu KD, McKay D, Molitoris BA, Nath KA, Nickolas TL, Okusa MD, Palevsky PM, Schnellmann R, Rys-Sikora K, Kimmel PL, Star RA; Kidney Research National Dialogue (KRND).AKI: A Path Forward. Clin J Am Soc Nephrol. 8(9):1606-8, 2013. PMCID: PMC3805072
296. Suram S, Silveira LJ, Mahaffey S, Brown GD, **Bonventre JV**, Williams DL, Gow NA, Bratton DL, Murphy RC, Leslie CC. Cytosolic phospholipase a2α and eicosanoids regulate expression of genes in macrophages involved in host defense and inflammation.PLoS One. 8(7), 2013. PMCID: PMC3742295
297. Humphreys BD, Xu F, Sabbisetti V, Grgic I, Naini SM, Wang N, Chen G, Xiao S, Patel D, Henderson JM, Ichimura T, Mou S, Soeung S, McMahon AP, Kuchroo VK, **Bonventre JV**. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest. 123(9):4023-35, 2013. PMCID: PMC3755983
298. Timsit MO, Adams WJ, Laguna-Fernandez A, Ichimura T, **Bonventre JV**, García-Cardeña G, Tullius SG.Flow Is Critical for Maintaining a Protective Phenotype in Renal Proximal Tubular Cells**.** Am J Transplant.13(6):1617-8, 2013. PMCID: PMC4625983
299. Zhang PL, Mashni JW, Sabbisetti VS, Schworer CM, Wilson GD, Wolforth SC, Kernen KM, Seifman BD, Amin MB, Geddes TJ, Lin F, **Bonventre JV**, Hafron JM. Urine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinoma.Int Urol Nephrol. 46(2):379-88, 2014. PMCID: PMC4066455
300. Waikar SS, Betensky RA, Emerson SC, **Bonventre JV**. Imperfect gold standards for biomarker evaluation.Clin Trials. 10(5):696-700, 2013. PMCID: PMC3800226
301. Fahmy N, Sener A, Sabbisetti V, Nott L, Lang RM, Welk BK, Méndez-Probst CE, Macphee RA, Vaneerdewijk S, Cadieux PA, **Bonventre JV**, Razvi H.Urinary expression of novel tissue markers of kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J Endourol. 27(12):1455-62, 2013. PMCID: PMC3997088
302. Freedman BS, Lam AQ, Sundsbak JL, Iatrino R, Su X, Koon SJ, Wu M, Daheron L, Harris PC, Zhou J, **Bonventre JV**. Reduced Ciliary Polycystin-2 in Induced Pluripotent Stem Cells from Polycystic Kidney Disease Patients with PKD1 Mutations. J Am Soc Nephrol. (10):1571-862013, 2014. PMCID: PMC3785271
303. Yun B, Lee H, Ghosh M, Cravatt BF, Hsu KL, **Bonventre JV**, Ewing H, Gelb MH, Leslie CC. Serine Hydrolase Inhibitors Block Necrotic Cell Death by Preventing Calcium Overload of the Mitochondria and Permeability Transition Pore Formation. J Biol Chem. 289(3):1491-504, 2014. PMCID: PMC3894331
304. Parrinello G, Greene SJ, Torres D, Alderman M, **Bonventre JV**, Di Pasquale P, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, Butler J, Paterna S, Stevenson LW, Gheorghiade M. Water and Sodium in Heart Failure: A Spotlight on Congestion. Heart Fail Rev. 20(1):13-24, 2014. PMCID: PMC4405162.
305. Lam AQ, Freedman BS, Morizane R, Lerou PH, Valerius MT, **Bonventre JV**. Rapid and Efficient Differentiation of Human Pluripotent Stem Cells into Intermediate Mesoderm That Forms Tubules Expressing Kidney Proximal Tubular Markers. J Am Soc Nephrol. 25(6):1211-25, 2014. PMCID: PMC4033376
306. Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, **Bonventre JV**, Pennathur S, Meyer TW, Krolewski AS. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 85(5):1214-24, 2014. PMCID: PMC4072128
307. Liu NK, Deng LX, Zhang YP, Lu QB, Wang XF, Hu JG, Oakes E, **Bonventre JV**, Shields CB, Xu XM. cPLA2 protein as a novel therapeutic target for spinal cord injury. Ann Neurol. 75(5):644-58, 2014. PMCID: PMC4320750
308. McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, **Bonventre JV**, Smyth RL, Pirmohamed M. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 8(10):1189-97, 2014. PMCID: PMC4076175
309. Bassi R, Vergani A, D'Addio F, Ben Nasr M, Mocci A, Rastaldi MP, Ichimura T, **Bonventre JV**, Fiorina P. Positive effects of a novel non-peptidyl low molecular weight radical scavenger in renal ischemia/reperfusion: a preliminary report. Springerplus. 3:158. doi: 10.1186/2193-1801-3-158. PMCID: PMC3979974
310. Gandhi R, Yi J, Ha J, Shi H, Ismail O, Nathoo S, **Bonventre JV**, Zhang X, Gunaratnam L. Accelerated Receptor Shedding Inhibits Kidney Injury Molecule-1 (KIM-1)-mediated Efferocytosis. Am J Physiol Renal Physiol. 307(2):F205-21, 2014. PMCID: PMC4380482
311. Mishima E, Inoue C, Saigusa D, Inoue R, Ito K, Suzuki Y, Jinno D, Tsukui Y, Akamatsu Y, Araki M, Araki K, Shimizu R, Shinke H, Suzuki T, Takeuchi Y, Shima H, Akiyama Y, Toyohara T, Suzuki C, Saiki Y, Tominaga T, Miyagi S, Kawagisihi N, Soga T, Ohkubo T, Yamamura K, Imai Y, Masuda S, Sabbisetti V, Ichimura T, Mount DB, **Bonventre JV**, Ito S, Tomioka Y, Itoh K, Abe T. Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage. J Am Soc Nephrol. 25(10):2316-26, 2014. PMCID: PMC4178440
312. Hsiao LL, Wu J, Yeh AC, Shieh EC, Cui C, Li A, Polding LC, Ahmed R, Lim K, Lu TS, Rhee CM, **Bonventre JV**. The Kidney Disease Screening and Awareness Program (KDSAP): A Novel Translatable Model for Increasing Interest in Nephrology Careers. J Am Soc Nephrol.25(9):1909-15, 2014. PMCID: PMC4147978
313. Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, Ito K, Sharma S, Ramadesikan S, Lee M, Briskin R, De Jager PL, Ngo TT, Radlinski M, Dear JW, Park KB, Betensky R, Krolewski AS, **Bonventre JV**. Blood Kidney Injury Molecule-1 Is a Biomarker of Acute and Chronic Kidney Injury and Predicts Progression to ESRD in Type I Diabetes. J Am Soc Nephrol. 25(10):2177-86, 2014. PMCID: PMC4178434
314. **Bonventre JV**, Boulware LE, Dember LM, Freedman BI, Furth SL, Holzman LB, Ketchum CJ, Little MH, Mehrotra R, Moe SM, Sands JM, Sedor JR, Somlo S, Star RA, Rys-Sikora KE; Kidney Research National Dialogue (KRND). Clin J Am Soc Nephrol. 9(10):1806-11, 2014. PMCID: PMC4186514
315. Fufaa GD, Weil EJ, Nelson RG, Hanson RL, **Bonventre JV**, Sabbisetti V, Waikar SS, Mifflin TE, Zhang X, Xie D, Hsu CY, Feldman HI, Coresh J, Vasan RS, Kimmel PL, Liu KD; for the Chronic Kidney Disease Biomarkers Consortium Investigators. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia. 58(1):188-98.2014. PMCID: PMC4258130
316. Pang P, Jin X, Proctor BM, Farley M, Roy N, Chin MS, von Andrian UH, Vollmann E, Perro M, Hoffman RJ, Chung J, Chauhan N, Mistri M, Muslin AJ, **Bonventre JV**, Siedlecki AM. RGS4 inhibits angiotensin II signaling and macrophage localization during renal reperfusion injury independent of vasospasm**.** Kidney Int. 87(4):771-83, 2014. PMCID: PMC4382433
317. Lagos-Arevalo P, Palijan A, Vertullo L, Devarajan P, Bennett MR, Sabbisetti V, **Bonventre JV**, Ma Q, Gottesman RD, Zappitelli M. Cystatin C in acute kidney injury diagnosis: early biomarker or alternative to serum creatinine? Pediatr Nephrol. 30(4):665-76. 2014. PMCID: PMC4372053
318. Xu JX, Lu TS, Li S, Wu Y, Ding L, Denker BM, **Bonventre JV**, Kong T. Polycystin-1 and Gα12 regulate the cleavage of E-cadherin in kidney epithelial cells. Physiol Genomics. 47(2):24-32, 2014. PMCID: PMC4313070
319. Besschetnova TY, Ichimura T, Katebi N, St Croix B, **Bonventre JV**, Olsen BR. Regulatory mechanisms of anthrax toxin receptor 1-dependent vascular and connective tissue homeostasis. Matrix Biol. 42:56-73, 2015. PMCID: PMC4409530
320. Khan NS, Song CY, Jennings BL, Estes AM, Fang XR, **Bonventre JV**, Malik KU. Cytosolic Phospholipase A2α Is Critical for Angiotensin II-Induced Hypertension and Associated Cardiovascular Pathophysiology. Hypertension. 65(4):784-92, 2015. PMCID: PMC4359078
321. Hsu CY, Ballard S, Batlle D, **Bonventre JV**, Böttinger EP, Feldman HI, Klein JB, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG; for the CKD Biomarkers Consortium. Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium. Clin J Am Soc Nephrol. 10(5):894-902, 2015 PMCID: PMC4422251
322. Yang L, Brooks CR, Xiao S, Sabbisetti V, Yeung MY, Hsiao LL, Ichimura T, Kuchroo V, **Bonventre JV**. KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest. 125(4):1620-36, 2015. PMCID: PMC4396492
323. Antoine DJ, Sabbisetti VS, Francis B, Jorgensen AL, Craig DG, Simpson KJ, **Bonventre JV**, Park BK, Dear JW. Circulating kidney injury molecule-1 predicts prognosis and poor outcome in patients with acetaminophen-induced liver injury. Hepatology. 62(2):591-9., 2015. PMCID: PMC4515147
324. Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li MK, Hughes MR, Werff RV, Peters DT, Lu J, Baccei A, Siedlecki AM, Valerius MT, Musunuru K, McNagny KM, Steinman TI, Zhou J, Lerou PH, **Bonventre** JV. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun. 6:8715, 2015. PMCID: PMC4620584
325. Deml KF, Schildhaus HU, Compérat E, von Teichman A, Storz M, Schraml P, **Bonventre JV**, Fend F, Fleige B, Nerlich A, Gabbert HE, Galer N, Grobholz R, Hailemariam S, Hinze R, Knüchel R, Lhermitte B, Nesi G, Rüdiger T, Sauter G, Moch H. Clear Cell Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor: Two Variants of a Morphologic, Immunohistochemical, and Genetic Distinct Entity of Renal Cell Carcinoma. Am J Surg Pathol. 39(7):889-901, 2015. PMCID: PMC4465996
326. Khan NS, Song CY, Thirunavukkarasu S, Fang XR, **Bonventre JV**, Malik KU. Cytosolic phospholipase A2α is critical for angiotensin II-induced hypertension and associated cardiovascular pathophysiology. Am J Hypertens. 65(4):784-92, 2015. PMCID: PMC4359078
327. Kishi S, Campanholle G, Gohil VM, Perocchi F, Brooks CR, Morizane R, Sabbisetti V, Ichimura T, Mootha VK, **Bonventre** JV. Meclizine Preconditioning Protects the Kidney Against Ischemia-Reperfusion Injury.EBioMedicine. 2(9):1090-101, 2015. PMCID: PMC4588407
328. Brooks CR, Yeung MY, Brooks YS, Chen H, Ichimura T, Henderson JM, **Bonventre JV**. KIM-1-/TIM-1-mediated phagocytosis links ATG5-/ULK1-dependent clearance of apoptotic cells to antigen presentation. EMBO J. 2015 Oct 1;34(19):2441-64, 2015. PMCID: PMC4601664
329. Movahedi Naini S, Sheridan AM, Force T, Shah JV, **Bonventre JV**. Group IVA Cytosolic Phospholipase A2 Regulates the G2-to-M Transition by Modulating the Activity of Tumor Suppressor SIRT2. Mol Cell Biol. 35(21):3768-84, 2015. PMC4589591
330. Foster MC, Coresh J, **Bonventre JV**, Sabbisetti VS, Waikar SS, Mifflin TE, Nelson RG, Grams M, Feldman HI, Vasan RS, Kimmel PL, Hsu CY, Liu KD; CKD Biomarkers Consortium. Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol. 10(11):1956-63, 2015. PMCID: PMC4633784
331. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, Kim YH, Mishima M, Ichimura T, **Bonventre JV**, Matsubara K. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol. 76(5):989-96, 2015. PMCID: PMC4624288
332. Yin W, Naini SM, Chen G, Hentschel DM, Humphreys BD, **Bonventre JV**. Mammalian Target of Rapamycin Mediates Kidney Injury Molecule 1-Dependent Tubule Injury in a Surrogate Model. J Am Soc Nephrol. 27(7):1943-57, 2016. PMCID: PMC4926976
333. Foster MC, Coresh J, **Bonventre JV**, Sabbisetti VS, Waikar SS, Mifflin TE, Nelson RG, Grams M, Feldman HI, Vasan RS, Kimmel PL, Hsu CY, Liu KD; CKD Biomarkers Consortium. Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol.10(11):1956-63, 2015. PMCID: PMC4633784
334. Suzuki T, Yamaguchi H, Kikusato M, Hashizume O, Nagatoishi S, Matsuo A, Sato T, Kudo T, Matsuhashi T, Murayama K, Ohba Y, Watanabe S, Kanno SI, Minaki D, Saigusa D, Shinbo H, Mori N, Yuri A, Yokoro M, Mishima E, Shima H, Akiyama Y, Takeuchi Y, Kikuchi K, Toyohara T, Suzuki C, Ichimura T, Anzai JI, Kohzuki M, Mano N, Kure S, Yanagisawa T, Tomioka Y, Tohyomizu M, Tsumoto K, Nakada K, **Bonventre JV**, Ito S, Osaka H, Hayashi KI, Abe T. Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage. J Am Soc Nephrol. 27(7):1925-32, 2016. PMCID: PMC4926982
335. Naini SM, Choukroun GJ, Ryan JR, Hentschel DM, Shah JV, **Bonventre JV**. Cytosolic phospholipase A2α regulates G1 progression through modulating FOXO1 activity. FASEB J. 30(3):1155-70. PMCID: PMC4750418
336. Ismail O, Zhang X, **Bonventre JV**, Gunaratnam L. G protein, 12 (Gα12) is a negative regulator of kidney injury molecule-1-mediated efferocytosis. Am J Physiol Renal Physiol. 310 (7), F607-F620. PMCID: PMC4971893
337. Khan NS, Song CY, Thirunavukkarasu S, Fang XR, **Bonventre JV**, Malik KU. Cytosolic Phospholipase A2α Is Essential for Renal Dysfunction and End-Organ Damage Associated With Angiotensin II-Induced Hypertension. Am J Hypertens. 29(2):258-65, 2016. PMCID: PMC4751243
338. Leaf DE, Christov M, Jüppner H, Siew E, Ikizler TA, Bian A, Chen G, Sabbisetti VS, **Bonventre JV**, Cai X, Wolf M, Waikar SS. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int. 89(4):939-48, 2016. PMCID: PMC4801748
339. Fischer K, Meral FC, Zhang Y, Vangel MG, Jolesz FA, Ichimura T, **Bonventre JV**. High-resolution renal perfusion mapping using contrast-enhanced ultrasonography in ischemia-reperfusion injury monitors changes in renal microperfusion. Kidney Int. 89(6):1388-98, 2016. PMCID: PMC4870008
340. Waikar SS, Sabbisetti V, Ärnlöv J, Carlsson AC, Coresh J, Feldman HI, Foster MC, Fufaa GD, Helmersson-Karlqvist J, Hsu CY, Kimmel PL, Larsson A, Liu Y, Lind L, Liu KD, Mifflin TE, Nelson RG, Risérus U, Vasan RS, Xie D, Zhang X, **Bonventre JV**; Chronic Kidney Disease Biomarkers Consortium Investigators. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol Dial Transplant. 31(9):1460-70, 2016. PMCID: PMC5009290
341. Cárdenas-González M, Osorio-Yáñez C, Gaspar-Ramírez O, Pavković M, Ochoa-Martínez A, López-Ventura D, Medeiros M, Barbier OC, Pérez-Maldonado IN, Sabbisetti VS, **Bonventre JV**, Vaidya VS. Environmental exposure to arsenic and chromium in children is associated with kidney injury molecule-1. Environ Res. 150:653-62, 2016. PMCID: PMC5003729
342. Wang X, Shaw DK, Hammond HL, Sutterwala FS, Rayamajhi M, Shirey KA, Perkins DJ, **Bonventre JV**, Velayutham TS, Evans SM, Rodino KG, VieBrock L, Scanlon KM, Carbonetti NH, Carlyon JA, Miao EA, McBride JW, Kotsyfakis M, Pedra JH. The Prostaglandin E2-EP3 Receptor Axis Regulates Anaplasma phagocytophilum-Mediated NLRC4 Inflammasome Activation. PLoS Pathog. 12(8):e1005803, 2016. PMCID: PMC4970705
343. Wu Y, Xu J, El-Jouni W, Lu T, Li S, Wang Q, Tran M, Yu W, Wu M, Barrera IE, **Bonventre JV**, Zhou J, Denker BM, Kong T. Gα12 is required for renal cystogenesis induced by Pkd1 inactivation. J Cell Sci. 129(19):3675-3684, 2016. PMCID: PMC5087651
344. Graw JA, Mayeur C, Rosales I, Liu Y, Sabbisetti VS, Riley FE, Rechester O, Malhotra R, Warren HS, Colvin RB, **Bonventre JV**, Bloch DB, Zapol WM. Haptoglobin or Hemopexin Therapy Prevents Acute Adverse Effects of Resuscitation After Prolonged Storage of Red Cells. Circulation. 134(13):945-60, 2016. PMCID: PMC5039096
345. Kefaloyianni E, Muthu ML, Kaeppler J, Sun X, Sabbisetti V, Chalaris A, Rose-John S, Wong E, Sagi I, Waikar SS, Rennke H, Humphreys BD, **Bonventre JV**, Herrlich A. ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight. 1(13), 2016. PMCID: PMC5026414
346. Morizane R, Bonventre JV. Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells. Nat Protoc. 12(1):195-207, 2017. PMID: 28005067
347. Hsu CY, Xie D, Waikar SS, **Bonventre JV**, Zhang X, Sabbisetti V, Mifflin TE, Coresh J, Diamantidis CJ, He J, Lora CM, Miller ER, Nelson RG, Ojo AO, Rahman M, Schelling JR, Wilson FP, Kimmel PL, Feldman HI, Vasan RS, Liu KD; CRIC Study Investigators; CKD Biomarkers Consortium. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int. S0085-2538(16)30486-0, 2016. PMCID: PMC5362331
348. Niewczas MA, Mathew AV, Croall S, Byun J, Major M, Sabisetti VS, Smiles A, **Bonventre JV**, Pennathur S, Krolewski AS. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care. 40(3):383-390, 2017. PMCID: PMC5319475
349. Sochol RD, Gupta NR, **Bonventre JV**. A Role for 3D Printing in Kidney-on-a-Chip Platforms. Curr Transplant Rep. 3(1):82-92, 2016. PMCID: PMC5232415
350. Mendu ML, Ciociolo GR Jr, McLaughlin SR, Graham DA, Ghazinouri R, Parmar S, Grossier A, Rosen R, Laskowski KR, Riella LV, Robinson ES, Charytan DM, **Bonventre JV**, Greenberg JO, Waikar SS. A Decision-Making Algorithm for Initiation and Discontinuation of RRT in Severe AKI. Clin J Am Soc Nephrol. In press, 2017. PMID: 28119408, PMCID in process.
351. Tögel F, Valerius MT, Freedman BS, Latrino R, Grinstein M, **Bonventre JV**. Repair after nephron ablation reveals limitations of neonatal neonephrogenesis. JCI Insight.26;2(2), 2017. PMCID: PMC5256143
352. Pickkers P, Ostermann M, Joannidis M, Zarbock A, Hoste E, Bellomo R, Prowle J, Darmon M, **Bonventre JV**, Forni L, Bagshaw SM, Schetz M. The intensive care medicine agenda on acute kidney injury. Intensive Care Med. In press, 2017. Review. PMID: 28138736, PMCID in process.
353. Emerson SC, Waikar SS, Fuentes C, **Bonventre JV**, Betensky RA. Biomarker validation with an imperfect reference: Issues and bounds.Stat Methods Med Res. 962280216689806. doi: 10.1177/0962280216689806, 2017. PMCID: PMC5494007.
354. Morizane R, **Bonventre JV**. Kidney Organoids: A Translational Journey. Trends Mol Med. 23(3):246-263, 2017. PMCID: PMC5442988
355. Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Zhang L, Kyttaris VC, Tsokos GC, Stillman IE, Ichimura T, **Bonventre JV**, Libby P, Shi GP. CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice. J Immunol. 198(7):2568-2577, 2017. PMCID: PMC5360510
356. Barasch J, Zager R, **Bonventre JV**. Acute kidney injury: a problem of definition. Lancet. 389(10071):779-781, 2017. PMCID: PMC5460771.
357. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, **Bonventre JV**, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators; CKD Biomarkers Consortium. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study**.** Clin J Am Soc Nephrol. 12(5): 761–771, 2017. PMCID: PMC5477212
358. Humanes B, Camaño S, Lara JM, Sabbisetti V, González-Nicolás MÁ, **Bonventre JV**, Tejedor A, Lázaro A. Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection. Nephrol Dial Transplant. 32(10):1645-1655, 2017. PMCID: PMC6251639
359. Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, **Bonventre JV**, Warram JH, Krolewski AS. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 92(1):258-266, 2017. PMCID: PMC5796779
360. Pazos MA, Lanter BB, Yonker LM, Eaton AD, Pirzai W, Gronert K, **Bonventre JV**, Hurley BP. Pseudomonas aeruginosa ExoU augments neutrophil transepithelial migration. PLoS Pathog. 13(8):e1006548, 2017. PMCID: PMC5557605.
361. Bhowmick R, Clark S, **Bonventre JV**, Leong JM, McCormick BA. Cytosolic Phospholipase A(2)α Promotes Pulmonary Inflammation and Systemic Disease during Streptococcus pneumoniae Infection. Infect Immun. 85(11), 2017. PMCID: PMC5649009.
362. Morizane R, Miyoshi T, **Bonventre JV**. Concise Review: Kidney Generation with Human Pluripotent Stem Cells. Stem Cells. 35(11):2209-2217, 2017. PMCID: PMC5805143.
363. Yonker LM, Pazos MA, Lanter BB, Mou H, Chu KK, Eaton AD, **Bonventre JV**, Tearney GJ, Rajagopal J, Hurley BP. Neutrophil-Derived Cytosolic PLA2α Contributes to Bacterial-Induced Neutrophil Transepithelial Migration. J Immunol. 199(8):2873-2884, 2017. PMCID: PMC5636676.
364. Song CY, Khan NS, Liao FF, Wang B, Shin JS, Bonventre JV, Malik KU. Brain Cytosolic Phospholipase A2α Mediates Angiotensin II-Induced Hypertension and Reactive Oxygen Species Production in Male Mice. Am J Hypertens. 1(5):622-629, 2018. PMCID: PMC5905655
365. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, O'Connor CM, Sabbisetti VS, **Bonventre JV**, Wilson FP, Coca SG, Testani JM. Worsening Renal Function in Acute Heart Failure Patients Undergoing Aggressive Diuresis is Not Associated with Tubular Injury. Circulation. 137(25):e853, 2018. PMID: 29352071, PMCID in process.
366. Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, **Bonventre JV**, Krolewski AS. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 93(5):1198-1206, 2018. PMCID: PMC5911430
367. Zuk A, Palevsky PM, Fried L, Harrell FE Jr., Khan S, McKay DB, Devey L, Chawla L, de Caestecker M, Kaufman JS, Thompson BT, Agarwal A, Greene T, Okusa MD, **Bonventre JV**, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star RA. Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Clin J Am Soc Nephrol. 13(7):1113-1123, 2018. PMCID: PMC6032575
368. Yu SM, **Bonventre JV**. Acute Kidney Injury and Progression of Diabetic Kidney Disease. Adv Chronic Kidney Dis. 25(2):166-180, 2018. PMCID: PMC5898826
369. Ismail OZ, Sriranganathan S, Zhang X, **Bonventre JV**, Zervos AS, Gunaratnam L. Tctex-1, a novel interaction partner of Kidney Injury Molecule-1, is required for efferocytosis .J Cell Physiol. 233(10):6877-6895, 2018. PMCID: PMC6066178.
370. Lemos DR, McMurdo M, Karaca G, Wilflingseder J, Leaf IA, Gupta N, Miyoshi T, Susa K, Johnson BG, Soliman K, Wang G, Morizane R, **Bonventre JV**, Duffield JS. Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis. J Am Soc Nephrol. 29(6):1690-1705, 2018. PMCID:

PMC6054344

1. Lei C, Berra L, Rezoagli E, Yu B, Dong H, Yu S, Hou L, Chen M, Chen W, Wang H, Zheng Q, Shen J, Jin Z, Chen T, Zhao R, Christie E, Sabbisetti VS, Nordio F, **Bonventre JV**, Xiong L, Zapol WM. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery. Am J Respir Crit Care Med. 98(10):1279-1287 2018. PubMed PMID: 29932345, PMCID in process.
2. Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, **Bonventre JV**, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 8(11):1404-1421, 2018. PMCID: PMC6365285
3. Leon J, Pérez-Sáez MJ, Uffing A, Murakami N, Watanabe A, Cureton P, Kenyon V, Keating L, Yee K, Fernandes Satiro CA, Yu B, **Bonventre JV**, Fasano A, Riella LV. Effect of Combined Gluten-Free, Dairy-Free Diet in Children With Steroid-Resistant Nephrotic Syndrome: An Open Pilot Trial. Kidney Int Rep. 3(4):851-860, 2018. PMCID: PMC6093178.
4. Yin W, Zhang PL, Macknis J, Lin F, **Bonventre JV**. Kidney Injury Molecule-1 Identifies Antemortem Injury in Postmortem Adult and Fetal Kidney. Am J Physiol Renal Physiol. 315(6):F1637-F1643, 2018. PMCID: PMC6337001.
5. Gupta N, Susa K, Yoda Y, **Bonventre JV**, Valerius MT, Morizane R. CRISPR/Cas9-based Targeted Genome Editing for the Development of Monogenic Diseases Models with Human Pluripotent Stem Cells. Curr Protoc Stem Cell Biol. 45(1):e50, 2018. PMCID: PMC6060633.
6. Scelo G, Muller DC, Riboli E, Johansson M, Cross AJ, Vineis P, Tsilidis KK,Brennan P, Boeing H, Peeters PHM, Vermeulen RCH, Overvad K, Bueno-de-Mesquita HB, Severi G, Perduca V, Kvaskoff M, Trichopoulou A, La Vecchia C, Karakatsani A, Palli D, Sieri S, Panico S, Weiderpass E, Sandanger TM, Nøst TH, Agudo A, Quirós JR, Rodríguez-Barranco M, Chirlaque MD, Key TJ, Khanna P, **Bonventre JV**,Sabbisetti VS, Bhatt RS. KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res. 24(22):5594-5601, 2018. PMCID: PMC6239904.
7. Waikar SS, Rebholz CM, Zheng Z, Hurwitz S, Hsu CY, Feldman HI, Xie D, Liu KD, Mifflin TE, Eckfeldt JH, Kimmel PL, Vasan RS, **Bonventre JV**, Inker LA, Coresh J; Chronic Kidney Disease Biomarkers Consortium Investigators. Biological Variability of Estimated GFR and Albuminuria in CKD. Am J Kidney Dis.72(4):538-546, 2018. PMCID: PMC6469385.
8. Chappell JC, Turner PK, Pak YA, Bacon J, Chiang AY, Royalty J, Hall SD, Kulanthaivel P, **Bonventre JV**. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 105(5):1187-1195, 2019. PMCID: PMC6465099
9. Bonventre JA, Holman C, Manchanda A, Codding SJ, Chau T, Huegel J, Barton C, Tanguay R, Johnson CP. Fer1l6 Is Essential for the Development of Vertebrate Muscle Tissue in Zebrafish. Mol Biol Cell. 0(3):293-301, 2018. PMCID: PMC6589578.
10. Liu L, **Bonventre JV**, Rittenhouse AR. cPLA2α-/- sympathetic neurons exhibit increased membrane excitability and loss of N-Type Ca2+ current inhibition by M1 muscarinic receptor signaling. PLoS One. 13(12), 2018. PMCID: PMC6296557.
11. Canaud G, Brooks CR, Kishi S, Taguchi K, Nishimura K, Magassas, Scott A, Hsiao LL, Ichimura T, Terzi F, Yang L, **Bonventre JV**. Cyclin G1 and TASCC regulate kidney epithelial cell G2-M arrest and fibrotic maladaptive repair. Sci Transl Med. 1(476). pii: eaav4754, 2019. PMCID: PMC6527117
12. Homan KA, Gupta N, Kroll KT, Kolesky DB, Skylar-Scott M, Miyoshi T, Mau D, Valerius MT, Ferrante T, **Bonventre JV**, Lewis JA, Morizane R. Flow-enhanced vascularization and maturation of kidney organoids in vitro. Nat Methods. 16(3):255-262, 2019. PMCID: PMC6488032
13. Docherty MH, O'Sullivan ED, **Bonventre JV**, Ferenbach DA. Cellular Senescence in the Kidney. J Am Soc Nephrol. 30(5):726-736, 2019. Review. PMCID: PMC6493983.
14. Rao VS, Ahmad T, Brisco-Bacik MA, **Bonventre JV**, Wilson FP, Siew ED, Felker GM, Anstrom KK, Mahoney DD, Bart BA, Tang WHW, Velazquez EJ, Testani JM. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circ Heart Fail. 12(6):e005552, 2019. PMCID: PMC6585463
15. Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G; International Conference on Onco-Nephrology Participants. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int. 96(3), 2019. PMID: 31445584.
16. Zhang X, Zhou Y, Yu X, Huang Q, Fang W, Li J, **Bonventre JV**, Sukhova GK, Libby P, Shi GP. Differential Roles of Cysteinyl Cathepsins in TGF-β Signaling and Tissue Fibrosis. iScience. 19:607-622, 2019. PMCID: PMC6715892.
17. **Bonventre JV**, Hurst FP, West M, Wu I, Roy-Chaudhury P, Sheldon M. A Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies: A Catalyst for Change. Clin J Am Soc Nephrol. 14(10):1539-1547, 2019. PMCID: PMC6777588.
18. Davidsohn N, Pezone M, Vernet A, Graveline A, Oliver D, Slomovic S, Punthambaker S, Sun X, Liao R, **Bonventre JV**, Church GM. A single combination gene therapy treats multiple age-related diseases. Proc Natl Acad Sci U S A. 116(47):23505-23511, 2019. PMCID: PMC6876218
19. Kishi S, Brooks CR, Taguchi K, Ichimura T, Mori Y, Akinfolarin A, Gupta N, Galichon P, Elias BC, Suzuki T, Wang Q, Gewin L, Morizane R, **Bonventre JV**. Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses. J Clin Invest. 129(11):4797-4816, 2019. PMCID: PMC6819104.
20. Yu SM, **Bonventre JV**. Acute kidney injury and maladaptive tubular repair leading to renal fibrosis. Curr Opin Nephrol Hypertens. 29(3):310-318, 2020. PMID: 32205583. PMC Journal – in process.
21. Greenberg JH, Abraham AG, Xu Y, Schelling JR, Feldman HI, Sabbisetti VS, Gonzalez MC, Coca S, Schrauben SJ, Waikar SS, Ramachandran VS, Shlipak MG, Warady B, Kimmel PL, **Bonventre JV**, Denburg M, Parikh CR, Furth S; CKD Biomarkers Consortium. Plasma Biomarkers of Tubular Injury and Inflammation Are Associated with CKD Progression in Children. J Am Soc Nephrol. 31(5):1067-1077, 2020. PMCID: PMC7217410.
22. Battistone MA, Mendelsohn AC, Spallanzani RG, Allegretti AS, Liberman RN, Sesma J, Kalim S, Wall SM, **Bonventre JV**, Lazarowski ER, Brown D, Breton S. Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice. J Clin Invest. 130(7):3734-3749, 2020. PMCID: PMC7324186.

Non-peer reviewed scientific or medical publications/materials in print or other media

|  |
| --- |
| Group materials into the following categories:  -Proceedings of meetings or other non-peer reviewed research publications  -Reviews, chapters, monographs and editorials  -Books/Textbooks for the medical or scientific community  -Case reports  -Letters to the Editor |

1. Beeuwkes R, **Bonventre JV**, Miller ED and Barger AC. The vascular and tubular organization of the kidney. Presented at the 5th International Congress of Nephrology (Mexico City), 1972. Generally distributed as an educational scientific film
2. Lechene C, **Bonventre JV** and Warner RR. Electron probe analysis of frozen bulk tissues. In: Lechene C, Warner RR, eds. Microbeam Analysis in Biology. New York, Academic Press, pp 409-423, 1979.
3. **Bonventre JV**, Blouch K and Lechene C. Biological sample preparation for electron probe analysis: Liquid droplets and isolated cells. In: Hayat MA, ed. X-ray Microscopy in Biology. Baltimore University Park Press, pp 307-366, 1980.
4. Leaf A, Cheung JY, Mills JW and **Bonventre JV**. The nature of the cellular insult in acute renal failure. In: Acute Renal Failure, edited by B.M. Brenner and J.M. Lazarus, W.B. Saunders Co., pp 2-20, 1983.
5. Ausiello DA and **Bonventre JV**. Calcium and calmodulin as mediators of hormone action and transport events. Semin Nephrol 4:134-143, 1984.
6. **Bonventre JV**. Cellular response to ischemia. In: Acute Renal Failure: Correlations Between Morphology and Function, eds. K. Solez and A. Whelton, New York, Marcel Dekker, Inc., pp 195-218, 1984.
7. Cheung JY, **Bonventre JV**, Malis CD and Leaf A. Calcium and ischemic injury. New Engl. J. Med. 314:1670-1676, 1986.
8. Corwin HL and **Bonventre JV**. Acute Renal Failure. Med. Clinics NA. 70: 1037- 1054, 1986.
9. Leaf A, Macknight ADC, Cheung JY and **Bonventre JV**. The cellular basis of ischemic acute renal failure, in Membrane Physiology, Andreoli TE, Hoffman JF, Fanestil DD and Schultz SG, eds. Plenum Medical Book Co., New York, 1986, pp 769-784. Also in: Clinical Disorders of Membrane Transport Processes , pp 3-18, 1986.
10. Corwin HL and **Bonventre JV**. Acute Renal Failure in the intensive care unit. Intensive Care Medicine. 14:10-16 (Part 1); 86-96(Part 2), 1988.
11. **Bonventre JV**. Mediators of ischemic renal damage. Ann Review of Medicine. 39:531-544, 1988.
12. **Bonventre JV**, Leaf A and Malis CD. The Nature of the cellular insult in ischemic acute renal failure. In: Acute Renal Failure. B.M. Brenner and J.M. Lazarus, eds. Churchill Livingstone, pp 3-43, 1988.
13. **Bonventre JV**. Vasopressin and calcium in cultured glomerular mesangial cells. In: Vasopressin: Cellular and Integrative Function, edited by AW Cowley, Jr., J-F Liard and DA Ausiello. Raven Press, pp 89-96, 1988.
14. Tolkoff-Rubin NE, Rubin RH and **Bonventre JV**. Non-invasive renal diagnostic studies. Clin.Lab. Med. 8:507-526, 1988.
15. Malis CD and **Bonventre JV**. Susceptibility of mitochondrial membranes to calcium and reactive oxygen species: Implications for ischemic and toxic tissue damage. In: Biological Membranes: Aberrations in Membrane Structure and Function. ML Karnovsky, A Leaf and Bolis, eds. New York, Alan R. Liss, 1988, pp 235-259, also In: Progress in Clinical and Biological Research 282; 235-259, 1988.
16. **Bonventre JV**. Pathophysiologic pathways for renal injury. In: Textbook of Internal Medicine, 1st edition, edited by WN Kelley, JB Lippincott, pp 743-748, 1989.
17. Corwin HL and **Bonventre JV**. Factors influencing survival in acute renal failure. Sem. Dialysis 2: 220-225, 1989.
18. **Bonventre JV**, CD Malis and JY Cheung. Role of calcium in ischemic injury. In: Clinical Ischemic Syndromes. GB Zelenock, ed. C.V. Mosby Co., pp. 227-242 1990.
19. **Bonventre JV**. Calcium and the renal mesangial cell. In Calcium Antagonists and the Kidney. Edited by M. Epstein and R. Loutzenhiser. Hanley & Belfus, Inc. pp 87-105, 1990.
20. Diamond JR and **Bonventre JV**. Ischemic acute renal failure. In: Principles and Practice of Nephrology. Edited by HR Jacobson, GE Striker and S Klahr. Philadelphia: B.C. Decker, Inc. pp 641-647, 1990.
21. **Bonventre JV** and Nemenoff RA. Renal tubular arachidonic acid metabolism. Kidney Int. 39: 438-449, 1991.
22. Cybulsky AV and **Bonventre JV**. Calcium, phospholipids and cell molecules. In: Hormones, Autocoids, and the Kidney. Contemporary issues in Nephrology. Edited by S Goldfarb and FN Ziyadeh. Pp 27-53, 1991.
23. **Bonventre JV**. Pathophysiologic pathways for renal injury. In: Textbook of Internal Medicine, 2nd ed. JB Lippincott, pp. 690-694, 1991.
24. **Bonventre JV**. Passive calcium transport mechanisms. In: Membrane Transport in Biology, Vol.5. Edited by Schafer JA, Ussing HH, Kristensen P, and Giebisch G. New York: Springer Verlag, pp.262-316, 1992.
25. **Bonventre JV** and Weinberg JM. Kidney preservation *ex vivo* for transplantation. Annu. Rev. Med. 43: 523-553, 1992.
26. **Bonventre JV**. Phospholipase A2 and signal transduction. Jour. Am. Soc. Neph. 3: 128-150, 1992.
27. **Bonventre JV**. Mechanisms of ischemic acute renal failure (Nephrology Forum) Kidney Int. 43: 1160-1178, 1993.
28. Force T and **Bonventre JV**. Cellular signal transduction mechanisms. In: Cellular and Molecular Physiology of Cell Volume Regulation. Edited by K. Strange, Ann Arbor, CRC Press, pp 147-180, 1994.
29. Lovis C, Mach F, Donati YRA, **Bonventre JV**, and Polla BS. Heat shock proteins and the kidney. Renal Failure. 16: 179-192, 1994.
30. **Bonventre JV** and Witzgall R. Cellular and molecular mechanisms of ischemic acute renal failure and repair. In: Mechanisms of Injury in Renal Disease and Toxicity, edited by R. S. Goldstein and M. E. Davis. Telford Press, pp. 15-42, 1994.
31. Saurina GR, and **Bonventre JV**. Acute renal failure. In: Conn’s Current Therapy. Ed by RE Rakel. Philadelphia: W. B. Saunders Company, p635-641, 1995.
32. **Bonventre JV**, Shah S, Walker PD, and Humphreys MH. Acute renal failure: ischemic, toxic, and other. In: Principles and Practice of Nephrology. Vol. 2. Edited by HR Jacobson, GE Striker and S Klahr. Philadelphia: B.C. Decker, Inc., p 564-576, 1995.
33. **Bonventre JV**. Phospholipases A2. In: Molecular Nephrology. Molecular Biology of the Kidney in Health and Disease, Edited by D. Schlondorff and **JV Bonventre**. New York: Marcel Dekker, Inc., p 681-697, 1995.
34. Safirstein R and **Bonventre JV**. Molecular responses to ischemic and nephrotoxic acute renal failure. In: Molecular Nephrology. Molecular Biology of the Kidney in Health and Disease, Edited by D. Schlondorff and **JV Bonventre**. New York: Marcel Dekker, Inc., p 839-854, 1995.
35. Witzgall R and **Bonventre JV**. Transcription factors in kidney development and renal injury. In: Molecular Nephrology. Molecular Biology of the Kidney in Health and Disease, Edited by D. Schlondorff and **JV Bonventre**. New York: Marcel Dekker, Inc., pp 535-550, 1995.
36. **Bonventre JV** and Kelly KJ. Adhesion molecules and acute renal failure. Advances in Nephrology 25: 159-176, 1996.
37. Thadhani R, Pascual M, and **Bonventre JV**. Acute renal failure. New Eng. J. Med. 334: 1448-1460, 1996.
38. Kelly KJ and **Bonventre JV**. Protection against ischemic renal injury with blockade of intercellular adhesion molecule-1. In: Acute Renal Failure, Edited by MS Goligorsky, New York: Churchill Livingstone. Pp 401-423, 1995.
39. **Bonventre JV**. Phospholipases A2 in cell injury. In: Acute Renal Failure, Edited by MS Goligorsky, New York: Churchill Livingstone. Pp. 23-44, 1995.
40. Force T, Pombo CM, Avruch JA, **Bonventre JV**, and Kyriakis JM. Stress-activated protein kinases in cardiovascular disease. Circulation Res. 78: 947-953, 1996.
41. Kelly DJ and **Bonventre JV**. Ischemia/reperfusion injury in transplantation. In: Transplantation Biology. Cellular and Molecular Aspects. Edited by NL Tilney, TB Strom and LC Paul. New York, Raven Press; pp. 257-274, 1996.
42. **Bonventre JV** and Colvin RB. Adhesion molecules in renal disease. Curr. Opinion in Nephrology and Hypertension. 5: 254-261, 1996.
43. Thadhani RI and **Bonventre JV**. Acute renal failure. In: Quick Consult Manual of Evidence-Based Medicine, edited by BW Lee, SI Hsu, and DS Stasior, New York, Lippincott-Raven, pp. 382-413, 1997.
44. Witzgall R, and **Bonventre JV**. Molecular responses to oxygen deprivation and ischemia. In: Comprehensive Toxicology, Vol. 7, Renal Toxicology, edited by RS Goldstein. New York: Elsevier Science, Inc., pp. 429-447, 1997.
45. **Bonventre JV**. Arachidonic acid metabolism. In Nephrology, Edited by R Wilkinson and R Jamison. Oxford, Chapman and Hall, pp 196-204, 1997.
46. Dubose TD, Warnock DG, Mehta RL, **Bonventre JV**, Hammerman MR, Molitoris BA, Paller MS, Siegel NJ, Scherbenske J, Striker GE. Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am. J. Kid. Dis. 29:793-799, 1997.
47. **Bonventre JV**. Ischemic acute renal failure. In: Textbook of Molecular Medicine, edited by L. Jamison. Blackwell Science Inc. 1998, pp. 651-657.
48. Force T and **Bonventre JV**. Growth factors and mitogen-activated protein kinases. Hypertension 31:152-161, 1998.
49. **Bonventre JV**. Rôle des Molecules d’adhésion dans l’insuffisance rénale aiguë ischemique. Néphrologie 19: 57-58, 1998.
50. **Bonventre JV** and Force T. Mitogen-activated protein kinases and transcriptional responses in renal injury and repair. Curr. Opin. Nephrol. Hypertens. 7: 425-433, 1998.
51. **Bonventre JV**. Ischemic acute renal failure. In: Principles of Molecular Medicine, edited by Jamison JL, New Jersey: Humana Press, pp 651-657, 1998.
52. Rabb H, **Bonventre JV**. Experimental strategies for acute renal failure: the future. In: Therapy in Nephrology and Hypertension; A companion to Brenner and Rector’s The Kidney. Edited by Brady HR and Wilcox CS. WB Saunders Co., pp 71-80, 1999.
53. **Bonventre JV**. Pathogenetic and regenerative mechanisms in acute tubular necrosis. Kidney Blood Pressure Res. 21: 226-229, 1998.
54. **Bonventre JV**, Brezis M, Siegel N, Portilla D, and Venkatachalam M. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. In: Acute renal failure forum, edited by W. Lieberthal and S. K. Nigam. Am. J. Physiol. 275: (Renal Physiol. 44) F623-F632, 1998.
55. Berl T and **Bonventre JV**. Disorders of Water, Electrolytes, and Acid-Base and Acute Renal Failure. Atlas of Diseases of the Kidney. Philadelphia: Current Medicine Inc. 1999
56. **Bonventre JV**. The 85 kDa cytosolic phospholipase A2 knockout mouse. A new tool for physiology and cell biology. J. Am. Soc. Nephrol. 10: 404-412, 1999.
57. Mallouk Y, Vayssier-Taussat M, **Bonventre JV**, Polla BS. Heat shock protein 70 and ATP as partners in cell homeostasis. Int. J. Mol. Med. 4: 463-474, 1999.
58. Rabb H, **Bonventre JV**. Leukocyte adhesion molecules in transplantation. Am. J. Med. 107:157-165, 1999.
59. Hsu SI-H, Ramirez S, Winn M, **Bonventre JV**, Owen W. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 57: 1818-1835, 2000.
60. Force T, Alessandrini A, **Bonventre JV**. Cell Signalling. In: The Kidney: Physiology and Pathophysiology. Edited by Seldin D and Giebisch G. Lippincott-Raven, pp. 823-848, 2000.
61. Sapirstein A and **Bonventre JV**. Phospholipases A2 in ischemic and toxic brain injury. Neurochem. Res. 25: 745-753, 2000.
62. Sheridan AM and **Bonventre JV**. Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr. Opinion in Nephrology and Hypertension 9: 427-434, 2000.
63. **Bonventre JV**. Pathophysiology of ischemic acute renal failure. In: 6th Taormina Course on Nephrology, edited by F. Consolo, G. Bellinghieri, and V. Savica. Editoriale Bios. Pp 49-53, 2000.
64. Sapirstein AM and **Bonventre JV**. Specific physiological roles of cPLA2 as defined by gene knockouts. Biochim. Biophys. Acta 1488: 139-148, 2000.
65. **Bonventre JV**. Pathophysiology of ischemic acute renal failure. In: 6th Taormina course in Nephrology, edited by Consolo F, Bellinghieri G, and Savica V. Editorial Bios; pp 49-53, 2000.
66. Sheridan AMand **Bonventre JV**. Pathophysiology of ischemic acute renal failure. Contrib Nephrol. 132:7-21, 2001.
67. Ichimura T and **Bonventre JV**. Growth factors, signaling, and renal injury and repair. In Acute Renal Failure. Edited by B. Molitoris and W. Finn. WB Saunders, Inc. 2001, pp. 101-118.
68. **Bonventre JV**. Complement and renal ischemia-reperfusion injury. Am. J. Kidney Dis. 38:430-436, 2001.
69. **Bonventre JV**. Kidney Ischemic Preconditioning. Curr Opin Nephrol Hypertens. 11:43-48, 2002.
70. **Bonventre JV**, Sapirstein A. Group IV cytosolic phospholipase A2 (PLA2) function: insights from the knockout mouse. Adv Exp Med Biol. 507:25-31, 2002.
71. **Bonventre JV**. Daily hemodialysis – will treatment each day improve the outcome in patients with acute renal failure. N Engl J Med. 346:362-4, 2002.
72. Gray ML, **Bonventre JV**. Training PhD researchers to translate science to clinical medicine: closing the gap from the other side. Nature Medicine. 8:433-6, 2002.
73. **Bonventre JV**. The kidney proteome: A hint of things to come. Kidney Int. 62:1470-1, 2002.
74. Auchincloss H, **Bonventre JV**. Transplanting cloned cells into therapeutic promise. Nat Biotechnol. 20:665-6, 2002.
75. Heyman SN, Lieberthal W, Rogiers P, **Bonventre JV**. Animal models of acute tubular necrosis. Curr Opin Crit Care. 8:526-34, 2002.
76. **Bonventre JV**. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 14(Suppl 1):S55-61, 2003**.**
77. **Bonventre JV.** Molecular response to cytotoxic injury: Role of inflammation, MAP kinases, and the endoplasmic reticulum stress response. Semin Nephrol 23:439-48, 2003.
78. **Bonventre JV**, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14:2199-210, 2003.
79. Luyckx VA and **Bonventre JV**. Dose of Dialysis in Acute Renal Failure. Semin Nephrol 17:30-36, 2004.
80. **Bonventre JV**. Cytosolic phospholipase A2a reigns supreme in arthritis and bone resorption. Trends Immunol 25:116-119, 2004.
81. De Broe ME, **Bonventre JV**, Molitoris BA, Haller H. Evolving basic concepts in ischemic injury. Kidney Int 66: 479, 2004.
82. **Bonventre JV**, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 66: 480-485, 2004.
83. **Bonventre JV**. Pathophysiology of ischemic acute renal failure. Inflammation, lung-kidney cross-talk, and biomarkers. Contrib Nephrol 144: 19-30, 2004.
84. Han WK, **Bonventre JV**. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 10:476-482, 2004.
85. Duffield, Jeremy S., **Bonventre JV**. Acute Renal Failure: Bench to Bedside. In: Chronic Kidney Disease, Dialysis, and Transplantation; A companion to Brenner and Rector’s The Kidney. Edited by Pereira Brian JG, Sayegh MH, Blake Peter, New Jersey: Elsevier, Inc., pp 765-786, 2005.
86. Lin J and **Bonventre JV**. Prevention of radiocontrast nephropathy. Curr Opin Nephrol Hypertens 14:105-110, 2005.
87. Hentschel DM, **Bonventre JV**. Novel non-rodent models of kidney disease.
88. Curr Mol Med.; 5(5):537-46, 2005.
89. Vidal BC, **Bonventre JV**, Hsu S-I: Towards the application of proteomics in renal disease diagnosis. Clin. Sci. ;109 (5):421-4302005, 2006.
90. Hung, CC and **Bonventre, JV**. Acute Kidney Injury. In: Educational Review Manual in Nephrology. 2007.
91. Humphreys, BD, Duffield JS and **Bonventre JV**. Renal Stem Cells in recovery from Acute Kidney Injury. Minerva Urol Nephrol. 58(1):13-21, 2006.
92. Duffield, JS and **Boventre JV**. Response to: “Could tubular interstitium be a source of adult epithelial stem cells?” Kidney Int. 70: 2040–2041, 2006.
93. Waikar SS and **Bonventre JV**. Can we rely on Blood Urea Nitrogen as a biomarker to determine when to initiate dialysis? Clin J Am Soc Nephrol. 1 (5): 903-904, 2006.
94. Vaidya VS, **Bonventre JV**. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin Drug Metab Toxicol. 2(5):697-713, 2006.
95. **Bonventre JV**. Diagnosis of Acute Kidney Injury: From Classic Parameters to New Biomarkers. Contrib Nephrol. ;156:213-9, 2007.
96. **Bonventre JV**. Pathophysiology of Acute Kidney Injury: Roles of Potential Inhibitors of Inflammation. Contrib Nephrol. ;156:39-46, 2007.
97. Humphreys BD, **Bonventre JV**. The contribution of adult stem cells to renal repair. Nephrol Ther. 3(1):3-10, 2007.
98. Vaidya VS, Ferguson MA, **Bonventre JV**. Biomarkers of Acute Kidney Injury. Annu Rev Pharmacol Toxicol. 10;48:463-493, 2008.
99. **Bonventre, JV**. Urine Neutrophil Gelatinase-Associated Lipocalin as a Marker of Acute Kidney Injury in Critically Ill Children. Nat Clin Pract Nephrol. Practice Point Commentary. Nat Clin Pract Nephrol. 4(2):78-9, 2008.
100. **Bonventre JV**. Pathophysiology of Acute Kidney Injury. Nephrology Rounds, Brigham and Women’s Hospital. 10/7, 2008.
101. Gunaratnam L and **Bonventre JV**. Pathophysiology of Acute Kidney Injury. In: Primer on Kidney Diseases, 5th edition. National Kidney Foundation, Arthur Greenberg editor. Philadelphia, Saunders/Elsevier, 270-276, 2009.
102. Waikar SS, **Bonventre JV**. Biomarkers for the diagnosis of acute kidney injury. Curr Opin Nephrol Hypertens. 16(6):557-64, 2007.
103. Lock EA, **Bonventre JV**. Biomarkers in translation; past, present and future. Toxicology. 245(3):163-6, 2007.
104. Ferguson MA, Vaidya VS, **Bonventre JV**. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 245(3):182-93, 2008.
105. Ferguson MA, Vaidya V, and **Bonventre JV**. Biomarkers in acute Kidney Injury. In: Biomarkers in Renal Disease, M.H. Rosner and M. Okusa, editors. Nova science Publishers, Inc., New York, Pp 43-74, 2008.
106. **Bonventre, JV**. Molecular and genetic aspects of ischemic acute kidney injury. In: Molecular and Genetic Basis of Renal Disease: A Companion to Brenner and Rector’s The Kidney, D.B. Mount and M. Pollack, Eds. Philadelphia, Saunders/Elsevier Pp 531-555, 2008.
107. Luyckx VA, **Bonventre JV**. Biomarkers in Acute Kidney Injury. In: Critical Care Nephrology, 2nd Ed., Ronco, Bellomo and Kellum editors. Philadelphia, Saunders/Elsevier, 259-263, 2009.
108. Luyckx VA, **Bonventre JV**. Models of Ischemic Renal Failure. In: Critical Care Nephrology, 2nd Ed., Ronco, Bellomo and Kellum editors. Philadelphia, Saunders/Elsevier, 225-228, 2009.
109. **Bonventre JV**. Dialysis in acute kidney injury--more is not better. N Engl J Med. 359(1):82-4, 2008.
110. **Bonventre JV**: Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl. 241:78-83, 2008.
111. **Bonventre JV** and Bellomo R, Editors: Nephron Journals Special Issue: Acute Kidney Injury - Scientific Evidence Driving Change in Patient Management. Nephron Clin Pract. 109(4), 2008.
112. Waikar SS, **Bonventre JV**. Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract. 109(4):c192-7, 2008.
113. Gunaratnam L, **Bonventre JV**. HIF in Kidney Disease and Development. J Am Soc Nephrol. 20(9):1877-87, 2009.
114. **Bonventre JV**. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 20(5):927-8, 2009.
115. **Bonventre JV**. Editorial: Microvesicles from mesenchymal stromal cells protect against acute kidney injury. J Am Soc Nephrol. 20(5):927-8, 2009.
116. **Bonventre JV.** Nouveaux biomarquers de l’insuffisence rénale aiguë organique. Actualités néphrologiques Jean Hamburger 2009. Lesavre P, Drueke T, Legendre C. and Niaudet P. editors. Paris, Flammarion, 169-185, 2009.
117. **Bonventre, JV**. Mechanisms of Acute Kidney Injury and Repair. In: Management of Acute Kidney Problems, A Jorres, C Ronco, and J Kellum editors. Berlin, Springer-Verlag, pp13-20, 2009.
118. **Bonventre JV** and Sabbisetti V. Acute kidney Injury: Biomarkers from Bench to Bedside. In: Chronic Kidney disease, Dialysis and transplantation Himmelfarb J and Sayegh M H, Editors. Philadelphia, Elsevier Saunders, 2010.
119. Waikar SS, Betensky RA, **Bonventre JV**. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant. 24(11):3263-5, 2009.
120. **Bonventre JV**. Pathophysiology of AKI: injury and normal and abnormal repair. Contrib Nephrol. Cardiorenal Syndromes in Critical Care, C Ronco, R Bellomo and PA McCullough editors. 165:9-17, 2010.
121. **Bonventre JV**, Yang L. Kidney injury molecule-1. Curr Opin Crit Care. 16(6) 556–561, 2010.
122. **H**umphreys BD and Bonventre JV. Mesenchymal Stem Cells. In: Regenerative nephrology. Goligorsky M, ed. Oxford, Elsevier, pp 153-163, 2011. Chapter
123. Yang L, Humphreys BD, **Bonventre JV**. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol. 174:149-55, 2011. Review
124. **Bonventre** JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 121(11):4210-21, 2011. PMCID: PMC3204829
125. Sabbisetti V, **Bonventre JV**. Biomarkers in Acute Kidney Injury and Chronic Kidney Disease. In: Brenner and Rector's The Kidney, 9th Edition, Taal, Chertow, Marsden, Skorecki, Yu, and Brenner, editors, pp. 1016-1024. Pennsylvania, Saunders, 2011. Chapter
126. Krolewski AS, **Bonventre JV**. High risk of ESRD in type 1 diabetes: call for action: introduction. Semin Nephrol. 32(5):405-6, 2012. Introduction to journal issue
127. Krolewski AS, **Bonventre JV**. Semin Nephrol. High risk of ESRD in type 1diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol. 32(5):407-14, 2012. PMCID: PMC3474985
128. **Bonventre JV**. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol. 32(5):452-62, 2012. PMCID: PMC3595316
129. Salahudeen AK, **Bonventre JV**.Onconephrology: The Latest Frontier in the War against Kidney Disease. JASN. 24(1):26-30, 2012. Review
130. Waikar SS, **Bonventre JV**. Acute kidney injury. In :Harrison's Principles of Internal Medicine, 18th ed., vol. 2, pp. 2293–2308. Longo et al., eds. New York: McGraw-Hill, 2012. Chapter
131. **Bonventre JV.** Antifibrotic vitamin D analogs. J Clin Invest. 123(11):4570-3, 2013. PMCID: PMC3809811
132. **Bonventre JV** and Vaidya V. Qualification of Urinary Biomarkers for Kidney Toxicity. In: The Path from Biomarker Discovery to Regulatory Qualification 1st Edition, Goodsaid F and Mattes WB, eds, pp 129-141. Elsevier, 2013. Chapter
133. Ronco C, **Bonventre JV**. Stigmata of death: for kidneys and patients. Nephrol Dial Transplant. 29(10):1797-8., 2014. PMCID: PMC4838006
134. **Bonventre JV**. Current Biomarkers in Kidney Disease: Dawning of a New Era. ASN Kidney News. 6:6, 7-8, 2014. Review
135. Canaud G, **Bonventre JV**. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant. 30(4):575-583, 2014. PMCID: PMC4370290
136. **Bonventre, JV**. Kidney injury molecule-1: a translational journey. Trans Am Clin Climatol Assoc. 125:293-9; discussion 299. PMCID: PMC4112686
137. Lam AQ, Freedman BS, **Bonventre JV**. Directed differentiation of pluripotent stem cells to kidney cells. 34(4):445-61. PMCID: PMC4893322
138. Wang X, **Bonventre JV**, Parrish AR. The aging kidney: increased susceptibility to nephrotoxicity. Int J Mol Sci. 1;15(9):15358-76, 2014. PMCID: PMC4200815. Review.
139. Bonventre JV. Maladaptive proximal tubule repair: cell cycle arrest. Nephron Clin Pract. 127(1-4):61-4, 2014. PMID: 25343823, review.
140. Ferenbach DA, **Bonventre JV**. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD.Nat Rev Nephrol. 11(5):264-76, 2015. PMCID: PMC4412815
141. Bonventre, JV. Adaptation of the Kidney to Injury. In: Harrison’s Principles of Internal Medicine, 19th Edition. McGraw-Hill Professional, 333e (digital only), Kasper et al., eds. New York: McGraw-Hill, 2015. Chapter
142. Waikar SS, Bonventre JV. Acute kidney injury. In :Harrison's Principles of Internal Medicine, 19th ed., vol. 2, pp. 1799-1811. Kasper et al., eds. New York: McGraw-Hill, 2015. Chapter
143. Lam AQ, **Bonventre JV**. Regenerating the nephron with human pluripotent stem cells.Curr Opin Organ Transplant. 20(2):187-92, 2015. Review. PMID: 25695593
144. Zuk A**, Bonventre JV**. Acute kidney injury: Can remote ischaemic preconditioning prevent AKI? Nat Rev Nephrol. 11(9):512-3, 2015. PMCID: PMC4951154
145. Olabisi, O and **Bonventre, JV**: Acute Kidney Injury in Cancer Patients. In: Onconephrolog. Jhaveri, K and Salahudeen, AK eds. Springer Science and Business Media, NY, NY. pp 1-24, 2015. Chapter

# Bonventre, JV. Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl. 4(1):39-44, 2015. PMCID: PMC4536970

1. Ferenbach DA and **Bonventre, JV**: The Molecular Response to Renal Injury: How Does Chronic Renal Damage Suppress Normal Repair Process? In: Kidney Development, Disease Repair and Regeneration. Little MH, Ed. Elsevier, 367-379, 2016. Chapter
2. Brooks CR, **Bonventre JV.** KIM-1/TIM-1 in proximal tubular cell immune response. Oncotarget. 6(42):44059-60, 2015. PMCID: PMC4792540
3. Zuk A, Bonventre JV. Acute Kidney Injury. Annu Rev Med.67:293-307, 2016. PMCID: PMC4845743
4. Ferenbach DA, **Bonventre JV**. Kidney tubules: intertubular, vascular, and glomerular cross-talk. Curr Opin Nephrol Hypertens. 25(3):194-202, 2016. PMCID: PMC4845750
5. Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: From the laboratory to the clinic. Nephrol Ther. 12 Suppl 1:S41-8, 2016. PMID: 26972097, PMC journal, in process
6. Li L, **Bonventre JV**. Endothelial Glycocalyx: Not Just a Sugar Coat. Am J Respir Crit Care Med. 194(4):390-3, 2016. PMID: 27525457
7. Barasch J, Zager R, **Bonventre JV**. The definition of acute kidney injury - Authors' reply. Lancet. 391(10117):203-204, 2018. PMID: 30277885.
8. **Bonventre JV**. Kidney organoids-a new tool for kidney therapeutic development. Kidney Int. 94(6):1040-1042,2018.PMID: 30466559.
9. Zuk A, **Bonventre JV**. Recent advances in acute kidney injury and its consequences and impact on chronic kidney disease. Curr Opin Nephrol Hypertens. 28(4):397-405, 2019. PMID: 30925515
10. McCracken KW, Bonventre JV. Stem cells in kidney development and regeneration . In: Principles of Tissue Engineering. 5 ed. Lanza R, Langer R, Vacanti J, Atala A, editors. Cambridge, MA: Elsevier, Academic Press; 2020. Chapter 44; p.805-818.

Books

|  |
| --- |
| Provide full citation for doctoral thesis |

1. **Bonventre JV**. Key References in Nephrology, Churchill Livingston, Inc., New York, 1982.
2. Schlondorff D and **Bonventre JV** eds. Molecular Nephrology. Molecular Biology of the Kidney in Health and Disease, New York: Marcel Dekker, Inc., 1995.
3. Vaidya V, **Bonventre JV** eds. Biomarkers in Medicine, Drug Discovery and Environmental Health. New Jersey: John Wiley and Sons, Inc., 2010.

Thesis

|  |
| --- |
| Provide full citation for doctoral thesis |

|  |
| --- |
| **Bonventre JV**. Renal concentration mechanism: Role of papillary epithelium and pelvic urine; corticomedullary gradient by electron probe analysis; a passive model with functional heterogeneity in the outer medulla. Ph. D. Thesis, Harvard University 1979. |

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

|  |
| --- |
| List abstracts published and exhibits presented at meetings during the last 3 years which have not already been published as full length manuscripts. May also list all abstracts or exhibits, regardless of date or publication as full-length manuscript, which received special recognition at a meeting (e.g., juried poster presentation, meeting commendation). |

1. **Bonventre JV** and Beeuwkes R. The configuration and vascular perfusion of human proximal tubules. The Physiologist 16:269, 1973.

2. Beeuwkes R and **Bonventre JV**. The organization and vascular perfusion of canine renal tubules. The Physiologist 16:264, 1973.

3. Lechene C, Fusco J, **Bonventre JV** and Schmidt-Nielson 0. Contact between pelvic urine and renal inner medulla as part of the concentrating mechanism. 6th International Congress of Nephrology 153A, 1975.

4. **Bonventre JV** and Lechene C. Effect of pelvic urine on renal concentrating ability. Federation Proceedings 35:372, 1976.

5. Lechene C, **Bonventre JV**, Merriam G and Horowitz P. X-ray analysis of the renal concentrating mechanism. Kidney International 8:469, 1976.

6. Lechene C, **Bonventre JV** and Karnovsky MJ. Permeability of the renal papillary epithelium and urinary concentration ability. Clinical Research 24:405A, 1976.

7. **Bonventre JV** and Lechene C. A new model of renal concentrating mechanism. Kidney International 14:715, 1978.

8. **Bonventre JV**, Roman R and Lechene C. Effect of vanadate on renal function. Federation Proceedings 38:1042, 1979.

9. **Bonventre JV**, Rabito CA and Lechene C. Measurement of intracellular electrocyte composition in isolated kidney epithelial cells. VIIIth International Congress of Nephrology, Athens, Greece, 1981.

10. Cheung JY, Bonventre den Hollander AM, Sonke PJ and Leaf A. Effects of prostaglandin E2 (PGE2) and angiotensin II (All) on the isolated perfused rat kidney. 14th Annual Meeting of the American Society of Nephrology, 1981.

11. Cheung JY, Thompson IG and **Bonventre JV**. Effects of calcium removal and anoxia on isolated rat cardiac myocytes. Fed. Proc. 41:1371,1982.

12. Cheung JY, Leaf A and Bonventre JV. Mechanism of protection by verapamil (V) and nifedipine (N) from anoxic injury in working isolated rat myocytes. Clin. Res. 30:480A, 1982.

13. Bonventre JV, Malis CD, Cheung JY and Leaf A. Mechanism of protection by verapamil (V) in norepinephrine (NE) -induced acute renal failure (ARF). Clin. Res. 30:538A, 1982.

14. **Bonventre JV**, Leaf A and Cheung JY. Metabolic acidosis protects isolated hepatocytes against anoxic injury. Clin. Res. 31:474A, 1983.

15. Bonventre JV. Effects of mannitol, polyethylenglycol (PEG) <10 M Ca2+ and acidosis on viability of isolated hepatocytes exposed to anoxia. Proc. Int. Union Physiol. Sci. 15:214, 1983.

16. Hartwig JH, **Bonventre J**, Johnson 0, Ausiello D and Stossel T. Role of the cortical actin gel and calcium in osmotic cell swelling. Clin. Res. 32:564A, 1984.

17. Haupert Jr GT, Ray S, Pichiarallo D, Kormos L and **Bonventre JV**. Absence of phospholipid degradation in isolated renal tubules and hepatocytes exposed to anoxia. Clin. Res. 32:449A, 1984.

18. **Bonventre JV** and Cheung JY. Intracellular free calcium concentration in cultured LLC-PK1 renal epithelial cells. IX Int. Cong. Nephrol., Los Angeles, CA, p.365A, 1984.

19. Cheung JY and **Bonventre JV**. Calcium homeostatsis in isolated cardiac myocytes. Int. Cong. on Isolated Cardiac Myocytes, Germany, 1984.

20. Cheung JY, Leaf A and **Bonventre JV**. Mitochondrial dysfunction in anoxic myocytes is not secondary to calcium overload. 57th Mtg. Am. Heart Assoc., 1984.

21. **Bonventre JV**, Cheung JY, Skorecki K, Kreisberg JI and Ausiello DA. Vaso ressin and angiotensin II increase cytosolic free Ca2+ levels in glomerular mesangial cells. Kidney Int. 27:230, 1985.

22. Diamond JR, Karnovsky MJ and **Bonventre JV**. The role of oxygen free radicals in aminonucleoside nephrosis. Kidney Int. 27:230, 1985.

23. Cheung JY and **Bonventre JV**. Mitochondrial function and calcium homeostasis in anoxic cardiac myocytes. Fed. Proc. 44:536, 1985.

24. **Bonventre JV** and Cheung JY. Calcium homeostatsis in cultured renal LLC-PK1 cells. Fed. Proc. 44:626, 1985.

25. Malis CD and **Bonventre JV**. Calcium potentiates oxygen free radical injury to renal mitochondria. Clin. Res. 33:492A, 1985.

26. Corwin HI, Schreiber MJ, Teplick R, Fang LST, **Bonventre JV** and Coggins CH. Prediction of outcome in acute renal failure. Kidney Int. 27:135, 1985.

27. Troyer DA, Venkatachalam MA, **Bonventre JV** and Kreisberg JI. Influence of Cyclic Nucleotides (cAMP) on Inositol phospholipid (InsPL) Metabolism in Cultured Mesangial Cells. Am. Soc. Nephrology, December, 1985.

28. Malis CD and **Bonventre JV**. Mechanism of Ca and Oxygen Free Radical (Oo) Injury to the Mitochondrial Electron Transport Chain. Am. Soc. Nephrology, December, 1985.

29. Troyer DA, Venkatachalam MA, **Bonventre JV** and Kreisberg JI. Influence of cyclic nucleotides (cAMP) on inositol phospholipid (InsPL) metabolism in cultured mesangial (MS) cells. Fed. Proc. 45:423, 1986.

30. Cheung JY, Constantine JM and **Bonventre JV**. Cytosolic free calcium concentration ([Ca]) does not mediate stimulation of glucose transport by insulin (I) in isolated cardiac myocytes. Clin. Res. 34:289A, 1986.

31. Cheung JY, Constantine JM and **Bonventre JV**. Regulation of cytosolic free calcium concentration ([Cai]) in renal epithelial cells. Clin. Res. 34:592A, 1986.

32. Swidler MA and **Bonventre JV**. Calcium dependency of prostaglandin E2 (PGE2) production in cultured mesangial cells. Clin. Res. 34:611A, 1986.

33. **Bonventre JV** and Weber P. Effect of platelet activating factor (PAF) and altelet derived growth factor (PDGF) on cytosolic free Ca + concentration ([Ca2+]F) and phospholipase A2 and C activation in glomerular mesangial cells. Kidney Int. 31:161, 1987.

34. Cantiello HF, Angel J, Ausiello DA and **Bonventre JV**. Ca modulates a Na/H exchanger in mesangial cells. Kidney Int. 3l:p162, 1987.

35. Malis CD and **Bonventre JV**. Incorporation of marine lipids into mitochondrial membranes increases susceptibility to Ca and oxygen free radical damage. Kidney Int. 31:370, 1987.

36. Cantiello HF, Mohrmann M, **Bonventre JV** and Ausiello DA. Role of cAMP in the regulation of Na+/H+ antiport activity in renal tubular and glomerular cells. Fed. Proc. 46:1229, 1987.

37. Polla OS and **Bonventre JV**. Heat shock protects cells dependent on oxidative metabolism from inhibition of oxidative phosphorylation. Clin. Res. 35:555A, 1987.

38. Polla BS, **Bonventre JV** and Krane SM. l,25-Dihydroxyvitamin D3 (l,25-(OH)2D3) increases H202 toxicity in the human monocyte line V937: role of calcium and heat shock (HS). Clin. Res. 35:627A, 1987.

39. Gronich JH, Nemenoff RA and **Bonventre JV**. Phorbol myristate acetate enhances phospholipase A2 activity in glomerular mesangial cells. Kidney Int. 33:265, 1988.

40. Cybulsky AV, Salant DJ, Quigg RJ, Badalamenti J and **Bonventre JV**. “Activation” of glomerular epithelial cells (GEC) by the membrane attack complex (MAC) of complement (C) Kidney Int. 33:153, 1988.

41. Malis CD, **Bonventre JV** and Cantiello HF. Furosemide inhibits renal mitochondrial oxidative metabolism and Ca2+ uptake. Implications for its protective effects in ischemic acute renal failure. Kidney Int. 33:361, 1988.

42. Cybulsky AV, Salant DJ, Quigg RJ, Badalamenti, J and **Bonventre JV**. The membrane attack complex (MAC) of complement (C) activates phospholipase (PL)C in cultured rat glomerular epithelial cells(GEC). FASEB J. 2: A627, 1988.

43. Nemenoff RA, **Bonventre JV**, and Gronich JH. Identification and characterization of a normmally regulated form of phospholipase A2. FASEB J. 2: Al366, 1988.

44. Nemonoff RA, Gronich JH, and **Bonventre JV**. Characterization of a normally-regulated form of phospholipase A2 in renal mesangial cells. J. Cell. Biochem. Suppl. 12E., 53, 1988.

45. Hallag HA, Meszoely I, **Bonventre JV** and Haupert Jr. GT Hypothalamic Na, K-ATPase inhibitor increases cytosolic free calcium in cultured cardiac myocytes. Circ. Res., 1988.

46. Force T, Malis C, Gverrero L, varadarajan GS, **Bonventre JV** Weber P and Leaf A. n-3 fatty acids reduce post-ischemic no-reflown but have no effect on extent of myocardial necrosis. Circ Res, 1988.

47. Malis CD, Veradarajan GS, Force T, Weber PC, Leaf A and Bonventre 3JV. Effects of dictary fish oils on vascular contractility subsequent to anoxia. Circulation 78:II-216, 1988.

48. Malis CD, Veradarajan Gs, Force T, Weber PC, Leaf A and **Bonventre JV**. Effect of anoxia and reoxygenation on vascular reactivity. Modification by dietary fish oil. Kidney Int. 35:412, 1989.

49. Ouellette AJ, Malt RA, Sukhatme VP and **Bonventre JV**. Induction of c-fos and the early growth response gene Egr-1 in mice after renal ischemia. Kidney Int. 35:415, 1989.

50. **Bonventre JV**, Sullivan S, Sukhatme VP, and Ouellette AJ Vasopressin increases the expression of the early growth response gene, Egr-l in cultured mesangial cells. Kidney Int. 35:169, 1989.

51. Gronich JH, **Bonventre JV** and Nemenoff RA. Purification of phospholipase A2 from rat kidney. Kidney Int. 35:292, 1989.

52. Cybulsky AV, **Bonventre JV**, Quigg RJ, Badalamenti J and Salant DJ. Extracellular matric (ECM) regulates proliferation and phospholipid turnover in a glomerular epithelial cells (GEC) Kidney Int. 35:179, 1989.

53. **Bonventre JV**, Gronich JH and Nemenoff RA. Epidermal growth factor enhances phospholipase A2 activity in mesangial cells by a protein kinase C and pertussis toxin independent mechanism. Clin. Res. 37:580A, 1989.

54. Nemenoff RA, Gronich JH and **Bonventre JV**. Characterization and partial purification of a hormonally-regulated form of phospholipase A2 from rat kidney. 9th Int. Washington Spring Symposium, 105, 1989.

55. Malis CD, Weber PC, Leaf A and **Bonventre JV**. Mitochondrial membranes enriched with n-3 fatty acids and exposed to Ca2+ and reactive oxygen species as more susceptible to damage induced by phospholipase A2. Kidney Int. 37:488, 1990.

56. Sellmayer A, Weber PC and **Bonventre JV**. Endogenous arachidonic acid metabolites modualte growth and mRNA levels of immediate early genes in rat mesangial cells. Kidney Int. 37:350, 1990.

57. Parini IM, Emmenegger V, **Bonventre JV** and Polla BS. 1,25-dihydroxy vitamin D3 (1,25-(OH)2 D3) induces prostaglandin E2 (PGE2) production by the human promonocyte line U937. 7th Int. Cong. Prostaglandins and Related Compounds, Florence, Italy, 1990.

58. Sellmayer A, Krane SM, Ouellette A and **Bonventre JV**. Effects of 1,25-(OH)2 vitamin D3 [1,25-(OH)2 D3] on expression of the genes for the calcium binding proteins MRP-8 and MRP-14 that are unique for myeloid lineage cells. J. Bone and Mineral Res. 5 (Suppl 2) S-131, 1990.

59. Force T and **Bonventre JV**. Endothelin and vasopressin enhance tyrosine phosphorylation by kinase c-dependent and independent pathways in glomerular mesangial cells. Clin. Res. 38:245A, 1990.

60. Force T, Hyman G, Sellmayer A and **Bonventre JV**. Cytochrome P-450 monoxygenase products modulate the calcium response to vasopressin in glomerular mesangial cells. Clin. Res. 38:371A, 1990.

61. **Bonventre JV**, Ouellette AJ, Sukhatme VP and Brown D. Localization of the Egr-1 protein product to the distal nephron after renal ischemia and reperfusion. Clin. Res. 38:442A, 1990.

62. Rordorf GA, Nemenoff RA, Uemura Y, and **Bonventre JV**. Characterization of phospholipase A2 (PLA2) activity in gerbil brain after ischemia and reperfusion. 20th Annual Meeting of the Society of Neurosciences, St. Louis, MO, Vol. 2: 1278, 1990.

63. Force T, **Bonventre JV**. Regulation of epidermal growth factor (EGF) and endothelin-induced protein tyrosine phosphorylation by non-cyclooxygenase products of arachidonate. JASN 1: 415, 1991.

64. Hajjar R, **Bonventre JV**. Intracellular [Ca2+] oscillation frequency depends on vasopressin concentration, basal [Ca2+], and temperature in mesangial cells. JASN 1: 471, 1991.

65. Nakamura H, **Bonventre JV**. Subcellular characteristics of phospholipase A2 (PLA2) in the rat kidney. Enhanced cytosolic, mitochondrial, and microsomal PLA2 activity after renal ischemia. JASN 1:600, 1991

66. Hyman GA, Force T, **Bonventre JV**. Inositol trisphosphate (IP3) sensitive calcium pools respond to epoxyeicosatrienoic acids (EETs) in cultured rat mesangial cells. JASN 1: 721, 1991.

67. G. Rordorf, W.J. Koroshetz, J.V. Bonventre. The heat shock response protects cultured neurons from glutamate toxicity. Neurology 41 (Suppl 1), page 162, abstr 170S, March 1991.

68. Wong JT, **Bonventre J**, Dunn S, Colvin RB. Isolated CD3:CD8 but not CD3:CD4 pairing enhances activation FASEB J 5: A993, 1991.

69. G. Rordorf, W.J. Koroshetz, R.A. Nemenoff and **J.V. Bonventre**. Glutamate increases phopsholipase A2 enzymatic activity in cultured rat cortical cells. International Society of Cerebral Blood Flow and Metabolism, Miami, June, 1991.

70. Rordorf G, **Bonventre JV**, Koroshetz WJ. The heat-shock response protects cultured neurons from glutamate toxicity. Ann. Mtg of AAN, 1991.

71. Force T, Rapp U, **Bonventre JV**. Endothelin activates Raf-1 kinase via a protein kinase C-dependent pathway. 64th Meeting of American Heart Association, Anaheim, CA, 1991.

72. Witzgall R, Guest S, Ouellette AJ, **Bonventre JV**. Cloning of a developmentally regulated, zinc-finger rich, putative transcription factor from the rat kidney. JASN, 1991.

73. Force T, **Bonventre JV**. Raf-1 kinase, phospholipase C, and PI kinase in mesangial cells stimulated with endothelin. J. Am. Soc. Neph. 1991.

74. **Bonventre JV**. Characterization of phospholipase A2 (PLA2) activity in gerbil brain and neurons in culture: subcellular localization, effects of ischemia and reperfusion and glutamate. 8th Int. Conf. on Prost. and Related Compounds, Montreal, Canada, July, 1992.

75. Dahlberg CG, Quinn DA, **Bonventre JV**, Joseph PM, Thompson BT, Hales CA. EGF causes intracellular alkalinization of bovine pulmonary artery smooth muscle cells in part via stimulation of Na+/H+ exchange. FASEB J. 6: A1603, 1992.

76. Witzgall R, O'Leary E, Lorenz F, Ouellette AJ, **Bonventre JV**. A novel putative transcription factor predominantly expressed in the kidney: structural features and patterns of expression with ontogeny and injury. JASN, 3: 482, 1992.

77. Force T and **Bonventre JV**. Endothelin activates *src* tyrosine kinase in glomerular mesangial cells. JASN, 3: 491, 1992.

78. Dahlberg CGW, Spence CR, Quinn DA, **Bonventre JV**, Joseph PM, Thompson BT, Hales CA. Heparin Interferes with PDGF-Stimulated Intracellular Alalinization of Bovine Pulmonary Artery Smooth Muscle Cells via Inhibition of Na+/H+ Exchange. Am Rev Respir Dis 147:A495, 1993.

79. Quinn DA, Dahlberg CGW, Thompson BT, Joseph PM, **Bonventre JV**, Hales CA. Stimulation by Platelet Derived Growth Factor (PDGF) and Epidermal Growth Factor (EGF) of the Na+/H+ Exchanger in Relation to Cell Proliferation. FASEB J, 7:A3152, 1993.

80. Dahlberg CG, Quinn DA, **Bonventre JV**, Joseph PM, Thompson BT, Hales CA. Heparin attenuates EGF-stimulated intracellular alkalin-ization of rat lung fibroblasts via attenuation of Na+/H+ exchange. Experimental Biology, FASEB Journal, 147:A357, 1993.

81. Force T, **Bonventre JV**, Heideckert G, Rapp U, Avruch J, Kyriakis JM. Enzymatic characteristics of the c-Raf-1 protein kinase. 5th Annual Meeting of the American Society of Renal Biochemistry and Metabolism, Bar Harbor, ME, 1993.

82. Witzgall R, Walker C, O’Leary E, **Bonventre J**. *Kid-1* mRNA levels are suppressed in renal cell carcinoma. 5th Annual Meeting of the American Society of Renal Biochemistry and Metabolism, Bar Harbor, ME, 1993.

83. Force T, Kyriakis J, **Bonventre J**. Endothelin activates c-src in glomerular mesangial cells by a tyrosine phosphatase-dependent mechanism. 5th Annual Meeting of the American Society of Renal Biochemistry and Metabolism, Bar Harbor, ME, 1993.

84. Kelly KJ, Williams WW, Colvin RB, **Bonventre JV**. Antibody to intercellular adhesion molecule-1 (ICAM-1) protects the kidney against ischemia. Journal American Society of Nephrology, 1993.

85. Kleinman JG, Brown D, **Bonventre JV**, Beshensky AM, Worcester EM. Distribution of Osteopontin in Rat Kidney: Upregulation in Ischemia JASN, 4: 611, 1993.

86. Witzgall RW, O’Leary E, Volk R, Yeung R, **Bonventre JV**. Characterization of the *Kid-1* gene and identification of the domain of Kid-1 that mediates its transcriptional repressor activity. JASN 4, 1993.

87. Witzgall RW, Brown D, Schwarz C, **Bonventre JV**. Localization of PCNA, vimentin, clusterin and c-fos in post-ischemic kidneys. Evidence for a large pool of mitotically active and dedifferentiated cells. JASN 4, 1993.

88. **Bonventre JV**. Phospholipase A2 activation ion cell injury and death. Society of Toxicology Symposium, Dallas TX, 1994.

89. Pombo CM, Kyriakis JM, **Bonventre JV**, Force TL. The p54 stress-activated protein kinases (SAPKs) are major c-jun amino-terminal kinases activated by ischemia and reperfusion. American Heart Association, Circulation 67th Scientific Session, Dallas TX, 1994.

90. Kim DK, Koroshetz WJ, Rordorf G, **Bonventre JV**. Two cytosolic forms of PLA2 in cortical cultures: glutamergic upregulation of enzyme activity. Annual Neurosciences Meeting, Miami FL, 1994.

91. Ross BM, Kim DK, **Bonventre JV**, Kish SJ. Characterization of novel phospholipase A2 activity in autopsied human brain. Annual Neuro-sciences Meeting, Miami FL, 1994.

92. Kelly KJ, Williams WW, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos J-C, **Bonventre JV**. Intercellular adhesion molecule-1 (ICAM-1) knockout mice are protected against renal ischemia. JASN, 5:900, 1994.

93. Rabb H, Mendiola C, Saba SR, Dietz J, Smith CW, **Bonventre JV**, Ramirez G. Antibodies to p-selectin and ICAM-1 protect kidneys from ischemic-reperfusion injury. JASN, 5:907, 1994.

94. Spech RA, Witzgall R, **Bonventre JV**. Overexpression of the cytosolic PLA2 (cPLA2) enhances susceptibility to oxidative injury in LLC-PK1 cells. JASN, 5:909, 1994.

95. Witzgall R, O’Leary E, Kim SS, **Bonventre JV**. Identification of consensus binding motif for the zinc fingers of Kid-1. JASN, 5:641, 1994.

96. Sheridan AM, Kim DK, **Bonventre JV**. Translocation of cytosolic PLA2 (cPLA2) induced by ATP depletion. JASN, 5:684, 1994.

97. Silverman ES, Goslant CE, Quinn DA, **Bonventre JV**, Joseph PM, Thompson BT, Hales CA. Serum stimulates Na+/H+ exchange in human pulmonary artery smooth muscle cells by increasing the PK0.5 and decreasing the hill coefficient of the allosteric internal modifier site. FASEB, 1994.

98. Silverman ES, Goslant CE, Quinn DA, **Bonventre JV**, Joseph PM, Thompson BT, Hales CA. A comparison of Na+/H+ exchange in human pulmonary artery smooth muscle cells and human aortic smooth muscle cells. ALA/ATS International Conference, Boston, MA, 1994.

99. Sapirstein A, Spech R, Witzgall R, **Bonventre JV**. Bcl-2 prevents cytosolic PLA2-mediated cell injury in renal epithelial cells. JASN, 6:988; 1995.

100. Morooka H, **Bonventre JV**, Kyriakis J, Force T. Modulation of ATF-2 DNA binding by an ischemia/reperfusion-activated ATF-2 kinase. JASN, 6:985; 1995.

101. Sheridan A, Force T, **Bonventre JV**. Identification of proteins which interact with the [Ca2+] phospholipid-binding (CaLB) domain of cytosolic phospholipase A2 (cPLA2) by two-hybrid cloning. JASN, 6:761, 1995.

102. Joseph PM, Tabak L, **Bonventre JV**, White H, Volokhov A, Carter E, Hales CA. Phospholipase A2 activity is increased by smoke inhalation injury but not surface burn or burn then smoke. ATS International Conference, Seattle WA, 1995.

103. Silverman ES, Kinane TB, O’Leary E, Thompson BT, **Bonventre JV**, Hales CA. Identification of hypoxic induced pulmonary artery smooth muscle cell cDNA fragments by differential display. ATS International Conference, Seattle WA, 1995.

104. Silverman ES, Thompson BT, Quinn DA, Kinane TB, **Bonventre JV**, Hales CA. Activation of Na+/H+ exchange in pulmonary smooth muscle segments during hypoxic-induced pulmunary vascular remodeling. Experimental Biology, FASEB J, 9:A432, 1995.

105. Burke S, Goldberg D, **Bonventre J**. RENAGEL™, A Nonabsorbed Phosphate Binding Polymer Lowers Serum Phosphorus in Hemodialysis Patients. XXXIIIrd Congress of the EDTA, Amsterdam, the Netherlands 1996.

106. Burke SK, Goldberg DI, **Bonventre JV**, Slatopolsky EA. RENAGEL™ A Calcium and Aluminum Free Phosphate Binder Inhibits Phospate Absorption in Normal Volunteers. XXXIIIrd Congress of the EDTA, Amsterdam, the Netherlands 1996.

107. Burke SK, Goldberg DI, **Bonventre JV**, Slatopolsky EA. RENAGEL™ A Calcium and Aluminum Free Phosphate Binder Lowers Serum Phosphorus in Hemodialysis Patients. XXXIIIrd Congress of the EDTA, Amsterdam, the Netherlands 1996.

108. Burke SK, Goldberg DI, **Bonventre JV**, Slatopolsky EA. RENAGEL™ A Calcium and Aluminum Free Phosphate Binder Lowers Serum Phosphorus in Hemodialysis Patients. Nephrol Dial Trans 1996.

109. Burke SK, Goldberg DI, **Bonventre JV**, Slatopolsky EA. RENAGEL™ A Calcium and Aluminum Free Phosphate Binder Inhibits Phosphate Absorption in Normal Volunteers. Nephrol Dial Trans 1996.

110. Kelly KJ, **Bonventre JV**. Ostogenic Protein-1 Protects the Rat Kidney from Ischemic Injury. Acute Renal Failure in the 21st Century, 1996.

111. Sheridan AM, Force T, Taheri MR, **Bonventre JV**. The Nuclear Localization of Cytosolic PLA2 (cPLA2): Role of a Novel Nuclear Protein, *PLIP*. JASN, 7:1650, 1996.

112. Kelly KJ, **Bonventre JV**. osteogenic Protein-1 Protects the Rat Kidney From Ischemic Injury. JASN, 7:1827, 1996.

113. Kelly KJ, Tolkoff-Rubin NE, Rubin RH, Williams Jr WW, Meehan SM, Meschter CL, Christenson J, **Bonventre JV**. An Oral Platelet Activating Factor Antagonist, Ro 24-4736, Protects The Rat Kidney From Ischemic Injury. JASN, 7:1827, 1996.

114. Kelly, Willimas Jr. WW, Meehan SM, Colvin RB, **Bonventre JV**. Protection From Toxic Nephropathy In The Rat With Blockade of Intercellular Adhesion Molecule-1. JASN, 7:1840-41, 1996.

115. Slatopolsky E, Garrett B, Gray J, Marbury T, Weinberg M, Wombolt D, Burke S, Goldberg E, **Bonventre J**. Effect of RENAGEL ™ A Novel ZPhosphate Binder on Serum Phosphorus and Parathyroid Hormone Levels in End State Renal Disease (ESRD) Patients. JASN, 7:1818, 1996.

116. Pombo C, **Bonventre JV**, Molnar A, Kyriakis J, Force T. Activation of a Human STE-20-Like Kinase by Oxidant Stress Defines a Novel Stress Response Pathway. JASN, 7:1684, 1996.

117. Witzgall R, Bölitz U, Phillippin B, **Bonventre JV**, Kriz W. The Kid-1 Protein is Expressed in a Speckled Pattern in the Nuclei of Proximal Tubular Cells. JASN, 7:1608, 1996.

118. **Bonventre, JV**. Adhesion Molecules and Their Antagonists in Acute Renal Failure. XIVth International Congress of Nephrology, Sydney, Australia, 1997.

119. Force T **Bonventre JV**. Stress and Oxidant Regulated Protein Kinases. Acute Renal Failure - Towards 2000. Cairns, Australia, 1997.

120. Alessandrini A, **Bonventre JV**. ERK1 Phosphorylates SMAD1 and SMAD2 and is Activated by Bone Morphogenetic Protein-7 (BMP-7) in IMCD-3 Cells. JASN, 8:432A; 1997.

121. Ichimura T, Wei H, Hession CA, Cate RL, Sanicola M, **Bonventre JV**. Renal Ischemia/Reperfusion Results in Upregulation of the *nmb* Gene. Identification by Respresentational Difference Analysis. JASN, 8:588A, 1997.

122. Ichimura T, **Bonventre JV**, Wei H, Bailly V, nHession CA, Cate RL, Sanicola. Kidney Injury Molecule-1 (KIM-1), A Member of the Immunoglobulin Gene Superfamily is Upregulated in Renal Epithelial Cells After Injury. JASN, 8:220A; 1997.

123. Choukroun G, Gustavson C, Brown D, **Bonventre JV**. Cytosolic Phospholipase A2 (cPLA2) Alters Intracellular Trafficking of Membrane Proteins. JASN, 8:59A; 1997.

124. Molnar A, Tsujita T, Kyriakis J **Bonventre JV**, Forde T. The STE20-Like Oxidant Stress Response Kinase-1 Induces Cell Cycle Arrest in G1 Via A P38 MAP Kinase-Independent Pathway. JASN, 8:591A, 1997.

125. Sheridan AM, Force T, O'Leary E, **Bonventre JV**. Nuclear Co-Localization of PLIP and cPLA2 Potentiates Cellular Arachidonate Release in Rat Mesangial Cells. JASN 8:418A; 1997.

126. Namura S, Alessandrini A, **Bonventre JV**, Moskowitz MA. Inhibition of MEK1/ERK pathway reduces brain damage following focal cerebral ischemia and reperfusion in mice. AHA, 23rd International Joint Conference on Stroke and Cerebral Circulation, 1998.

127. Quinn DA, Hales CA, Tager A, **Bonventre JV**, Force T. Stress activated protein kinases with cell stretch. ALA/ATS International Conference, 1998.

128. Quinn, DA, Hales CA, Joseph PM, **Bonventre JV**, Force T. Stretch induces activation of stress activated protein kinases (SAPK) in type II alveolar cells. Experimental Biol 1998.

129. Sapirstein A, Zhihong H, Chin MY, O'Leary E, Taheri MR, LiE, Moskowitz A, **Bonventre, JV**. Cytosolic phospholipase A2 deficient mice have abnormal fertility and are protected against focal ischemic injury to the brain. Keystone Symposia Conference on Molecular and Celllar Biology, 1998.

130. Quinn, DA, Tager A, **Bonventre JV**, Force T, Hales CA. Stretch-Induced MAP kinase activation and interleukin-8 production in type II alveolar cells. Aspen Lung Conference, June 1998.

131. Namura S, Alessandrini A, **Bonventre JV**, Moskowitz MA. Inhibition of MEK/ERK pathway reduces brain damage following focal cerebral ischemia and reperfusion in mice. 23 International Joint Conference on Stroke and Cerebral Circulation 326:P142, 1998.

132. **Bonventre JV**. Role of Adhesion Molecules in Ischemic Kidney Injury. University of Alberta, Edmonton, Canada, March 1998.

133, Namura S, Alessandrini A, **Bonventre JV**, Moskowitz MA. Activation of MEK1/ERK pathway after focal cerebral ischemia and reperfusion. 53th Annual Meeting of the Japan Neursurgical Society, Sapporo, Hokkaido October 1998.

134. Choukroun G, Gustafson CE, Hajjar R, Brown D, **Bonventre JV**. La phospholipase A2 cytosolique desorganise l'appareil de golgi et modifie le transport intracellulaire des proteines membranaires. Kidney International 1998.

135. Quinn DA, Choukroun G, Tager A, **Bonventre JV**, Hales CA, Force T. SAPK regulation of stretch-induced IL-8 production in type II alvelor cells-an in vitro model of ventilator induced lung injury. AHA 1998.

136. Schulze-Lohoff E, Wei H, Ichimura T, Chen A, Hession CA, Cate RL, Sanicola M, **Bonventre JV**. Denovo gene expression of the cell membrane glycoprotein PE4 in the kidney after ischemia and reperfusion. Congress for Nephrology, Erlangen, Germany 1998.

137. Alessandrini A, Dudley A, Robertson E, Choukroun G, **Bonventre JV**. The MEK1/ERK Pathway is required for brancing morphogenesis in IMCD3 cells and 11.5 day kidney rudiments. JASN 9: 418A, 1998.

138. Downey P, Sapirstein A, O'Leary E, Brown D, **Bonventre JV**. Cytosolic phospholipase A2 (cPLA2) deficient mice develop a urinary concentrating defect with abnormal proximal tubule aquaporin. JASN 9: 18A, 1998.

139. Choukroun G, Gustafson CE, McKee M, Brown D, **Bonventre JV**. Cytosolic phospholipase A2 regulates the structure of the Golgi apparatus. JASN 9: 62A, 1998.

140. Choukroun G, Force T, Alessandrini A, Sun XM, **Bonventre JV**. Cytosolic phospholipase A2 regulates serum-induced mesangial cell proliferation. JASN 9: 411A, 1998.

141. Schulze-Lohoff E, Wei H, Ichimura T, Chen A, Hession CA, Denis M, Cate RL, Sanicola, **Bonventre JV**. Upregulation of cell surface glycoprotein pE4 in proximal tubules after renal ischemia and reperfusion. JASN 9: 587A, 1998.

142. Sheridan AM, Force T, O'Leary E, Choukroun GJ, **Bonventre JV**. PLIP, a nuclear cytosolic phospholipase A2 (cPLA2)-interacting protein, increases TNF-induced PGE2 release and apoptosis. JASN 9: 415A, 1998.

143. Sapirstein A, Saito H, O'Leary E, Sun XM, **Bonventre JV**. Mesangial cells derived from cPLA2-deficient mice have decreased cyclooxygenase-2 mRNA response to TNFa. JASN 9: 485A, 1998.

144. Bonventre, JV, Huang, Moskowitz MA and Sapirstein A. The cytosolic phospholipase A2 knockout mouse. Sixth International Congress on Platelet- activating Factor and Related Lipid Mediators New Orleans, LA, 1998.

1. Ichimura T, Wei H, Hession C, Cate RL, **Bonventre JV** and Sanicola, M. Identification of renal regeneration specific genese by representational difference analysis (RDA). NIDDK, ARF in the 21st Century, 1998.
2. Zervos AS, Faccio L, Chen A, **Bonventre JV**. Mxi2 stress activated kinase, a kidney-specific kinase localized to the distal tubule, is regulated by ischemia/reperfusion and interacts with a novel chaperone protein with protease activity. JASN 10: 643A, 1999.
3. Sheridan AM, Force T, Sapirstein A, **Bonventre JV**. PLIP increases TNF-induced COX-2 expression and has in vitro histone acetyltransferase (HAT) activity. JASN 10: 471A, 1999.
4. Alessandrini A, Linde P, Choukroun G, Matsui T, Rosenzweig A, Force T, **Bonventre JV**. Effects of the MEK1/ERK and the phosphatidylinositol (PI) 3-kinase pathways on cyst formation and branching in IMCD3 and MDCK cells. JASN 10: 472A, 1999.
5. **Bonventre JV**, Sapirstein A. The cytosolic phospholipase A2 knockout mouse. Inflammation Paris 99, 1999.
6. Choukroun G, Force T, **Bonventre JV**. Role de la phospholipase A2 cytoslique dans la proliferation des cellules mesangiales. Secretariat Congres SN-SFD, 1999.
7. Chen, Ang and **Bonventre, JV**. Ischemic Pretreatment, Tunicamycin, or Ureteral Obstruction, Protects against a Subsequent Ischemic Insult to the Mouse Kidney. JASN 10: 630A, 1999.
8. Choukroun G, Force T, Alessandrini A, Sun X, **Bonventre JV**. Cytosolic Phospholipase A2 Regulates Mesangial Cell Proliferation by Modulating Expression of p27Kip1 and p21Cip1. JASN 10: 467A, 1999.
9. Hentschel D, Mifsud A, Yong E, **Bonventre JV**, Hsu S. C/EBPα and C/EBPβ Compete with the Androgen Receptor for Binding and Transcriptional Activation of the Human Prostate Specific Antigen (PSA) Promoter. JASN 10: 493A, 1999.
10. Hsu S, Hentschel D, O’Leary E, **Bonventre JV**. TRIP-Br: A Novel Family of PHD Zinc Finger and Bromodomain Interacting Proteins That Regulate the Transcriptional Activity of E2F-1/DP-1. JASN 10: 494A, 1999.
11. Hsu S, Thio S, **Bonventre JV**. Identification of a Novel Interaction between the PHD-Bromodomain of KRIP-1(TIF1β) and the Mammalian Transcriptional Co-Repressor CtBP-2. JASN 10: 494A, 1999.
12. Han W, et al. Kidney Injury Molecule-1 (KIM-1) is a new biomarker for human renal proximal tubule injury. JASN 11: 129A, 2000.
13. Alessandrini A, et al. Analysis of ERK1/2 and Akt/PKB Following Ischemic Acute Renal Failure in the Rat. JASN 11: 437A, 2000.
14. Yang CM, Sim KG, **Bonventre JV**, Hsu SI. TRIP-Br Proteins Regulate E2F-1/DP-1 Transcriptional Activity and Cell Cycle Progression. JASN 11: 449A, 2000.
15. Park KM, et al. Castration protects male mice against ischemic acute renal failure. A critical role for testosterone and leukocyte trapping in the outer medulla. JASN 11: 594A, 2000.
16. Keuhn EW, Berrou J, Ichimura T, Hession CA, Sanicola M, **Bonventre JV**. Identification of a 4.8kb fragment in the 5’ Upstream Region of the Human Kidney Injury Molecule-1 (Kim-1), Which is Inducible by Chemical Anoxia In Vitro. Implications for targeting Strategies In Vivo. JASN 11: 592A, 2000.
17. Taussat M V, Yoon HJ, Haq S, Alessandrini A, **Bonventre JV**. Heat shock protects against TNFa-induced Apoptosis by activation of ERK. JASN 11: 466A, 2000.
18. Yoon HJ, Choukroun G, Taussat VM, **Bonventre JV**. Cytosolic Phosolipase A2 Plays a Primary Role in Tumor Necrosis Factor-induced Apoptosis in Non-transformed Cells. JASN 11: 470A, 2000.
19. Sheridan A, Yoon HJ, Force T, **Bonventre JV**. PLIP increases serum deprivation-induced apoptosis and PGE2 production in cPLA2 +/+ but not cPLA2 -/- mouse mesangial cells. JASN 11: 436A, 2000.
20. Marshansky V, Brown D, **Bonventre JV**. Trafficking of membrane proteins from Golgi to plasma membrane in kidney epithelial cells expressing cytosolic PLA2
21. Kramers C, Park KM, Kwon YJ, **Bonventre JV**. Reduction in Na, K-ATPase Expression in Proximal Tubular Cells in the Outer Medulla Post-Ischemia Is Not Associated With Impaired Ability of the Kidney to Reabsorb Na+. JASN 11:785A, 2001.
22. Ranu KH, Martin BD, **Bonventre JV**, Sheridan AM. The role of PLIP in the Cell Cycle. JASN 11: 619A, 2001.
23. Han WK, Sapirstein A, Alessandrini A, **Bonventre JV**. Cross-Talk Between Group Iva Phospholipase A2 (cPLA2) and Group IIa and V PLA2 in Hydrogen Peroxide-Induced Arachidonic Acid Release in the Murine Mesangial Cell. JASN 11: 583A, 2002.
24. Ichimura T, Berrou J, Hung CC, Wei H, Hession CA, Cate RL, Sanicola M, **Bonventre JV**. Nmb, a PKD domain protein, is highly expressed in macrophages during early development and in the kidney after renal ischemia. JASN 11: 782A, 2001.
25. Kuehn W, Mauiyyedi S, Somlo S, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) is expressed in human as well as murine polycystic kidney disease. JASN 12: 538A, 2001.
26. Sim KG, Yang CM, **Bonventre JV**, Hsu SI. Decoy Peptides Reveal Novel Functions for the TRIP-Br Proteins in the Regulation of Cell Cycle Progression. JASN 11: 621A, 2001.
27. Mattheus T, Schulze-Lohoff E, Ichimura T, Weber M, Andeucci M, Park KM, Alessandrini A, **Bonventre JV**. Co-regulation of the neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the post-ischemic rat kidney. JASN 11: 787A, 2001.
28. Park KM, Kramers C, Taussat MV, Ang C, **Bonventre JV**. Prior transient ureteral obstruction results in persistent upregulation of HSP 25, reduced post-ischemic activation of JNK 1/2, and protection against renal injury. JASN11: 789A, 2001.
29. **Bonventre JV**. Ischemic Acute Renal Failure: Bench to Bedside. Journal of the International Pediatric Nephrology Association. Offprint of Pediatric Nephr. 16, C-19 – C-198. Presented at the IPNA conference in Seattle, WA. 2001.
30. Huang Z, Austin S, Salomone S, Plumire JC, Fitzgerald G, **Bonventre JV**, Moskowitz M. Enhanced Susceptibility to Focal Ischemic Injury in Mice Lacking Prostacyclin Receptors. 27th # Abstract 5032. International Stroke Conference. 2001.
31. Hung C, Takaharu I, Stevens J, **Bonventre JV**. Endoplasmic reticulum Stress Proteins block H2O2-induced Cell Death in LLC-PK1 Cells by Preventing Cytoplasmic Ca2+ Perturbation and Modulation ERK1/2 and JNK Signaling Pathways. JASN 13: 286A, 2002.
32. Thio SC, **Bonventre JV**, Hsu SI. TIF1α and CtBP-2 form a Novel Co-Repressor Complex. JASN 13: 23A, 2002.
33. SIM KG, Yang CM, **Bonventre JV**, Hsu SI. The Integrator Function of TRIP-Br Transcription Factors is Required for Proper Execution of Mammalian Cell Cycle Progression. JASN 13: 33A, 2002.
34. Hung CC, Ichimura T, Stevens JL, Bonventre JV. Endoplasmic reticulum stress Proteins Block H2O2 –Induced Cell death in LLC-PK1 Cells by Preventing Cytoplasmic Perturbation and Modulating ERK1/2 and JNK Signaling Pathways. JASN 13: 286A, 2002.
35. Han W, Keating J, Alinani A, Loda M, **Bonventre JV**. Kindey Injury Molecule-1(KIM-1): Expression in Human Renal Cell Carcinoma. JASN 13: 472A, 2002.
36. Ichimura T, Hung C, Stevens J, **Bonventre JV**. Induction of Kidney InjuryMolecule-1(KIM-1) Protein by the Nephrotoxicants Cisplatin, Folic Acid and S-(tetrafluoroethyl)-L-cysteine. JASN 13: 7A, 2002.
37. Kuehn EW, Park KM, Somlo S, **Bonventre JV**. Expression of Kidney Injury Molecule-1 (KIM-1) is associated with the development of interstitial fibrosis. JASN 13: 314A, 2002.
38. Park KM, Byun J, Huang P, **Bonventre JV**. Inducible Nitric Oxide Synthase Is an Important Contributor to Ischemic Preconditioning in the Mouse Kidney. JASN 13: 314A, 2002.
39. Said SM, Henstchel DM, **Bonventre JV**, Hsu SI. C/EBPα and C/EBPβ Repress the Prostate spcific Antigen (PSA) Promoter by Competing with the Androgen Receptor for Binding to Androgen Response. JASN 13: 505A, 2002.
40. Goruppi S, **Bonventre JV**, Kyriakis JM. Signaling pathways and Late-Onset Gene Induction Associated with Renal Mesangial Cell Hypertrophy. JASN 13: 738A, 2002.
41. Alkassab F, Muckova K, **Bonventre JV**, Sheridan A. Tip60 and PLIP localize to different compartments of renal proximal tubule cells derived from cPLA2+/+and cPLA2-/- mice. JASN 13: 544A, 2002.
42. Muckova K, **Bonventre JV**, Alessandrini A, Sheridan A. The Role of a putative Calcium/Calmodulin Kinase (CamK) II site in the regulation of Cytosolic Phospholipase A2 (cPLA2) activity. JASN 13:83A, 2002
43. Zhang Z, Wu W, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Modulates Cell Adhesion to Matrix by Metalloproteinase-Regulated Ectodomain Shedding. JASN 13: 322A, 2002.
44. Brown N, Song H, Morrow J, **Bonventre J**, Dey S, Reese. Does cPLA2 play a role in Parturition?
45. Beck P, Wong J, Podolsky D, **Bonventre J**. Alterations in cytosolic or soluble phospholipase A2 modulates the severity of intestinal inflammation in a murine model of colitis. Gastroenterology 122 (4): S832 Suppl. 2002.
46. **Bonventre J**, Park KM. How does renal injury precondition the kidney, protecting it against ARF 2003.
47. Park KM et al. GRP78 mediates the protection afforded by ischemic preconditioning.
48. Park KM, Kim, JI, Bonventre A, **Bonventre JV**. Inducible nitric oxide synthase induced by lipopolysaccharide is an important contributor to the kidney resistance to ischemia/reperfusion injury.
49. Park KM et al. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury.
50. cPLA2 is an important factor in the renal fibrosis and renal hypertrophy.
51. Kim-1 in development
52. Ichimura T, Hung CC, Yang SA, Zhang ZW, and **Bonventre JV**. KIM-1 protects renal epithelial cells against oxidant injury, potentiates homotypic and heterotypic cell adhesion and promotes proliferation of epithelial cells-features important for proximal tubule repair after injury. JASN 14: 568A, 2003.
53. Muckova K, Held KD, **Bonventre JV**, Sheridan AM, Tip60 Splice Variants Localize to Different Cellular Compartments in Response to Ionizing Irradiation and H2O2. JASN 14: 84A, 2003.
54. Kewalramani R, Park KM, **Bonventre JV**, Sayegh M, Chandraker A. Kidney Injury Molecule (KIM)-1 Expression In Acute Rejection Modulation of Ischemic Injury by CD28-B7 Blockade. JASN 14: 178A, 2003.
55. Muckova K, **Bonventre JV**, Sheridan AM Effects of Cytosolic Phospholipase A2α(cPLA2α)-Interaction Protein (PLIP) on Tumor Suppressor Proteins pRB and p53 ASN 2003.
56. Park KM, **Bonventre JV**, Testosterone Results in Inhibition of Akt Kinase and cNOS Activities and Confers Increased Susceptibility to Kidney Ischemia/Reperfusion Injury by Nongenomic Effects. JASN 14: 353A, 2003.
57. Ichimura T, Hung CC, Yang SA, **Bonventre JV**, Kidney Injury Molecule – 1 (KIM-1): A Urinary Biomarker for Nephrotoxicants. JASN 14: 355A, 2003.
58. Han, WK, Alinani A, Wu CL, Thadhani RI, McGovern FJ, Moses MA, **Bonventre JV.** Kidney Injury Molecule-1 (KIM-1) Is a Urinary Tumor Marker for Renal Cell Carcinoma. JASN 14: 454A, 2003.
59. Park KM, Bonvnetre AJ, Kim JI, **Bonventre JV**, Lipopolysaccharide Activates Inducible Nitric Oxide Synthase Which Is Responsible for Subsequent Kidney Resistance to Ischemia/Reperfusion Injury. JASN 14: 569A, 2003.
60. Kwon YJ, Won NH, Jo SK, Cho WY, Pyo HJ, Kim HK, Park KM, **Bonventre JV**, Prior Ischemia Results the Resistance to Second Ischemic Insult. JASN 14: 569A, 2003.
61. Ichimura T, Duffield JS, Hung CC, **Bonventre JV**, Nmb, a PKD Domain Membrane Glycoprotein, is Highly Expressed In Macrophages During Development and in the Kidney after Renal Injury, and is Localized to the Cell Surface and Intracellular Vesicles. JASN 15: 716A, 2004.
62. Zhang Z, Humphreys BD, Hung CC, **Bonventre JV**, role of Tyrosine Phosphorylation in the Ectodomain Shedding of Kidney Injury Molecule-1 (KIM-1) JASN 15: 448A, 2004.
63. Duffield JS, Park KM, Hsaio LL, Kelley V, **Bonventre JV**, Tubular Cell Replenishment is Independent of bone Marrow Stem Cells (BMSCs) in the Post-Ischemic Mouse Kidney. JASN 15:38A, 2004.
64. Hentschel DM, Drummond I, **Bonventre JV**, Acute Renal Failue in Zebrafish Brachydanio Rerio. JASN 15: 261A, 2004.
65. Han WK, Alinani A, Wu W, Michaelson D, Loda M, McGovern FJ, Thadhani RI, **Bonventre JV**, Human Kidney Injury Molecule-1 (hKIM-1) Is a Biomarker for Renal Cell Carcinoma (RCC). JASN 15:501A, 2004.
66. Liangos O, Perianayagam MC, Rao M, Balakrishnan VS, Pereira BJG, **Bonventre JV**, Jabe BL Urinary N-Acetyl-Beta-(D)-Glucosaminidase Is Associated with Disease Severity in Acute Renal Failure. JASN 15: 577A, 2004.
67. Hsiao LL, Sun XM, O”Leary E, **Bonventre JV**, SDF-1 as Chemoattractant for Homing of Bone Marrow Cells to Renal Proximal Tubular Epithelium in an Injury Model In Vitro. JASN 15: 648A, 2004.
68. Hamed A, Kazis L, Brenner L, Huang Y, Miller D, **Bonventre JV*,*** Acute Renal Failure Accounts for a Large Component of Inpatient Resource Utilization in the Veterans Health Administration. JASN 15: 583A, 2004.
69. Sheridan AM, Duffield JS, Held KD, **Bonventre JV**, Muckova K cPLA2-Interacting Protein PLIP Contributes to Mesangial Cell Cycle Regulation and Apoptosis. J Am Soc Nephrol 16: 386A, 2005.
70. Park KM, Kim J, Kil IS, Yang ES, Seok YM, Kim JI, Park JW, **Bonventre JV**. Orchiectomy-Induced Increases of Post-Ischemic Manganese Superoxide Dismutase Activity Attenuates Kidney Ischemia/Reperfusion Injury in Mice. J Am Soc Nephrol 16: 397A, 2005.
71. Humphreys BD, Vaidya VS, Samarakoon R, Hentschel DM, Park KM, **Bonventre JV**. Early and Sustained Expression of Kidney Injury Molecule-1 (Kim-1) after Unilateral Ureteral Obstruction. J Am Soc Nephrol 16: 425A, 2005.
72. Hentschel DM, Cate R, Peyman J, Park KM, Chen A, **Bonventre JV**. A Genomic Approach to Preconditioning. J Am Soc Nephrol 16: 623A, 2005.
73. Duffield JS, Hong S, Vaidya VS, Fredman G, Serhan CN, **Bonventre JV**. Omega-3 Lipid Mediators Resolvin D and Protectin D Limit Injury and Acute Renal Failure Following Ischemia/Reperfusion. JASN 16: 17A, 2005.
74. Vaidya VS, Ramirez V, Bobadilla N, **Bonventre JV**. A Microfluidics Based Assay To Measure Kidney Injury Molecule-1 (Kim-1) in the Urine as a Biomarker for Early Diagnosis of Acute Kidney Injury. J Am Soc Nephrol 16: 192A, 2005.
75. Han WK, Waikar S, Alinani A, Curhan GC, **Bonventre JV**. Urinary Biomarkers for Detection of Acute Kidney Injury. J Am Soc Nephrol 16: 316A, 2005.
76. Liangos O, Wald R, Perianayagam MC, Han W, Balakrishnan VS, MacKinnon RW, Li L, Pereira BJG, **Bonventre JV**, Jaber BL. Urinary N-Acetyl(β)-D-Glucosaminidase (NAG) Concentration is Associated with Disease Severity and Outcomes in Acute Renal Failure (ARF). J Am Soc Nephrol 16: 317A, 2005.
77. Liangos O, Han WK, Wald R, Perianayagam MC, Balakrishnan VS, MacKinnon RW, Warner K, Symes JF, Li L, Kouznetsov A, Pereira BJG, **Bonventre JV**, Jaber BL. Urinary Kidney Injury Molecule-1 (KIM-1) and N-Acetyl(β)-D-Glucosaminidase (NAG) Levels in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass (CPB). J Am Soc Nephrol 16: 318A, 2005.
78. Liangos O, Han WK, Wald R, Perianayagam MC, Balakrishnan VS, MacKinnon RW, Li L, Kouznetsov A, Pereira BJG, **Bonventre JV**, Jaber BL. Urinary Kidney Injury Molecule-1 Levels Are Associated with Renal Replacement Therapy (RRT) and Death in Acute Renal Failure (ARF). J Am Soc Nephrol 16: 318A, 2005.
79. P. Espandiari P, Miller T, Zhang J, Knapton A, Goering P, Brown R, Vaidya VS, Johnson A, **Bonventre JV**, Rosenzweig B, Thompson K, Pine P, Schnackenberg L, Beger R, Herman E, Weaver J, Hanig J. Characterization of a Rodent Pediatric Nephrotoxicity Model. Society of Toxicology Annual Meeting, 2006.
80. Vaidya VS, C. Fernandez A, Humphreys BD, Sugimoto H, Kalluri R, Moses MA, **Bonventre JV**. Potential Role of Kidney Injury Molecule-1 in Endothelial Cell Migration and Angiogenesis. Society of Toxicology Annual Meeting, 2006.
81. Prozialeck WC, Vaidya VS, Johnson A, Liu J, Waalkes MP,Edwards JR, Diamantakos E, LamarPC, Theusch J, **Bonventre JV**. Kidney Injury Molecule-1 (Kim-1) as an Early Biomarker of Cadmium (CD) Nephrotoxicity. Society of Toxicology Annual Meeting, 2006.
82. Goering PL, Vaidya VS, Brown RP, Vakili Z, Rosenzweig BA, Johnson AM, Thompson KL and **Bonventre JV**. Kidney Injury Molecule-1 (Kim-1) Expression in Kidney and Urine Following Acute Exposure to Gentamicin and Mercury. Society of Toxicology Annual Meeting, 2006.
83. Hentschel DM, Roemmler F, Albertin C, **Bonventre JV**. Suppression of the Zebrafish cytosolic phospholipase A2 (cPLA2) orthologues during development is associated with bradycardia, edema, and renal dysfunction. JASN .17: 51A, 2006.
84. Hentschel DM, Piecewicz S, Albertin C, Sengupta S, **Bonventre JV**. Zebrafish N-deacetylase/N-sulfotransferase-1 (zNDST1) is necessary for vasculogenesis and development of glomerular capillaries.JASN 17: 485A, 2006.
85. Liangos O, HanWK, Wald R, Perianayagam MC, Mackinnon RW, Dolan N, Warner KG, Symes JF, **Bonventre JV**, Jaber BL. Urinary Kidney Injury (KIM)-1 Level is an Early and Sensitive Marker of Acute Kidney Injury (AKI) Following Cardiopulmonary Bypass (CPB). JASN 17: 403A, 2006.
86. Han WK, Waikar SS, Johnson A, Curhan GC, Devarjan P, Bonvente JV. Urinary Biomarkers for Early Detection of Kidney injury. JASN 17: 403A-403B, 2006.
87. Hsiao LL, Vaidya VS, Mizuno M, Sun XM, Lombardi M, Jensen RV, **Bonevntre JV**. Microarray Analysis of Expressing Kidney Injury Molecule-1 (Kim-1): A Potential Role for hKim-1 Functional Regulation of the Cell Junction During Injury. JASN 17: 440A, 2006.
88. Hentschel DM, Albertin C, **Bonventre JV**. Zebrafish Kidney Injury Molecule-1 (zKim-1) is Expressed after Kidney Injury and Regulates the Development of Otoliths, cardiac Outflow Tract and the Renal Tubule. JASN 17: 528A, 2006.
89. Kim J, Seok YM, Kim KY, Kim JI, Kwon TH, **Bonventre JV**, Park KM. Restoration of Dameged Tubular epithelial Cells After Ischemia/Reperfusion in Mouse Kidney. JASN 17: 532A, 2006.
90. Best-Popescu CA, Vaidya VS, **Bonventre JV**, O’Leary E, Sheridan AM. Tip60 is Associated with senescence in High Glucose-Treated Mesangial Cells in Kidneys from Streptozoticin-Treated Mice. JASN 17:593A, 2006.
91. Zhang ZW, Humphreys BD, Han WK, **Bonventre JV**. Kidney Injury Molecule-1 (Kim-1) Enhance Epithelail Cell Adhesion to Fibronectin and Adhesion is Regulated by Phosphorylation of Tyr 350 in the Kim-1 Cystolic Domain. JASN 17: 633A, 2006.
92. Humphreys BD, Garcia AM, Schueller O, Wong E, Ferkaney J, Soeung S, **Bonventre JV**, Sweetnam P. Selective ROCK-2 Inhibition Attenuates Renal Fibrosis in Unilateral Ureteral Obstruction. JASN 17: 251A, 2006.
93. Zhang PL, Blasick TM, HanWK, Rothblum LI, **Bonventre JV**Kidney Injury Molecule-1 (KIM-1) Expression in Injured Proximal Tubules is Highly Correlated with Extent of Impaired Renal Function in Native Renal Biopsies. JASN 17: 797A, 2006.
94. Hsu SI, Bonventre JV, Safabakhsh S. The Micronesian Institute for Disease Prevention and Research (MIDPR) – A Public Health Care Approach to Meeing the Crisis of type 2 Diabetes Mellitus. JASN 17: 915A, 2006.
95. Samarkoon R, Gunaratnam L, Park KM, Hentschel DM, Han WK, **Bonventre JV**. Kidney injury Molecule-1 (kim-1) Induces Epithelial Plasticity and Potentiates TGF-beta Mediated Induction of Dedifferentiated Phenotype in Kidney Epithelial Cells. JASN 17: 634A, 2006.
96. Humphreys BD, Sipila P, **Bonventre JV**, McMahon AP. Renal Epithelial Indian Hedgehog Expression is Not Required for Normal Development or Recovery from Ischemia Perfusion Injury. JASN 17: 664A, 2006.
97. Kim J, Kil IS, Seok YM, Yang ES, Kim DK, Lim DG, Park JW, **Bonventre JV**, Park KM. Orchiectomy Attenuates Post-Ischemic Oxidative Stress and Ischemia/Reperfusion Injury in Mice. A Role for Manganese Superoxide Dismutase. JASN 17: 714A, 2006.
98. Zhang PL, Han WK, Blasick TM, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) is a Specific and Stable target for Identifying Proximal Tubular Injury in Humans. Jan 2006
99. Shi J, Yang XJ, Zhang PL, Chuang ST, Hwang H, Luan C, Han WK, **Bonventre JV**, and Lin F. Evaluation of expression of hKIM-1, P504S, S100, Vimentin and EMA in renal cystic lesions. United States and Canadian Academy of Pathology 96th Annual Meeting, San Diego, CA, 2007.
100. Zhou Y, Vaydia VS, Keenan J, Shaw M, Brown RP, Zhang J, Ferguson M, **Bonventre JV**, Goering PL. Comparison of Urinary Biomarkers to detect metal-induced nephrotoxic effects in gentamin-pretreated rats. SOT abstract, in preparation. Society of Toxicology Annual Meeting, 2007.
101. Prozialeck WC, Edwards JR, Diamantakos EA, Vaidya VS, **Bonventre JV**. Expression of Kidney Injury Molecule-1 (Kim-1) Preceeds Necrotic and Apoptotic Cell Death in Cadmium-Induced Renal Injury. JASN 18: 145A, 2007.
102. Han WK, Hsiao L, SignorettI S, **Bonventre JV**, Steele G. Kidney Injury Molecule-1 (KIM-1) and Carbonic Anhydrase IX (CAIX) as Urinary Biomarkers for Renal Cell Carcinoma. JASN 18: 222A, 2007.
103. Zhang PL, Mainali R, Bock GH, Lin F, Prichard JW, Hatle JE, **Bonventre JV**. Human Kidney Injury Molecule-1 (KIM-1) Expression Helps Identify Tubular Injury in Renal Biopsies from Uncommon Renal Diseases. JASN 18: 225A, 2007.
104. Zhang PL, Blasick TM, KotruA, Schultz M, **Bonventre JV.** Comparison of Kidney Injury Molecule-1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) as Immunohistochemical Markers of Renal Transplant Tubular Injury in Man. JASN 18: 241A, 2007.
105. Liangos O, Perianayagam M, Kolyada A, Tighiouart H, MacKinnon R, WaldR, Han WK, **Bonventre JV**, Jaber. Comparative Analysis of Urinary Biomarkers for the Early Detection of Acute Kidney Injury (AKI) Following Cardiopulmonary Bypass (CPB). JASN 18: 41A, 2007.
106. Ferguson MA, Vaidya VS, Waikar SS, Collings FB, Sunderland K, Gioules C, **Bonventre JV.** Liver-Type Fatty Acid-Binding Protein (L-FABP): A Novel Urinary Biomarker of Acute Kidney Injury. JASN 18: 41A, 2007.
107. Hentschel DM, Albertin C, Mengel M, Boehme L, Liebsch F, **Bonventre JV**, Haller H, Schiffer M. Rapid Screening of Glomerular Slit Diaphragm Integrity in Larval Zebrafish. JASN 18:353A, 2007.
108. Waikar SS, Vaidya VS, Ferguson MA, Sunderland K, Collings FB, Gioules C, **Bonventre JV**. Stability and Collection Requirements of Urinary Biomarkers of Acute Kidney Injury. JASN 18: 577A, 2007.
109. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, GioulesC, Curhan GC, **Bonventre JV**. Diagnostic Performance Characteristics of Nine Urinary Biomarkers of Acute Kidney Injury in a Cross Sectional Study in Humans. JASN 18: 581A, 2007.
110. IchimuraT, Asseldonk EV, Humphreys BD, Gunaratnam L, Duffield JS, **Bonventre JV.** KIM-1, a Novel Phosphatidylserine Receptor, Converts Epithelial Cells to Phagocytes. JASN 18: 383A, 2007.
111. Naini SM, Ichimura T, **Bonventre JV.** Kidney Injury Molecule -1 (KIM-1) Modulates Macrophage Chemotaxis by Renal Epithelial Cells Via Monocyte Chemoattractant Protein -1 (MCP-1, CC2L). JASN 18: 383A, 2007.
112. Gunaratnam L, De Lucas C, Zhu D, Negoro H, Denker BM, **Bonventre JV.** KIM-1/TIM-1 Inhibits Gα± 12/13-Mediated Rho Signaling in Renal Epithelial Cells. JAN 18: 99A, 2007.
113. Humphreys BD, Valerius T, Kobayashi A, Duffield JS, McMahon AP, **Bonventre JV**. Intrinsic Tubular Epithelial Cells Repair the Kidney after Injury. JASN 18: 598A, 2007.
114. Zhang Z, Parker A, Humpherys BD, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Enhances Renal Epithelial Cell Repair That Is Mediated by ERK MAP Kinase Pathway. JASN 18: 648A, 2007.
115. van Timmeren MM, Vaidya VS, van Ree RM, Oterdoom LH, de Vries APJ, Gans ROB, van Goor H, Stegeman CA, **Bonventre JV**, Bakker SJL, High Urinary Excretion of Kidney Injury Molecule-1 (KIM-1) Is an Independent Predictor of Graft Loss in Renal Transplant Recipients. JASN 18: 679A, 2007.
116. Waikar SS, Vaidya VS, Sunderland K, Collings FB, Curhan GC, **Bonventre JV.** Urinary Biomarkers Following Cardiac Catheterization. JASN 18: 796A, 2007.
117. Jaber B, Liangos O, Perianayagam M, MacKinnon R, Wald R, Vaidya VS, Balakrishnan V, Schmid C, **Bonventre JV**, Pereira B. Cytokine Gene Polymorphisms in Acute Renal Failure: Associations with Disease Severity and Adverse Outcomes. JASN 18: 800A, 2007.
118. Zhang PL, Schworer CM, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Expression in the S3 Segment of Proximal Tubules in Humans Is Detectable within 90 Minutes of Ischemia. JASN 19: 564A, 2008.
119. Koyner JL, Vaidya VS, Bennett M, Trevino S, Devarajan P, **Bonventre JV**, Murray PT. Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) Predicts Severity of Injury in Patients Developing Acute Kidney Injury (AKI) Following Adult Cardiac Surgery. JASN 19: 566A, 2008.
120. Koyner JL, Vaidya VS, Trevino S, Devarajan P, **Bonventre JV**, Murray PT. Kidney Injury Molecule-1 (Kim-1) is an Early Biomarker of Acute Kidney Injury (AKI) Following Cardiac Surgery. JASN 19: 568A, 2008.
121. Waikar SS, Vaidya VS, Gioules C, Sunderland K, Collings FB, Curhan GC, Frendl G, Sugarbaker DJ, **Bonventre JV**. Urinary Biomarkers of Acute Kidney Injury in a High Risk Cohort: Cytoreductive Surgery and Intracavitary Cisplatin Lavage for Mesothelioma. JASN 19: 569A, 2008.
122. Waikar SS, **Bonventre JV**. Transient Changes in Creatinine-Normalized Urinary Biomarker Concentrations in Acute Kidney Injury: Caveats for Interpretation. JASN 19: 572A, 2008.
123. Waikar SS, **Bonventre JV**. The Definition of Acute Kidney Injury: An Argument for Absolute Rather Than Percentage Increases in Serum Creatinine. JASN 19: 573A, 2008.
124. Nowlin BT, Ichimura T, Lin SL, Castano A, **Bonventre JV**, Swanson KD, Duffield JS. Reparative Macrophages and Injured Epithelia Express Gpnmb, a Novel Autophagosome Associated Glycoprotein, Which Directs Phagocytic Trafficking for Degradation and Reveals Convergence of Autophagic and Phagocytic Pathways. JASN 19: 85A, 2008.
125. Masuda S, Ichimura T, **Bonventre JV**. Characterization of KIM-1 as a Novel Target Receptor for Renal Clear Cell Carcinoma. JASN 19: 634A, 2008.
126. Padigala KK, Zhang PL, Varma CR, Kotru A, Gupta M, Akers GR, Mainali R, Hartle JE, Schultz MF, **Bonventre JV**. Kidney Injury Molecule-1 Is a Sensitive and Specific Injury Biomarker in Identifying Acute FK506 Nephrotoxicity in Humans. JASN 19: 672A, 2008.
127. Akers G, Zhang PL, Varma CR, Schultz MF, Prichard J, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Expression Is Positively Correlated to Renal Indices of Dysfunction in Renal Transplant Biopsies. JASN 19: 673A, 2008.
128. Vaidya VS, Niewczas M, Ficociello LH, Collings FB, Walker W, Warram JH, **Bonventre JV**, Krolewski A. Markers of Tubular Injury, NAG and KIM-1, Are Predictors for Remission and Progression of Mircoalbuminuria in Type 1 Diabetes. JASN 19: 27A, 2008.
129. Lin SL, Humphreys BD, Nowlin B, **Bonventre JV**, Valerius T, McMahon AP, Duffield JS. Evidence That Epithelial to Mesenchymal Transition Does Not Result in the Generation of Myofibroblasts in the Kidney. JASN 19: 32A, 2008.
130. Maan A, **Bonventre JV**, Hentschel DM. Nephrogenesis in Adult Zebrafish. JASN 19: 117A, 2008.
131. Humphreys BD, Czerniak SM, Hasnain W, Cheema RA, **Bonventre JV**. Lineage Analysis in Papilla and Proximal Tubule Indicates That Injured Epithelia Repair by Self-Duplication. JASN 19: 171A, 2008.
132. Brooks CR, Ichimura T, Yang L, **Bonventre JV**. Kim-1 Mediated Phagocytosis Is Cytoprotective and Induces Autophagy in Renal Tubular Cells. JASN 20: 5A, TH-FC019, 2009.
133. Duffield JS, Humphreys BD, Lin SL, Kobayashi AE, Hudson TE, **Bonventre JV**, McMahon AP, Duffield JS. Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis. JASN 20: 24A, TH-FC100, 2009.
134. Zappitelli M, Bennett M, Devarajan P, Drolet J, Vertullo L., MacLean K, Blinova A, Lai P, Patel R, Gottesman R, **Bonventre JV**, Sabbisetti V. Comparison of Defining Acute Kidney Injury (AKI) Using Serum Cystatin C (CysC) Versus Serum Creatinine (SCr) in Critically Ill Children. JASN 20: 39A, F-FC164, 2009.
135. Movahedinaini S, Maan A, Englert C, Kim A, Traver D, **Bonventre JV**, Hentschel DM. Regenerative Figures in Adult Zebrafish Express WT-1, but Not Kim-1 or NaK-ATPase. JASN 20: 267A, TH-PO665, 2009.
136. Zhang PL, Schworer CM, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Expression in Human Polycystic Kidney Disease. JASN 20: 276A, TH-PO711, 2009.
137. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder D, Bobadilla NA, Marrrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering P, Sistare F, **Bonventre JV**. Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-Site Preclinical Biomarker Qualification Studies. JASN 20: 324A, TH-PO934, 2009.
138. Palmer SC, Ichimura T, Mizuno M, Hung CC, Masuda S, **Bonventre JV**. Kidney Injury Molecule 1 (KIM-1) Recruits the Hepatocyte Growth Factor Signaling Pathway in Renal Epithelial Cells. JASN 20: 330A, TH-PO958, 2009.
139. van Venrooij NA, Hobbs DJ, Ferguson MA, Devarajan P, **Bonventre JV**, Crumb TL, Davis AT, Bunchman TE. Sequential Urinary NGAL, IL-18 and KIM-1 in Premature Infants. JASN 20: 356A, F-PO1064, 2009.
140. Zappitelli M, Bennett M, Ferguson MA, Sabbisetti V, Ma Q, Hyder A, Vertullo L, Drolet JA, Gottesman R, Edelstein CL, **Bonventre JV**, Devarajan P, Goldstein SL. Acute Kidney Injury (AKI) Diagnosis Is Improved by Biomarker Combinations: A USA-Canada 2-Center Study. JASN 20: 360A, F-PO1078, 2009.
141. Takakura A, Contrino L, Zhou X, **Bonventre JV**, Sun Y, Humphreys BD, Zhou J. A “Three-Hit” Model of Cystogenesis in Autosomal Dominant Polycystic Kidney Disease. JASN 20: 495A, F-PO1661, 2009.
142. Wortmann J, Albertin CB, Görner B, **Bonventre JV**, Hentschel DM. Developing Zebrafish Nephrons Have High Oxygen Demand and Are Prone to Hypoxic Injury. JASN 20: 523A, F-PO1791, 2009.
143. Zhang PL, Schworer CM, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Staining Identifies the S3 Segment as the Most Sensitive Region of Proximal Tubules to Ischemic Injury in Humans. JASN 20: 792A, SA-PO2985, 2009.
144. Zhang PL, Sarmarapungavan D, Parasuraman R, Forinola MA, Cohn SR, Reddy GH, Rooney MT, Chang CH, Dumler F, **Bonventre JV**. Kidney Injury Molecule-1 Staining Helps Confirm Acute Tubular Injury in Type I Acute Antibody Mediated Rejection. JASN 20: 791A, SA-PO2986, 2009.
145. Endre ZH, Pickering JW, Walker RJ, Devarajan P, Edelstein CL, Bonventre JV. Duration of Injury and Baseline Renal Function Define Biomarker Performance in Acute Kidney Injury. J Am Soc Nephrol 21:3A, 2010.
146. Endre ZH, Pickering JW, Walker RJ, Devarajan P, Edelstein CL, Bonventre JV. Duration of Injury and Baseline Renal Function Define Biomarker Performance in Acute Kidney Injury. J Am Soc Nephrol 21:3A, 2010.
147. Lam AQ, Bonventre JV. Generation of Inducible Pluripotent Stem Cells from Patients with Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 21:192A, 2010.
148. Gunaratnam L, Bonventre JV, Zhang X. Engulfment of Apoptotic Cells by Kidney Injury Molecule-1 Is Mediated by Tyrosine Phosphorylation and Src Kinase Signaling. J Am Soc Nephrol. 21:285A, 2010.
149. Zhou L, Ichimura T, Ferguson MA, Waikar SS, Bonventre JV. Glycoprotein nmb (Gpnmb) Is Highly Upregulated Macrophage Protein in Ischemia/Reperfusion Injured Kidneys and Shed into Urine. J Am Soc Nephrol 21:287A, 2010
150. Nepal M, Zhang PL, Kotru A, Dorion P, Schultz MF, Bonventre JV. Presence of Calcium Oxalate Deposits in Protocol Transplant Biopsies Does Not Affect Kidney Allograft Prognosis. J Am Soc Nephrol. 21:336A, 2010.
151. Movahedi-Naini S, Bonventre JV. Cytosolic Phospholipase A2α (IVa) Interacts with Sirt2 and Attenuates Its Deacetylase Activity. J Am Soc Nephrol 21, 2010: 344A
152. Palmer S, Ichimura T, Humphreys BD, Bonventre JV. Dendritic Cells Induce an Anti Inflammatory Phenotype on Tubule Epithelial Cells after Kidney Injury. J Am Soc Nephrol 21:345A, 2010.
153. Yang L, Brooks CR, Bonventre JV. Kidney Injury Molecule-1 (Kim-1) Down-Regulates the Proximal Tubule Innate Immune Response to Injury. J Am Soc Nephrol 21346A, 2010.
154. Masuda S, Nishihara K, Yonezawa A, Ozawa A, Ichimura T, Bonventre JV, Inui KI. Microarray Analysis of Isolated Proximal Tubules in Rats with Cisplatin-Induced Nephrotoxicity. J Am Soc Nephrol. 21:352A, 2010.
155. ZhangPL, Nepal M, Schultz MF, Dumler F, Bonventre JV. Kidney Injury Molecule-1 Identifes High Proximal Tubular Injury as a Prominent Component of Monoclonal Nephropathy. J Am Soc Nephrol 21:425A, 2010.
156. Waikar SS, Betensky RA, Bonventre JV. Fool’s Gold: Creatinine as the Diagnostic Standard for AKI Biomarker Studies. J Am Soc Nephrol 21:582A, 2010.
157. Sato T, Masuda S, Ozawa A, Togashi Y, Kim YH, Mishima M, Ichimura T, Bonventre JV, Inui KI. Time-Dependent Changes of Urinary Biomarkers in Lung Cancer Patients after Cisplatin-Based Chemotherapy. J Am Soc Nephrol. 21:588A, 2010.
158. Ichimura T, Zhao H, Palmer S, Mou S, Cina DP, Woo HM, Bonventre JV. Kidney Injury Molecule-1 (Kim-1) Mediates Tubular Epithelial Cell Injury in Diabetic Nephropathy. J Am Soc Nephrol.21:692A, 2010.
159. Zhang PL, Sabbisetti V, Bonventre JV. Altered Exon 4 KIM-1 Gene Sequence in Renal Cell Carcinoma (RCC) and Concordant Expression of KIM-1 and CD68. J Am Soc Nephrol. 21: 839A, 2010.
160. Brooks CR, **Bonventre JV**. Protein Domains of Kidney Injury Molecule 1 That Mediate Phagocytosis and Induction of Autophagy. J Am Soc Nephrol. 22:11A, 2011.

1. Patel DD, Palmer S, Brooks CR, Ichimura T, Bonventre JV. Exosomes Released from Dendritic Cells Are Taken up by Kim-1-Expressing Proximal Tubule Cells and Increase Cellular MHC-II Protein Levels [Abstract]. J Am Soc Nephrol. 22:62A, 2011.
2. Zhang PL, Bonventre JV. Proximal and Distal Tubule Epithelial Cells Express CD133 during Repair after Acute Kidney Injury in Humans [Abstract]. J Am Soc Nephrol. 22:83A, 2011.
3. Dhruti D. Patel DD,1,2 Liangying Gan L,1 Ningning Wang N,1 Takaharu Ichimura T,1 Humphreys BD,1 Joseph V. Bonventre JV. Iron Facilitates Kidney Inflammation in a Model of Chronic Renal FailureInduced by Persistent Expression of Kidney Injury Molecule-1 [Abstract]. J Am Soc Nephrol. 22: 107A, 2011.
4. Gan L, Campanholle G, Gohil VM ,2 Venkata Sabbisetti V,1 Vamsi K. Mootha VK, Ichimura T, Joseph V. Bonventre JV. Preconditioning with Meclizine Protects the Kidney Against Ischemia Reperfusion Injury. J Am Soc Nephrol. 22: 115A, 2011.
5. Waikar SS, Sabbisetti V, Ngo T, Berkley JA, Radlinski M, Bonventre JV, Betensky RA, De Jager PL. Reference Ranges and Biological Variability of Kidney Injury Biomarkers. J Am Soc Nephrol. 22:200A, 2011.
6. Freedman BS, Lam AQ, Bonventre JV. Modeling Polycystic Kidney Disease Using Human Induced Pluripotent Stem Cells [Abstract]. J Am Soc Nephrol. 22,: 214A 2011
7. Ichimura T, Mou S, Zhao H, Xiao S, Woo HM, Palmer S, Brooks CR, Wang C, Henderson JM, Kuchroo VK, Bonventre JV. Proximal Tubule Endocytosis by Kidney Injury Molecule-1 Mediates Early Diabetic Nephropathy. J Am Soc Nephrol. 22:234A, 2011.
8. Al-Ismaili Z, Bonventre JV, Devarajan P, Piccioni M, Sabbisetti V, Bennett MR, Ma Q, Zappitelli M. Urine Biomarkers of Aminoglycoside Nephrotoxicity in Children. .J Am Soc Nephrol. 22:360A 2011.
9. Piccioni M, Al-Ismaili Z, Devarajan P, Bonventre JV, Sabbisetti V, Bennett MR, Ma Q, Michael Zappitelli M. Biomarkers of Cisplatin and Ifosfamide Nephrotoxicity in Children. [Abstract]. J Am Soc Nephrol. 22:360A: 2011.
10. Palijan A, Devarajan P, Bonventre JV, Bennett MR , Ma Q, Sabbisetti V, Zappitelli M. Acute Kidney Injury and AKI Biomarkers Are Associated with Fluid Overload in Critically Ill Children. J Am Soc Nephrol. 22:608A, 2011.
11. Sabbisetti V, Wang C, Ito K, Bonventre JV. Kidney Injury Biomarkers Kim-1, NGAL, Clusterin, and Cystatin C in Mouse Models of Ischemia Reperfusion Injury. J Am Soc Nephrol. 22:619A 2011.
12. Yang L, Brooks CR, Xiao S, Sabbisetti V, Ichimura T, Kuchroo VK, Bonventre JV. Tubular Kidney Injury Molecule-1 Mediated Phagocytosis Downregulates the Kidney’s Innate Immune Response after Injury. J Am Soc Nephrol 23:52A 2012.
13. Liu Y, Ichimura T, Yang L, Bonventre JV. Activation of DNA Injury-Associated Histone H2AX-ATM Complex and Expression of Development-Associated Regulator β Catenin in Pro-Fibrotic Kidney Injury Models. J Am Soc Nephrol 23:110A, 2012.
14. Yin W, Movahedi Naini S, Hentschel DM, Bonventre JV. Characterization of Kidney Injury Molecule (Kim) Family of Proteins in Zebrafish. J Am Soc Nephrol 23:112A, 2012.
15. Zeng X, Bonventre JV, Zhang PL. Kidney Injury Molecule-1 Staining Is a Specific Marker of Acute Tubular Injury in Pediatric Renal Biopsies. J Am Soc Nephrol 23:126A, 2012.
16. Freedman BS, Lam AQ, Sundsbak JL, Iatrino R, Koon SJ, Wu M, Zhou J, Harris PC, Bonventre JV. Reduced Ciliary Polycystin-2 in Induced Pluripotent Stem Cell Lineages from Patients with Polycystic Kidney Disease. J Am Soc Nephrol 23:248A, 2012.
17. Lam AQ, Freedman BS, Bonventre JV. Highly Efficient Differentiation of Human Embryonic and Induced Pluripotent Stem Cells into Targeted Mesendoderm, Endoderm, and Mesoderm Cell Fates. J Am Soc Nephrol 23:417A 2012.
18. Pang P, Roy N, Bonventre JV, Siedlecki AM. RGS4 Protects against Vascular Smooth Muscle Cell-Mediated Reperfusion Injury in the Kidney. J Am Soc Nephrol 23:481A, 2012.
19. Zeng X, Bonventre JV, Waikar SS. Comparison of Creatinine-Based Definitions of Acute Kidney Injury. J Am Soc Nephrol 23:647A, 2012.
20. Brooks CR, Chen H, Henderson JM, Ichimura T, Bonventre JV. KIM-1-Mediated Phagocytosis Induces Autophagy and MHC Antigen Presentation in Epithelial Cells. J Am Soc Nephrol. 24:5A, 2013.
21. Pang P, Kramann R, Loscalzo J, Bonventre JV, Siedlecki AM. Uremic Cardiomyopathy Is Associated with Glutathione Peroxidase 3 Deﬁciency. J Am Soc Nephrol. 24:11A, 2013.
22. Lam AQ, Freedman BS, Morizane R, Valerius MT, Bonventre JV. Rapid and Efﬁcient Differentiation of Human Pluripotent Stem Cells into Intermediate Mesoderm Cells That Form Tubules and Express Proximal Tubule Markers. J Am Soc Nephrol. 24:21A, 2013.
23. Sabbisetti V, Waikar SS, Antoine DJ, Bonventre JV. Plasma Kidney Injury Molecule-1 Is a Sensitive and Speciﬁc Biomarker of Kidney Proximal Tubule Injury. 1 J Am Soc Nephrol. 24: 42A, 2013.
24. Humphreys BD, Sabbisetti V, Xu F, Grgic I, Movahedi Naini S, Wang N, Guochun Chen G, Sheng Xiao S, Dhruti D. Patel DD, Joel M. Henderson JH, Takaharu Ichimura T, Shan Mou S, Savuth Soeung S, Andrew P. McMahon AP, Joseph V. Bonventre JV. Chronic Epithelial Kidney Injury Molecule-1 Expression in Mice Causes Inﬂammation, Fibrosis and Kidney Failure. J Am Soc Nephrol. 24:64A, 2013.
25. Kishi S, Campanholle G, Jain M,3 Brooks CR, Gohil VM, Ichimura T, Bonventre JV. Meclizine Preconditioning Protects against Ischemic Kidney Injury. J Am Soc Nephrol. 24:121A, 2013.
26. Fischer K, Meral C, Jolesz FA, Ichimura T, Bonventre JV. Regional Renal Perfusion Assessment with Contrast Enhanced Ultrasound in Ischemia-Reperfusion Injury. J Am Soc Nephrol. 24:130A, 2013
27. Jae-Hyung Chang, Takaharu Ichimura, Joseph V. Bonventre. Tubular DNA Damage Response and Cell Cycle Arrest Mediate Progression of Diabetic Nephropathy. J Am Soc Nephrol. 24:133A, 2013.
28. Niewczas MA, Sirich TL, Mathew AV, Skupien J, Smiles A,1 Karoly ED, Bonventre JV, Pennathur S, Meyer TM, Warram J, Krolewski AS. Global Metabolomic Proﬁle in Type 2 Diabetes and Subsequent Progression to ESRD. J Am Soc Nephrol. 24:204A, 2013.
29. Shinke H, Ikemi Y, Tadehara M, Matsubara K, Togashi Y, Kim YH, Mishima M, Ichimura T, Bonventre JV, Masuda S. Kidney Injury Molecule-1 and Monocyte Chemotactic Protein-1 as Sensitive Biomarkers for Detecting Cisplatin-Induced Nephrotoxicity in Patients with Lung Cancer. J Am Soc Nephrol. 24:373A, 2013.
30. Shinke H, Tsuchimoto A, Sabbisetti V, Uesugi M, Hashimoto E, Matsubara K, Fujimoto Y, Kaido T, Uemoto S, Yanagita M, Ichimura T, Bonventre JV, Masuda S. Urinary Kidney Injury Molecule-1 (KIM-1) Levels Immediately after Surgery Predict the Development of Tacrolimus-Related Chronic Kidney Disease in Liver Transplantation Recipients. J Am Soc Nephrol. 24:373A, 2013.
31. Pang P, Khamlue P, Bonventre JV, Siedlecki AM. RGS4 Inhibits Angiotensin II Signaling and Macrophage Localization during Renal Reperfusion Injury Independent of Vasomotor Tone. J Am Soc Nephrol. 24:379A, 2013.
32. Yin W, Movahedi Naini S, Hentschel DM, Bonventre JV. Nephron-Speciﬁc Kidney Injury Molecure-1 Overexpression Induces Tubular Damage and Kidney Failure in Transgenic Zebrafish. J Am Soc Nephrol. 24:384A, 2013.
33. Freedman BS, Lam AQ, Sundsbak JL, Iatrino R, Su X, Koon SJ, Wu M, Harris PC, Zhou J, Bonventre JV. Ciliary Defects in Induced Pluripotent Stem Cells from Patients with Polycystic Kidney Disease and Ciliopathies. J Am Soc Nephrol. 24:392A, 2013.
34. Foster MC, Coresh J, Bonventre JV, Hsu CY, Kimmel PL, Mifﬂin TE, Nelson RG, Ramachandran VS, Sabbisetti V, Waikar SS, Liu KD. Urinary Biomarkers as Risk Factors of End-Stage Renal Disease in the General Population: CKD Biomarkers Consortium. J Am Soc Nephrol. 24:427A, 2013.
35. Bottinger EP, Teixeira A, Nadkarni GN, Daehn IS, Bonventre JV, Liu KD, Hsu CY, Rovin BH, Nelson RG, Kimmel PL, Feldman HI, Ramachandran VS. Urine Complement C3 Cleavage Fragments Are Associated with Abnormal Kidney Function and CKD. J Am Soc Nephrol. 24:427A, 2013.
36. Fufaa GD, Weil EJ, Nelson RG, Bonventre JV, Sabbisetti V, Waikar SS, Mifﬂin TE, Zhang X, Xie D, Feldman HI, Coresh J, Ramachandran VS, Kimmel PL, Hsu CY, Liu KD. Association of Urinary LFABP, KIM-1, and NAG with Incident End-Stage Renal Disease and Mortality in Type 2 Diabetes. J Am Soc Nephrol. 24:428A, 2013.
37. Toegel FE, Leal-Ekman S, Zhou L**, Bonventre JV**. Mir-421 Regulates ATM after Acute Kidney Injury J Am Soc Nephrol. 24:640A, 2013.
38. Ferenbach DA, Xin C, Wilflingseder J, Hughes J, **Bonventre JV**. The Impact of a Young Circulation on Renal Injury and Fibrosis in Aged Mice. J Am Soc Nephrol. 28, 2017: 29.
39. Gupta N, **Bonventre JV**, Morizane R. Ureteric Bud Organoids Derived from Human Pluripotent Stem Cells Facilitate Self-Organization of Nephron Organoids. J Am Soc Nephrol. 28, 2017: 62.
40. Homan K, Gupta NR, Kroll KT, Kolesky D, Skylar-Scott MA, Miyoshi T, Valerius MT, **Bonventre JV**, Lewis JA, Morizane R.2 Fluidic Shear Stress Induces Vascular and Glomerular Development in Kidney Organoids . J Am Soc Nephrol. 28, 2017: 62.
41. Morizane R, Miyoshi T, Gupta NR, Susa K, Garcia E, Lam AQ, Zhou J, Valerius MT, **Bonventre JV**. Nephron Organoids Derived from Patients with ARPKD Model Polycystic Kidney Disease Respond to a cAMP Inducer and an Src Inhibitor and Provide a Platform for Drug Screening In Vitro J Am Soc Nephrol. 28, 2017:65.
42. erstanding AKI to CKD Progression
43. Li L, Xiao X, Ichimura T, Wilflingseder J, **Bonventre JV**. Role of COUP-TFII in Pericyte Activation and Kidney Fibrosis. J Am Soc Nephrol. 28, 2017: 66.
44. stract SaturdayAKI KD Progression
45. Akinfolarin AA, Ajay AK, Sabbisetti V, **Bonventre JV**. The Breast Cancer Type 1 Susceptibility Protein (BRCA1) Mediates Fibrotic Kidney Disease. J Am Soc Nephrol. 28, 2017: 94.
46. to CKD Progression
47. Wilflingseder J, Willi M, Wang C, Olauson H, Ichimura T, Valerius MT, Lothar Hennighausen L, **Bonventre JV**. BET Protein Family Member BRD4 Promotes Transcription through Super-Enhancer Activation in Kidney Repair and Progression of Fibrosis. J Am Soc Nephrol. 28, 2017: 97.
48. Scott AW, Brooks CR, Ichimura T, **Bonventre JV**. Role of Cyclin G1 in Maladaptive Repair and Kidney Fibrosis. J Am Soc Nephrol. 28, 2017: 98.

ew in Diabetic Kidney Disease - II

1. Tsay JJ, Smiles A, Croall SE, **Bonventre JV**,1,4 Andrzej S. Krolewski AS, Niewczas MA. Complement System and Rapid Renal Function Decline in Type 1 (T1D) and Type 2 Diabetes (T2D) – Application of Novel SOMAscan-Based Proteomic Technology. J Am Soc Nephrol. 28, 2017: 99.
2. Death and Biomarkers
3. Yin W, Valerius MT, **Bonventre JV**. Proximal Tubular Epithelial Expression of Kim-1 Causes Progressive Kidney Injury in Mice. J Am Soc Nephrol. 28, 2017: 100.
4. and Transcription
5. Akinfolarin AA, Sabbisetti S, Ajay AK, Christie E, Joseph V. **Bonventre JV**. The Yes Associated Protein (YAP) Facilitates Kidney Fibrosis in a Kidney Injury Molecule-1 (KIM-1) Dependent Manner J Am Soc Nephrol. 28, 2017: 101.
6. Lemos DR, Morizane R, Gupta NR, Garcia E, Wilflingseder J, Miyoshi T, Susa K, GuanghaiWang G, Duffield JS, **Bonventre JV**. Analysis of Molecular Mechanisms of Human Kidney Tubulointerstitial Disease Driven by Interleukin 1β J Am Soc Nephrol. 28, 2017: 102.
7. and Tubulointerstitial Disorders
8. Nowak NZ, Skupien J, Smiles A, Yamanouchi M, A. Niewczas MA, Duffin KL, Breyer MD,4 Pullen N, **Bonventre JV**, Krolewski AS. Multiple Determinants of Early Renal Decline in Type 2 Diabetes. J Am Soc Nephrol. 28, 2017: 103.
9. Xu F,1 Ho LL, Denker BM, Kong T, **Bonventre JV**, Lu T. ADAM10-MMP14 Complex Regulates Renal Cystogenesis in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 28, 2017: 104.

riday

1. Hsu CY, Xie D, Zhang X, **Bonventre JV**, Chen J, Drawz PE, Feldman HI, Go AS, Horwitz EJ, Kimmel PL, Lunn MR, Mifflin TE, Ricardo AC, Waikar SS, Yang J, Liu KD. Urine Injury Biomarker Level before and after AKI: Results from the CRIC Study and CKD Biomarker Consortium. J Am Soc Nephrol. 28, 2017: 164.
2. Biomarkers
3. Hod T, Freedberg KJ, Chen ME, **Bonventre JV**, Waikar SS. AKI after Cytoreductive Surgery and Intraoperative Cisplatin Exposure for Malignant Pleural Mesothelioma. J Am Soc Nephrol. 28, 2017: 165.
4. Mori Y, Galichon P, Brooks CR, Ichimura T, **Bonventre JV**. Kidney Injury Molecule-1 (KIM-1) Mediates the Proximal Tubule Uptake of Free Fatty Acids (FFA) Resulting in Mitochondrial Injury and the DNA Damage Response (DDR). J Am Soc Nephrol. 28, 2017: 166.
5. Susa K, Gupta NR, **Bonventre JV**, Morizane R. Kidney Organoids Replicate Drug-Induced AKI in a Segment-Specific Manner J Am Soc Nephrol. 28, 2017: 167.
6. Li L, Galichon P, Ichimura T, Bonventre JV. Orphan Nuclear Receptor COUP-TFII Regulates Pericyte Detachment in AKI [Abstract]. J Am Soc Nephrol, 29: 3, 2018
7. Galichon P, Li L, Valerius MT, Bonventre JV. Stress Response Gene NUPR1 Protects Renal Tubular Cells from Proliferation-Induced Energy Exhaustion [Abstract]. J Am Soc Nephrol, 29: 4, 2018
8. Yin W, Brooks CR, Valerius MT, Joseph V. Bonventre JV. Inactivation of Mtorc1 in Proximal Tubular Epithelial Cells Reduces KIM-1-Mediated Kidney Fibrosis and Inflammation in Mice [Abstract]. J Am Soc Nephrol, 29: 5, 2018
9. Homan K, Gupta NR, Kroll KT, Kolesky DB, Skylar-Scott MA, Miyoshi T, Mau D, Valerius TM, Ferrante T, Bonventre JV, Lewis JA, Morizane R. Mechanistic Analysis of Flow-Enhanced Vascularization in Kidney Organoids [Abstract]. J Am Soc Nephrol, 29: 38, 2018
10. Wilflingseder J, Willi M, Ichimura T, Wang C, Olauson H, Valerius MT, Erben R, Hennighausen L, Bonventre JV. Enhancer and Super-Enhancer Dynamics in Kidney Repair [Abstract]. J Am Soc Nephrol, 29: 144, 2018
11. Yin W, Gupta NR, Miyoshi T, Valerius MT, Bonventre JV, Morizane R. Xenogeneic Kidney Generation with Human Nephron Progenitor Cells in Zebrafish [Abstract]. J Am Soc Nephrol, 29: 284, 2018
12. Tamura A, Susa K, Galichon P, Gupta NR, Miyoshi T, Sabbisetti V, Bonventre JV, Morizane R. Kidney Organoids for Improved Prediction of Human Nephrotoxicity [Abstract]. J Am Soc Nephrol, 29: 286, 2018
13. Kishi S, Brooks CR, Ichimura T, Nishimura K, Morizane R, Bonventre JV. Proximal Tubule ATR in Humans and Mice Is a Key Regulator of the DNA Repair Response Protecting the Kidney Against Maladaptive Repair and Fibrosis After Tubular Injury [Abstract]. J Am Soc Nephrol, 29: 356, 2018
14. Xin C, Gupta NR, Ajay AK, Akinfolarin AA, Garcia E, R Morizane, Bonventre JV, Sabbisetti V. Inhibition of Fibronectin Fibrillogenesis Attenuates Progression of Fibrosis in Animal and Kidney Organoid Models [Abstract]. J Am Soc Nephrol, 29: 360, 2018
15. Cardenas-Gonzalez M,3,1 C. De silva PM, Ekanayake DV, Wanniarachchi GT, Srayoshi N, Jayasinghe S, Chandana EPS, Jayasumana C, Siribaddana S, Sabbisetti V, Bonventre JV. KIM-1 as an Early Biomarker of Kidney Injury in Agricultural Communities in Sri Lanka [Abstract]. J Am Soc Nephrol, 29: 397, 2018
16. Gerlach CV, Lin JR, Everley RA, Bonventre JV, Vaidya VS. MicroRNA-132 Mediates Tubular Cell Sensitivity and Increases Kidney Injury in Mice [Abstract]. J Am Soc Nephrol, 29: 436, 2018
17. Xu J, Lin HY, Ho LL, Lim K, Hiemstra TF, Bonventre JV, Lu T. Cerebral Microvasculature Impairments Induced Dementia in CKD [Abstract]. J Am Soc Nephrol, 29: 454, 2018
18. Mori Y, Chang JC, Mou S, Zhao H, Li J, Galichon P, Brooks CR, Xiao S, Sabbisetti V, Palmer S, Kuchroo VK, Ichimura T, Bonventre JV. Proximal Tubular Uptake of Free Fatty Acid (FFA) by Kidney Injury Molecule-1 (KIM-1) Mediates Tubulointerstitial Disease in Diabetic Mice [Abstract]. J Am Soc Nephrol, 29: 527, 2018
19. Scovner KM, Li L, Bonventre JV. Hypokalemia as the Smoking Gun of Paraneoplastic Syndrome [Abstract]. J Am Soc Nephrol, 29: 570, 2018
20. Ajay AK, Vig S, Akinfolarin AA, Sabbisetti V, Bonventre JV. STAT3 Deletion from Stromal Cells Protects Mice from Folic Acid or Aristolochic Acid-Induced Kidney Fibrosis by Limiting Differentiation and Migration of Pericytes [Abstract]. J Am Soc Nephrol, 29: 950, 2018
21. Yin W, Zhang PL, Macknis JK, Bonventre JV. Kidney Injury Molecule-1 (KIM-1) Identifies Antemortem Injury in Fetal Postmortem Kidney. [Abstract]. J Am Soc Nephrol, 29: 1024, 2018
22. Ping L. Zhang,1 Wenqing Yin,2 Xu Zeng,3 Joseph V. Bonventre. Kidney Injury Molecule-1 Staining Reflecting Proximal Tubule Injury Is a Common Finding in Pediatric and Adult Kidney Diseases [Abstract]. J Am Soc Nephrol, 29: 1046, 2018
23. Wilflingseder J, Willi M, Lee HK, Olauson H, Ichimura T, Erben R, Valerius MT, Hennighausen L, Bonventre JV. Enhancer and Super-Enhancer Dynamics in Repair After Ischemic AKI [Abstract]. J Am Soc Nephrol, 30:7, 2019
24. Brooks CR, Kishi S, Taguchi K, Bonventre JV. 2ATR Deletion Drives TOR-Autophagy Spatial Coupling Compartment (TASCC) Formation and Kidney Fibrosis [Abstract]. J Am Soc Nephrol, 30: 51, 2019
25. Brooks CR, Kishi S, Taguchi K, Bonventre JV. ATR Deletion Drives TOR-Autophagy Spatial Coupling Compartment (TASCC) Formation and Kidney Fibrosis [Abstract]. J Am Soc Nephrol, 30:51, 2019
26. Mori Y, Ajay AK, Chang JH, Zhao H, Kishi S, Li J, Galichon P, Brooks CR, Xiao S, Sabbisetti V, Palmer S, Henderson JM, Ichimura T, Bonventre JV. Proximal Tubular Uptake of Free Fatty Acid (FFA) by Kidney Injury Molecule-1 (KIM-1) Mediates Tubulointerstitial Damage in Diabetic Kidney Disease (DKD), Which Is Attenuated by a Novel Inhibitor [Abstract]. J Am Soc Nephrol, 30:74, 2019
27. Shlipak M, Ix JH, Katz R, Waikar SS, Greenberg JH, Furth SL, Bonventre JV, Schrauben SJ, Kimmel PL, Parikh CR, Ramachandran VS, Feldman HI, Schelling JR, Coca SG, Sarnak MJ, Gutierrez OM. Association of Urine Biomarkers of Kidney Tubule Health with Incident CKD in the REGARDS Cohort [Abstract]. J Am Soc Nephrol, 30:229, 2019
28. Ajay AK, Zhao L, Jadhav S, Ding Y, Hsiao L, Bonventre JV. The Transcription Factor STAT3 Plays Key Roles in the Development of Kidney Fibrosis by Increasing Proliferation and Differentiation of Pericytes into Myofibroblasts [Abstract]. J Am Soc Nephrol, 30:250, 2019
29. Greenberg JH, Abraham AG, Xu Y, Schelling JR, Feldman HI, Waikar SS, Shlipak M, Sabbisetti V, Cardenas-Gonzalez M, Warady BA, Kimmel PL, Bonventre JV, Parikh CR, Mitsnefes M, Denburg M, Furth SL.12 CKD Biomarkers Consortium Plasma Kidney Injury Molecule 1 Is Associated with Left Ventricular Hypertrophy in Children with CKD [Abstract]. J Am Soc Nephrol, 30:318, 2019
30. Nadkarni GN, Fleming F, Mccullough J, Chauhan K, Verghese DA, He JC, Quackenbush J, Bonventre JV, Murphy BT, Parikh CR, Donovan MJ, Coca vSG. Prediction of Rapid Kidney Function Decline in Type 2 Diabetes Using Machine Learning Combining Blood Biomarkers and Electronic Health Record Data [Abstract]. J Am Soc Nephrol, 30:359, 2019
31. Schrauben SJ, Shou H, Anderson AH, Bonventre JV, Chen J, Coca SG, Furth SL, Greenberg JH, Gutierrez OM, Ix JH, Lash JP, Parikh CR, Rebholz C, Sarnak MJ, Shlipak M, Kimmel PL, Ramachandran VS, Feldman HI, Schelling JR. Plasma Biomarkers and Diabetic Kidney Disease (DKD) Progression: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study [Abstract]. J Am Soc Nephrol, 30:363, 2019
32. Jose Perez Saez M, Uffing A, Leon J, Murakami N, Watanabe A, Borges TJ, Sabbisetti V, Cureton P, Kenyon V, Keating L, Yee K, Satiro CA, Serena G, Hildebrandt F, Riella C, Libermann T,2 Wang M, Pascual J, Bonventre JV , Fasano A, Riella LV. A Pilot Study of a Gluten-Free Dairy-Free Dietary Intervention in Children with Steroid-Resistant Nephrotic Syndrome [Abstract]. J Am Soc Nephrol, 30: 380, 2019
33. Yang M, Mori Y, Murakami N, Ichimura T, Bonventre JV. Kidney Injury Molecule-1 (KIM-1) Promotes Tertiary Lymphoid Tissue (TLT) Development in the Kidney Through LTaβ/LTβR Signaling [Abstract]. J Am Soc Nephrol, 30:540, 2019
34. Lee L, Choi KH, Zeleznik Ramuta T, Bonventre JV. Optimizing Human Kidney Organoids for Modeling Nephrotoxicity, Kidney Injury, and Kidney Diseases and for Screening to Identify Therapeutic Options [Abstract]. J Am Soc Nephrol, 30:649, 2019
35. Susa K, Tamura A, Galichon P, Gupta NR, Matsumoto T, Miyoshi T, Sabbisetti V, Bonventre JV, Morizane R. A Drug-Specific Nephrotoxicity Prediction System Using Kidney Organoids [Abstract]. J Am Soc Nephrol, 30:642 2019
36. Mori Y, Ichimura T, Patel AB, Siedlecki AM, Bonventre JV. Protocol to Make Renal Tubuloids from Human Kidneys [Abstract]. J Am Soc Nephrol, 30:776, 2019
37. Lee N, Olauson H, Cheng SY, Choi KH, Zeleznik Ramuta T, Bonventre JV. Identification of Very Early Response Genes and Sex-Dependent Response Genes for Ischemia-Reperfusion Injury in Human Transplant Patients [Abstract]. J Am Soc Nephrol 30:781, 2019
38. Taguchi K, Elias BC, Kishi S, Canaud G, Bonventre JV, Brooks CR. Cyclin G1-Mediated Dedifferentiation of Proximal Tubular Cells Drives Fibrosis [Abstract]. J Am Soc Nephrol, 30:796, 2019
39. Li L, Figueroa Ramirez AC, Tamayo D, Mccracken K, Bonventre JV. COUP-TFII Enhances TGFβ-Induced Metabolic Reprogramming in Stromal Cells and Contributes to Kidney Fibrosis [Abstract]. J Am Soc Nephrol, 30:797, 2019
40. Ester L, Mccracken K, Bonventre JV. Rapid and Efficient Method to Generate Donor Vectors for Homology-Directed Repair Mediated Genome Editing [Abstract]. J Am Soc Nephrol, 30:881, 2019
41. Ferenbach DA, Xin C, O Sullivan ED, Denby L, Bonventre JV. Intrarenal Hh Signalling Mediates Fibrosis in Aged and Injured Kidneys [Abstract]. J Am Soc Nephrol, 30:883, 2019
42. Ajay AK, Sabbisetti V, Mori Y, Bonventre JV. Screening for Small Molecule Inhibitors of Kidney Injury Molecule-1 (KIM-1) Using a Cell-Based Functional Assay. [Abstract]. J Am Soc Nephrol 30:1127, 2019

Narrative Report (limit to 500 words)

|  |
| --- |
| In general, we suggest the following structure for the narrative:   * An opening paragraph that provides an overall summary of your major activities and achievements. Include an estimate of the proportion of your effort dedicated to teaching, research, clinical service, administrative activities and other relevant professional roles * Description of achievements in your **Area of Excellence** (Investigation, Teaching and Educational Leadership, or Clinical Expertise and Innovation); may include a description of work in progress such as pending grants or manuscripts in preparation * Description of contributions to **Teaching and Education** (if not your area of excellence). This may include a description of mentorship activities not discussed elsewhere in the CV * Description of contributions in **Significant Supporting Activities**, if any * A final paragraph that integrates and summarizes the contributions described above |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | 1. | Pathophysiology of Kidney Tubular Epithelial Injury and Chronic Fibrosis | | 2.  3. | Stem Cells in Repair of the Kidney  Biomarkers of Kidney Tubular Epithelial Injury |   My major research interests listed above reflect overlapping themes related to kidney injury and repair in animals and human beings which can be recognized as threads throughout my research.  Kidney Injury and Repair.  Pathophysiology of Kidney Tubular Injury and Chronic Fibrosis: A major focus of the laboratory has been the study of the pathophysiology of acute renal failure and processes involved with repair. There are many parallels between repair and the normal development of the kidney. While repair is generally considered to be adaptive it can be maladaptive, especially when the acute injury is superimposed on chronic kidney disease. Hence the large effort that has gone into understanding developmental systems will potentially translate into therapeutic approaches to treatment of adult as well as pediatric renal diseases. As a result of our experiments we have placed inflammation at the core of the pathophysiology and are continuing to explore the role of inflammation in the pathophysiology of acute renal injury and ways in which we can interrupt this response and reduce injury. We have found two proteins, KIM-1, an epithelial protein and nmb, a macrophage protein, which we believe play critical roles in the response of the kidney and have created a Kim-1 knockout/Gal4 knockin animal which will potentially allow us to use the characteristics of the promoter region of Kim-1 to express proteins specifically in the S3 segment of the proximal tubule, where most of the injury occurs. In addition, we want to understand the factors determining the recovery of the kidney in order to design strategies to enhance and hasten the processes necessary for recovery. These latter goals necessitate multiple experimental approaches. My laboratory carries out whole animal experiments on normal or knockout animals in order to test potential pharmacologic treatments or to test the hypothesis that a particular protein is important to the injury or repair process. More recently we have established models of preconditioning in the mouse in which we have uncoupled exposure to ischemia from the normal functional consequences of ischemia. We are employing genomic approaches to identify genes whose expression patterns might explain the profound protection we can induce in these models. We are using blood and urine proteomic approaches to identify new biomarkers and targets for therapy. Current studies have focused on genetic mouse models and zebrafish and include the role of stem cells in the repair process of the kidney post-ischemia.  Kidney Stem Cells: Kidney possesses the intrinsic capacity for repair after injury but whether adult kidney stem cells are responsible for epithelial regeneration is unresolved. During nephrogenesis, renal epithelia develop from precursors located in the metanephric mesenchyme that condense to form the nephron. Persistence of such cells in the adult could constitute a stem cell niche available for repair of damaged kidney. We evaluated the potential role of bone marrow derived stem cells in repair and concluded that these cells do not play a major role as precursors of the new epithelial cells with repair although they may have significant paracrine roles. Attention is now focused on the identification of intrarenal stem/precursor cells that may participate in repair. Genetic lineage approaches are in place and have provided a great deal of insight into the source of the cells that replace the dead cells. Other experiments are devoted to defining the factors responsible for directing embryonic stem cells down the kidney lineage. Bioengineering approaches are employed to understand the optimal cell-environmental interactions that optimize kidney cell differentiation in vitro to develop kidney assist devices and in vitro approaches to kidney toxicity prediction.    Biomarkers: Reliance on current measures of renal dysfunction, such as serum creatinine and blood urea nitrogen, has contributed to the slow translation of basic science discovery to therapeutically effective approaches in clinical practice. Insensitivity of commonly used biomarkers of renal dysfunction not only prevents timely diagnosis and estimation of injury severity, but also delays administration of putative therapeutic agents. We have cloned and characterized Kidney Injury Molecule-1 (KIM-1) as a very sensitive and specific biomarker of proximal tubular injury in a variety of species including man. The role of KIM-1 in the injured kidney is being explored using genetic and cell biological approaches and the role of this biomarker in a large number of kidney diseases in rodents and man is being evaluated. The laboratory serves as a Biomarker Core facility evaluating a number of urinary proteins that have been identified that are potential sensitive and specific biomarkers for kidney injury. Further characterization of these candidate biomarkers will clarify their utility and define new diagnostic and prognostic paradigms for AKI, facilitate clinical trials and lead to novel effective therapies. Thus, we are positioned to soon have clinically useful biomarkers which, either alone or in combination, will facilitate earlier diagnosis, earlier targeted intervention, and improved outcomes. |